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ABSTRACT 
 
Suja S. Rajan 
Effects of Primary Prophylaxis of Neutropenia on Outcomes, Utilization and Expenditures for Elderly 
Breast Cancer Patients Receiving Chemotherapy 
(Under the direction of Sally C. Stearns) 
 
 
Systemic chemotherapy is a well-established primary as well as adjuvant therapy for breast 
cancer, and is highly successful in ensuring recurrence free survival among patients. However, 
toxicity due to chemotherapy, specifically an early onset hematologic toxicity called neutropenia, 
restricts the use and therefore the efficacy of chemotherapy in breast cancer patients, especially in the 
elderly. The prophylactic use of granulocyte-colony stimulating factors (G-CSF), helps prevent 
neutropenia, improves the tolerance of chemotherapy in the elderly, and improves the prognosis of 
breast cancer. Nevertheless, evidence supporting the clinical and cost effectiveness of prophylactic G-
CSF in the elderly is limited, and thus the American Society of Clinical Oncology (ASCO) guidelines 
for use of prophylactic G-CSF in the elderly are not explicit.  
 
This study aims to assess the effect of primary prophylactic G-CSF on - the occurrence of 
chemotherapy-induced neutropenia hospitalization and length of stay; Medicare expenditures due to 
neutropenia management; overall expenditures in the first year after the start of chemotherapy; and 
successful administration of systemic cancer therapies that are otherwise hindered by the occurrence 
of neutropenia, in elderly breast cancer patients receiving chemotherapy.  
 
The study found that primary prophylactic G-CSF reduced the probability of neutropenia 
hospitalization and improved the provision of systemic chemotherapy and radiation therapy during 
 iv
the first course of the treatment in elderly breast cancer patients. The study also found that duration of 
primary prophylactic G-CSF administration was significantly associated with better outcomes, with 
lower rates of neutropenia hospitalization and better adherence to systemic cancer therapies. These 
findings have implications for ASCO guidelines and Medicare coverage policies for G-CSF 
administration and duration of administration in elderly breast cancer patients. 
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CHAPTER 1 
Introduction 
 
Breast cancer is the most common cancer among women in the United States and the second 
leading cause of cancer deaths among women (USCS, 2004). Systemic chemotherapy is a well-
established primary as well as adjuvant therapy for breast cancer and is more commonly used in 
breast cancer compared to other cancers (EBCTCG, 2005; Jamul, 2005). However, toxicity due to 
chemotherapy, specifically an early onset hematologic toxicity called neutropenia, restricts the use 
and therefore the efficacy of chemotherapy in breast cancer patients (Webster, 1996). The rate of 
occurrence of the toxicity is especially high in the elderly (> 65 years) since increasing age is one of 
the strongest risk factor for neutropenia and other chemotherapy-induced toxicities (Lyman, 2003a; 
Lyman, 2003c; Lyman, 2001). Neutropenia involves significant increase in expenditure due to the 
need for aggressive in-patient management, and a drop in treatment efficacy as a result of reduction 
and delay in both chemotherapy and radiation therapy, especially among the elderly. High risk of 
toxicity in the elderly is unfortunate because the incidence of breast cancer increases five times for 
women above the age of 65 years compared to younger women (Ries, 2008). The elderly also have a 
higher probability of detection at more advanced stages of breast cancer and a higher probability of 
metastasis, and therefore are more in need of a systemic therapy like chemotherapy and radiation 
therapy (Freyer, 2006; Gennari, 2004; Singh, 2004; Crivellari, 2007).  
 
The use of hematopoietic growth factors, specifically granulocyte-colony stimulating factors 
(G-CSF), helps prevent neutropenia, thereby improving the tolerance of systemic therapy in the 
elderly and hence the prognosis of breast cancer (Osby, 2003; Lyman, 2003a; Lyman, 2002; Webster, 
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1996; Welte, 1996). However, evidence supporting the clinical and cost effectiveness of prophylactic 
G-CSF in the elderly is limited. As a result, the American Society of Clinical Oncology (ASCO) 
guidelines for use of prophylactic G-CSF in the elderly are not explicit (ASCO, 2006). The ASCO 
guidelines recommend the use of physician discretion in administering prophylactic G-CSF in 
“special circumstances” such as elderly >65 years, without explicitly stating whether or not to 
administer it to all elderly or specifying any high-risk sub-groups of elderly to whom it should be 
administered to (Gridelli, 2007). The lack of external validity and inadequacies of the clinical trials in 
the elderly call for nationally representative population based studies to establish the utility of 
prophylactic G-CSF use in the elderly (Hassett, 2006).  
 
This study aims to assess the population level effects of primary prophylactic G-CSF on: the 
occurrence of chemotherapy-induced neutropenia hospitalization and length of stay; Medicare 
expenditures due to neutropenia management, and overall expenditure in the first year after the start 
of chemotherapy; and successful administration of systemic cancer therapy that could otherwise be 
hindered by occurrence of neutropenia. The study uses Surveillance, Epidemiology and End Results 
(SEER) data from 1994 to 2002 linked to Medicare claims through 2004 to examine primary 
prophylactic G-CSF administration and related outcomes. The target population consists of elderly 
(>65 years) female Medicare enrollees, newly diagnosed with stage I to III breast cancer between the 
years 1994 to 2002 and receiving chemotherapy.    
 
The specific aims of the study are: 
1. To explore the socio-demographic and clinical determinants of primary prophylactic G-CSF 
administration in the clinical setting. 
2. To estimate the effect of primary prophylactic G-CSF administration on: 
a. Hospitalization and duration of hospitalization for neutropenia management in 
elderly female breast cancer patients receiving chemotherapy 
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b. Neutropenia-related Medicare expenditures and overall Medicare expenditures in 
elderly female breast cancer patients receiving chemotherapy.  
c. Successful administration of systemic cancer therapy, which could otherwise be 
hindered by occurrence of neutropenia. 
3. To explore the determinants and effects of duration of primary prophylactic G-CSF 
administration. 
 
A population level study verifying the effect of primary prophylactic G-CSF on outcomes and 
costs in elderly patients is an important step in validating the use of the expensive G-CSF in the 
elderly. The results will contribute towards ASCO and Medicare policies.  
 
The study found that the key determinants of primary prophylactic G-CSF administration in 
elderly patients receiving chemotherapy were – Race, SEER region, year of diagnosis/chemotherapy 
initiation and characteristics of the chemotherapy regimen, with SEER region and chemotherapy 
characteristics being the strongest predictors in terms of magnitude. Whites have a higher probability 
of receiving primary prophylactic G-CSF compared to other races. Women from SEER regions of 
California, Louisiana and Connecticut have a higher probability of receiving primary prophylactic G-
CSF. Women diagnosed with breast cancer and receiving chemotherapy in later years (especially 
after the year 1999) were also more likely to receive primary prophylactic G-CSF. Women receiving 
a more intense chemotherapy regimen characterized by – administration of anthracycline, more drugs 
in the first cycle, and shorter duration between the first and second cycle, were more likely to receive 
primary prophylactic G-CSF. Unexplained and significant variations in primary prophylactic G-CSF 
administration based on race and region are a concern.  
 
The study also found that primary prophylactic G-CSF reduced the probability of neutropenia 
hospitalization and improved the efficacy of systemic chemotherapy and radiation therapy during the 
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first course of the treatment. Primary prophylactic G-CSF was not found to be significantly associated 
with lower average length of stay and expenditure for neutropenia hospitalizations though the lack of 
significance may be due to small sample size; the direction of the effect did illustrate a lower average 
length of stay and hospitalization expenditures in women receiving primary prophylactic G-CSF. 
Patients receiving primary prophylactic G-CSF also had higher overall Medicare expenditures during 
the first year after the start of chemotherapy (which is the time when the bulk of the cancer-related 
therapies are provided). Duration of primary prophylactic G-CSF administration, and not just the 
administration itself, was significantly associated with better outcomes, with lower rates of 
neutropenia hospitalization and better adherence to systemic chemotherapy. These findings have 
implications for ASCO guidelines and Medicare coverage policies for provision of G-CSF and 
duration of provision in elderly breast cancer patients.
   
 
 
CHAPTER 2 
Background and Significance 
 
2.1 Burden of breast cancer 
 
Breast cancer is the most common cancer among women in the United States and the second 
leading cause of cancer deaths among women (USCS, 2004). The probability of developing invasive 
breast cancer for women in the United States is 1 in 8, and the probability of death due to breast 
cancer is 1 in 33. In addition to the high prevalence of the disease compared to other cancer types, the 
incidence of breast cancer has also been increasing since the 1970s. The age-adjusted incidence of 
female breast cancer has increased since the last few decades from 105.0/100,000 in 1975 to 
140.8/100,000 in 1998, and has stabilized in the last few years at 128.2/100,000 from 2003. 
Moreover, the mortality rates have decreased in the past few years from 31.4/100,000 in 1975 to 
26.0/100,000 in 2002, thereby increasing the number of people needing post-diagnosis management 
and recurrence prevention (USCS, 2004; Ries, 2008). Every year $5.3 billion is spent nationally on 
the treatment of this disease, thus making breast cancer the second most expensive cancer in terms of 
treatment (Brown, 2002). Almost 50% of the overall national spending for breast cancer is covered by 
Medicare.  
 
The US population is aging; the proportion of individuals, 65 years and older, is expected to 
double from 11.3% (25.5 million) in 1980 to 20.1% (70.2 million) in 2030 (Yancik, 1997). Since 
breast cancer occurrence is age-related, the absolute number of incident cases is predicted to increase 
in the nation (Statistical abstract of the United States, 1997). Also, epidemiological studies show that 
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by the end of the 20th century nearly 60% of all newly diagnosed breast cancers had occurred in 
women 65 years and older (Baranovsky, 1986) indicating an increase in the incidence of breast cancer 
in older individuals. The increase in breast cancer cases in the general population and among the 
elderly accentuates the need for cancer control and therapy in the aging population. One of the 
reasons for choice of the study population in this study is the cancer burden in United States, 
especially with respect to the elderly. 
 
2.2 Stage, grade and corresponding treatment protocol for breast cancer 
 
Protocols for treatment and management of breast cancer after diagnosis depend primarily on 
the American Joint Committee on Cancer (AJCC) staging of the tumor. Table 1 describes the stages 
and the relevant treatment for each stage. The staging has five categories, ranging from stage 0 to IV, 
based on the tumor size, the lymph node involvement, and the metastasis of the disease, all of which 
indicate the degree of spread of the disease. Stage 0 is called “carcinoma in situ”, a non-invasive stage 
where abnormal cells are found in the affected breast tissue but have not developed into a tumor and 
have not spread outside the affected tissue. When an invasive cancer develops into a tumor of size 
less than 2 centimeters but does not spread outside the breast to the lymph nodes or other parts of the 
body then the cancer is classified as stage 1. Based on the size of the tumor (from 2 to 5 centimeters 
or more), and extent of cancer spread to lymph nodes and tissues around the breast like the chest 
muscles, the cancer is categorized into various subcategories of stages 2 and 3. Once the cancer 
metastasizes to other organs in the body, mostly the bones, lungs, liver, or brain, it is classified as 
stage 4.  
 
The cancer grade, on the other hand, is determined by the histological examination of the 
cells. The grade is indicative of how aggressively the cells are multiplying and growing, and is an 
indicator for the spread of the cancer. The SEER classifies the cancer into four grades.  
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The treatment protocol for breast cancer is determined by the stage at which the cancer is first 
diagnosed. Treatment is started immediately after diagnosis. Traditionally for stages I to III (the 
stages of interest in this study) the treatment starts after a Biopsy confirms the diagnosis and 
establishes the extent of spread. It involves surgery, followed by chemotherapy, radiation therapy and 
finally hormonal therapy (Figure 1). Since chemotherapy is administered in multiple cycles for a 
couple of months, radiation therapy can be started soon after surgery while the patient is still 
receiving chemotherapy.   
 
In advanced cases, where the tumor is large and needs to be shrunk before surgery is 
performed, chemotherapy is administered immediately after Biopsy. Chemotherapy is followed by 
surgery, radiation therapy and hormonal therapy in that case (Figure 2). Additional chemotherapy can 
also be administered after surgery for a second time.  
 
In the traditional scenario, surgery involves either lumpectomy or mastectomy, and is 
typically performed within a few days after diagnosis - often within the first month after diagnosis. 
Even if the surgery is delayed due to patient preference or any other constraint, it is performed within 
the first three months at most.  
 
Chemotherapy is begun three to six weeks after surgery, once the surgical wound heals. This 
first regimen of chemotherapy administration is called the first course and it is administered over 
multiple days (cycles). Patients typically receive the first course chemotherapy within 3 months of 
breast cancer diagnosis. A delay in chemotherapy administration might occur if the patient suffers 
from surgical complications like infection. Chemotherapy could also be delayed if the patient is 
initially reluctant to receive it due to its associated toxicities but later decides to receive the therapy. 
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However, the vast majority of the patients scheduled to receive chemotherapy will have the process 
initiated within the first 6 months of diagnosis.  
 
A single course of chemotherapy comprises of multiple cycles of administration interspersed 
with brief recovery period. Multiple administrations ensure that the chemotherapy is able to destroy 
more cancer cells, and at the same time provides rest periods in between to help the body recoup from 
the toxic side effects of chemotherapy. Normal cells usually repair the damage from chemotherapy 
more effectively than cancer cells, so in the rest periods the normal cells recoup but there is no danger 
of the cancer cells recovering. The number of administrations (cycles) usually range from 4 to 8. The 
period between each cycle ranges from 2 to 3 weeks. Thus the entire course lasts for 3 to 6 months. A 
chemotherapy cycle can be administered within one or a few days.  
 
Radiation therapy usually lasts for six to seven weeks and is administered almost daily 
Monday to Friday. Finally hormonal therapy may be started after all radiation and chemotherapy are 
completed and administered for up to five years.  
 
In cases where the tumor is very large and spreads aggressively, chemotherapy is begun first, 
within a week or two of diagnosis. Chemotherapy is administered for up to 3 to 6 months and then the 
patient is scheduled for surgery. Radiation therapy and hormonal therapy follow as mentioned before.  
 
When employed, primary prophylactic G-CSF is typically administered at least 24 hours after 
the first chemotherapy cycle, but mostly within 2-3 days of completing the first cycle of 
chemotherapy. One course is administered for 5-10 consecutive days. A G-CSF course can be 
administered after every cycle of chemotherapy.   
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 2.3 Significance of chemotherapy in female breast cancer patients 
 
Chemotherapy is an established treatment for many types of cancer, and breast cancer is the 
most common indication for chemotherapy among women (Jemal, 2005, NCCN, 2000; Shifflett, 
1999). Chemotherapy involves the use of cytotoxic drugs for controlling the growth and spread of 
cancer cells. Chemotherapy has been proved to be effective and efficacious in treating and containing 
breast cancer, irrespective of age, nodal status, estrogen receptor status, and administration with or 
without other systemic therapies like radiation and hormonal therapy (EBCTCG, 1988; EBCTCG, 
1992; EBCTCG, 1998; EBCTCG, 2005; Fisher, 1999; Hortobagyi, 1998; Fisher, 1990). 
Chemotherapy is utilized following the initial diagnosis in an effort to reduce the risk of recurrence 
and eventual death from cancer. 
 
As can be seen from Table 1, chemotherapy plays a pivotal role in most stages of breast 
cancer. Chemotherapy is recommended in women with breast cancer as an adjuvant therapy after 
surgery in early breast cancer stages of I to III; as primary therapy in inoperable cases of stage 3; and 
as palliative therapy after metastasis of breast cancer (NCCN, 2000; Shifflett, 1999). Even in the 
absence of breast cancer metastasis (in stages I to III), adjuvant systemic chemotherapy after surgery 
is recommended because in spite of early detection and treatment, undetected micro-metastasis might 
exist thereby increasing the possibility of recurrence and death (EBCTCG, 1998). The primary role of 
chemotherapy in early stages of I to III is to prevent breast cancer recurrence and breast cancer related 
mortality (EBCTCG, 2005).   
 
2.4 Impediments for chemotherapy administration in breast cancer patients 
 
In spite of its success in breast cancer treatment and management, the use of chemotherapy is 
restricted due to the toxicity associated with the therapy (Webster, 1996; Perry, 1984). Given the 
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pivotal role of chemotherapy in the treatment and management of this high burden disease, 
impediments for the effective administration of chemotherapy are a matter of concern. Chemotherapy 
drugs are the leading cause of therapeutic adverse effects among female breast cancer patients 
(Hassett, 2006). These toxicities are a result of the cytotoxic properties of the therapy; the therapy is 
geared towards hindering the rapid division and formation of new cancer cells. However, as a side-
effect the therapy interferes with the growth of other healthy cells that are dividing and growing in the 
adults, such as bone marrow cells, skin, hair follicles, reproductory cells and gastrointestinal lining 
cells. Thus, some of the observed symptoms of chemotherapy-induced toxicity are hair loss, anemia, 
hemorrhage, infection, fever, nausea, emesis, diarrhea, dehydration, electrolyte abnormality, 
malnutrition, malaise, fatigue, delirium, and infertility (Perry, 1984).  
 
Hematologic toxicity, caused by suppression of the hematopoietic processes (the process of 
bone marrow cells producing blood cells), is one of the most serious toxicities of chemotherapy at the 
early stage of the therapy. It begins within a week after chemotherapy administration and peaks after 
two weeks (Perry, 1984; Shapiro, 2001; Chrischilles, 2003a). Among the various manifestations of 
hematologic toxicity, neutropenia, which is marked by a drop in the neutrophil count in the blood 
below 2000/microL, is of major a concern (Du, 2005; Shapiro, 2001; Perry, 1984). The drop in the 
neutrophils in the blood reduces the body’s capacity to resist infections, which might lead to 
neutropenic fever (febrile neutropenia), and a sequel of life threatening systemic infections or sepsis. 
Unfortunately neutropenia is specifically higher among breast cancer patients receiving chemotherapy 
compared to other cancer patients receiving chemotherapy (Shayne, 2007).  
 
Infection and fever associated with a drop in the neutrophil count are the most common 
presenting symptoms of neutropenia (Hassett, 2006; Perry, 1984). Fever > 100.6F associated with 
neutropenia involving a neutrophil count of < 1000 cells/microL is termed as febrile neutropenia 
(Chrischilles 2002). The increase in the risk of infection and mortality increases proportionately with 
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the severity and duration of neutropenia in a patient (Lyman, 1998). Chemotherapy patients face high 
risk of death if not treated aggressively for systemic infections and febrile neutropenia (Perry, 1984).  
 
Standard practices to control chemotherapy-induced neutropenia, especially in the presence 
of infections and fever, are immediate hospitalization for evaluation of neutropenia and aggressive 
administration of empiric broad-spectrum antibiotics to control any infections (Perry, 1984; Baquiran, 
2001). This is followed by dose modification/reduction or dose delay of the chemotherapy, and 
delaying or cancelling the required radiation therapy. The largest share of direct medical costs for 
cancer patients suffering from neutropenia are expensive hospitalization costs including diagnostic 
tests and antibiotic administration for treating life threatening systemic infections and febrile 
neutropenia (Eldar-Lissai, 2007; Kuderer, 2006; Lyman, 1993; Lyman, 1998; Weycker 2007). 
Hospitalization especially accounts for 62% to 82% of direct healthcare cost of febrile neutropenia 
management (Leese, 1993; Dranitsaris, 1995), and most of the hospitalization cost is associated with 
length of stay and level of neutropenia complications (Eldar-Lissai, 2007). 
 
Dose reduction and dose delay to control neutropenia hinder the effective administration of a 
planned treatment regimen, diminish the efficacy of chemotherapy and radiation therapy, harm 
patient health outcomes and prognosis, increase the probability of recurrence and mortality, and might 
also increase the overall treatment costs due to lose of efficacy of the chemotherapy regimen (Shayne, 
2006; Hershman, 2007; Weycker, 2006; Ozer 2000; Baquiran, 2001; Webster, 1996; Welte, 1996; 
Ziegler, 2006). Adjuvant chemotherapy for breast cancer loses its clinical benefit when dose intensity 
is reduced (Ziegler, 2006; Budman, 1998). Reducing the dose or increasing the duration between each 
chemotherapy administration cycle makes it difficult to prevent tumor re-growth. Hence dose 
reduction to control toxicity is referred to as “killing with kindness” (Hryniuk, 1988). Neutropenia-
related adverse effects are the main dose-limiting toxicities for systemic chemotherapy (Lyman, 
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1998), leading to increased healthcare costs of managing recurrence and worse prognosis, and 
compromising quality of life.  
 
Radiation therapy could worsen neutropenia as it is also a systemic therapy that impedes the 
production of any new cells in the body. Thus, in an event of neutropenia, radiation therapy is also 
reduced until the patient recovers.  
 
2.5 Chemotherapy for female breast cancer patients who are elderly 
 
Breast cancer is an age-related tumor. Epidemiological studies show that by the end of 20th 
century nearly 60% of all newly diagnosed breast cancers had occurred in women 65 years and older 
(Baranovsky, 1986). Older individuals are also the ones who have a higher incidence of breast cancer 
and metastasis, larger tumors (Landis, 1998; Diab, 2000), higher node involvement (Molino, 2006; 
Daidone, 2003; Gennari, 2004) worse survival rate after metastasis (Yancik, 1989), higher probability 
of detection at more advanced stages (Molino, 2006; Shayne, 2007), and higher risk of disease 
recurrence after surgery (Gennari, 2004), necessitating systemic chemotherapy (Freyer, 2006; 
Gennari, 2004; Singh, 2004; Crivellari, 2007). Increase in the risk of breast cancer with age is 
attributed to higher duration of carcinogenic exposure over time during the lifetime of a person, and 
to breast tissue aging (Franceschi, 2001; Pike 1983). The higher incidence of metastasis, larger 
tumors, and late detection could be attributed to fewer breast examinations and screening 
mammograms (Worden, 1983; Zapka, 1989; NCI, 1990), reduced screening compliance with age 
(Beghe, 1994), reduced breast awareness among older women (Coates, 1999; Siahpush, 1995) and 
overall reduction in preventive services received with age (Earle, 2003). Higher risk of breast cancer 
and later stage of detection make systemic therapy like chemotherapy a very essential part of disease 
management in the elderly.  
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Increase in age is the strongest risk factor for chemotherapy-induced side-effects making 
elderly more vulnerable to chemotherapy-induced toxicities such as neutropenia (Lyman, 1998; 
Balducci, 2000; Lyman, 2003a; Armitage, 1984). Numerous studies examining the risk of 
neutropenia and neutropenic complications identify age (particularly >70 years) as an independent 
and significant risk factor (Lyman 2003a; Lyman 2001). Older individuals also have a higher risk of 
neutropenia-related mortality and morbidity, requiring hospitalization and aggressive treatment with 
antibiotics (Balducci, 2000). The higher risk is probably because of their lower marrow reserve, 
presence of co-morbidities, changes in liver and kidney functions, and lower baseline health (Hassett, 
2006; Lyman 2003a; Chrischilles, 2002). Given the essential role of chemotherapy in breast cancer 
treatment and management, toxicity prevention is critical in elderly who have both higher risk of 
breast cancer and higher risk of chemotherapy induced toxicity.  
 
The benefit of chemotherapy for elderly as compared to the younger patients could be 
questioned on the basis of the higher risk of toxicity due to the aging process and possible reduction 
in effectiveness of chemotherapy in the elderly. Due to the higher risk of toxicity and possible lower 
effectiveness, receipt of chemotherapy is often shown to decrease with age (Allen, 1986; Silliman, 
1989; Busch, 1996). There are three reasons for possible lower effectiveness of chemotherapy in the 
elderly. 
 
1. Elderly are often less responsive to chemotherapy (Lyman, 2003a). 
 
2. Reduced metabolism of drugs with age make it very difficult to determine if standard drug 
dose is ideal for older patients. In order for chemotherapy to be effective specific blood 
concentration of the chemotherapeutic drugs should be maintained. Changes in intestinal 
absorption, reduced serum albumin, and reduced hepatic and renal functions make it difficult 
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to estimate the appropriate dosage in elderly (Chrischilles, 2002). If the dose administered is 
inadequate, then the therapy’s effectiveness reduces.  
 
3. A significant proportion of physicians believe breast cancer to be biologically indolent in 
elderly and thereby not requiring chemotherapy (Carey, 2006; Diadone, 2003). 
 
Nevertheless, chemotherapy is essential in breast cancer patients of all ages. First, older 
women in good health tolerate standard doses of chemotherapy as well as the younger women (Muss, 
1994). Second, for a breast cancer event with less aggressive biological characteristics, the baseline 
prognosis (when no chemotherapy is administered) of breast cancer is always better and the marginal 
change due to chemotherapy is lesser in magnitude, on average, than a faster spreading more 
aggressive event. Thus, the marginal benefit of chemotherapy is lesser on average for older 
individuals compared to younger individuals. Nonetheless, the marginal benefit exists and the 
improvement is still clinically efficacious and cost effective (EBCTCG, 1998). Third, although the 
elderly tend to be estrogen receptor (ER) positive with a higher probability, thus giving them the 
option of receiving hormonal therapy for a systemic treatment, it has been shown that in case of 
recurrence prevention, hormonal therapy cannot be a complete substitute to chemotherapy (EBCTCG, 
1998). Administration of chemotherapy significantly increases recurrence free survival in ER positive 
patients receiving hormonal therapy, irrespective of the nodal and menopausal status. Thus, 
chemotherapy and hormonal therapy seem to be complementary in their actions, and not duplicative 
(EBCTCG, 1998). Fourth, there are elderly with early breast cancer and ER-ve status who only have 
the option of chemotherapy for preventing recurrence. Fifth, the belief that breast cancer is 
biologically indolent has proven to be controversial by many studies, which have demonstrated that 
breast cancer could be as aggressive in the elderly as in the younger population (Gennari, 2004; 
Mueller, 1978; Singh 2004). Thus, improving chemotherapy tolerance in elderly is important.  
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2.6 The role of Colony Stimulating Factors in sustaining chemotherapy and reducing healthcare 
costs 
 
The introduction of hematopoietic growth factors, also known as Colony Stimulating Factors 
(CSF), as prophylactic or therapeutic drugs for chemotherapy-induced toxicity, has provided a 
method to prevent neutropenia and has improved the dose tolerance and outcomes of chemotherapy in 
cancer patients (Table 2). The CSFs, used for prevention and management of neutropenia, stimulate 
the production of neutrophils. They are called Granulocyte-Colony Stimulating Factors (G-CSFs) 
because neutrophils are a type of granulocytes. G-CSFs are glycoproteins that aid the reproduction 
and maturation of neutrophils, and this maintains the body’s ability to fight infections (Welte, 1996). 
G-CSFs could be used as a primary prophylactic measure to prevent neutropenia after chemotherapy 
in patients with no prior documentation of neutropenia, as a secondary prophylactic measure after a 
cycle of chemotherapy with documentation of neutropenia in prior cycles, or as a therapeutic agent 
after neutropenia occurs, to aid the recovery of neutrophil production (Bennett, 1999).  
 
The most noteworthy contribution of prophylactic G-CSF has been in sustaining dose 
intensity, especially in chemotherapy patients receiving high dose regimens (Lyman, 1998; Webster, 
1996; Shayne, 2006). Maintaining the planned schedule of chemotherapy has been shown to increase 
recurrence free and overall survival in non-Hodgkin’s Lymphoma patients (Chrischilles, 2003). 
Increasing dose intensity has now become quite popular for breast cancer due to better prognosis of 
high intensity treatment especially among node-positive patients (Ziegler, 2006; Citron, 2003). Dose 
intensity can be increased by either increasing the dose, or by increasing the frequency with which 
chemotherapy cycles are administered. Dose intensity is often expressed as Relative dose intensity 
(RDI), which is defined as the amount of drug administered per unit of time, expressed as the fraction 
of the amount recommended in the standard, evidence-based regimen. Studies show that increasing 
RDI by increasing dose frequency is more effective than increasing the amount of dose administered 
in preventing recurrence and breast cancer related mortality, as increasing the frequency is better able 
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to prevent tumor re-growth before the next dose is administered (Norton, 1997; Citron, 2003; Ziegler, 
2006). Increasing the frequency of the hematotoxic chemotherapeutic drugs however, does not allow 
sufficient time between the chemotherapy cycles for the neutrophil production and blood count to 
recover. The rate of neutropenia and febrile neutropenia is very high among patients receiving both 
standard and higher RDI. The febrile neutropenia incidence are reported to be between 57%-98% in 
case of higher RDI therapy (Baldini, 1997; O’Shaughnessy, 1994) and 23% in case of standard RDI 
therapy (Rahman, 1997). Neutropenia incidence is 60% in case of standardized RDI therapy 
(Rahman, 1997).  
 
Prophylactic G-CSF enables the frequency increase of chemotherapy by shortening the time 
to neutrophil recovery and decreasing neutropenia-related toxicity (Ziegler, 2006). One particular 
study also showed that the chemotherapy dose tolerance and ability to keep up the dose intensity 
according to the planned chemotherapy regimen was higher for older patients receiving primary 
prophylactic G-CSF (Osby, 2003).  
 
There is a need for scientific evidence documenting the value of primary prophylactic G-CSF 
in chemotherapy dose sustenance for patients with curable early stage (stage I to III) breast cancer 
(Webster, 1996). Past studies demonstrate the importance of chemotherapy in recurrence free and 
overall survival in early stage breast cancer patients (EBCTCG, 1992; EBCTCG, 1998; EBCTCG, 
2005). Hence, these women have more to lose in terms of quality of life and survival, if the highly 
effective systemic chemotherapy is stopped or reduced due to toxicity (Budman, 1998; Bonneterre, 
2005). Nevertheless, nearly 30% to 50% of these early stage breast cancer patients experience dose 
reduction below RDI <85% thereby jeopardizing their chance of complete cure and recurrence free 
survival (Shayne, 2006; Lyman, 2003b). One study showed that neutropenia hospitalization was the 
primary determinant of early termination of chemotherapy, in not only women who were at a early 
stage of breast cancer, but who were clinically proven to be responsive to chemotherapy (Chrischilles, 
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2003). RDI was especially lower in patients receiving a 28-day chemotherapy schedule compared to a 
21-day chemotherapy schedule (Shyane, 2006).  
 
In addition to chemotherapy dose sustenance primary prophylactic G-CSF can also reduce 
costs related to neutropenia management. Cancer care accounts for nearly 10% of the healthcare 
expenditure in the US, and currently stands at about $100 billion per annum, with the hospital care of 
cancer patients amounting to 50% of the total cancer-related expenditure. More than 60,000 
neutropenia hospitalizations occur each year in the United States (Caggiano, 2005), and each 
neutropenia hospitalization could cost $10,000 to $30,000 on average (Eldar-Lissai, 2007; Kuderer, 
2006; Weycker, 2007; Weycker 2006a). The disease burden and healthcare expenditures of 
neutropenia can hardly be overlooked. 
 
The CSFs are also expensive and hence their administration should be justified both clinically 
and economically. Primary prophylactic G-CSF’s clinical and cost effectiveness in older adults has 
been established in clinical trials and other studies (Table 2). Most of these studies involved lung 
cancer and Non-Hodgkin’s lymphoma studies (Crawford, 1991; Chrichilles 2002; Scott, 2003; 
Weycker 2006). Primary prophylactic G-CSF is effective in reducing the incidence of neutropenia, 
neutropenia-related serious infections, and reducing number of hospitalization days and intravenous 
antibiotic use in patients receiving chemotherapy (Zagonel, 1994; Heil, 1997; Moore, 1997; Lyman, 
2002; Weycker, 2004; Kuderer, 2007). Neutropenia hospitalization is the largest component of 
neutropenia-related direct medical expenditures (Eldar-Lissai, 2007; Kuderer, 2006; Lyman, 1993; 
Lyman, 1998; Weycker 2007). The administration of primary prophylactic G-CSF offsets the cost of 
neutropenia hospitalization by reducing both the probability of hospitalization (Lyman, 1993; Lyman, 
1998; Crawford, 1991; Weycker, 2004) and the duration of hospitalization (Eldar-Lissai, 2007; 
Chrischilles, 2002). However, cost-effectiveness of primary prophylactic G-CSF in the general 
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population has not been ambiguously established (Glaspy, 1993; Zagonel, 1994; Dranitsaris, 1995; 
Bassan, 1997; Eldar-Lissai, 2007; Uyl-de Groot, 1996; Lyman 2004; Lyman, 1993).    
 
The use of G-CSF grew substantially in the last decade, after its approval by the U.S. Food 
and Drug Administration (FDA) in 1991. It is important to realize that G-CSFs do have side effects, 
including musuloskelatal complications like bone and muscle pain (Kuderer, 2005). Some researcher 
believe that the risk of acute myeloid leukemia or myelodysplastic syndrome may be increased due to 
G-CSF administration (Hershman, 2007). Chemotherapy often causes mutation in blood cells at an 
early stage of their development. Typically these mutated cells destroy themselves, but the G-CSF 
administration saves them from destruction leading to their developing into blood cancer cells. G-
CSF also, has some direct mutant effects on the blood cells. Nevertheless the benefits of G-CSF 
outweigh the side effects (Hershman, 2007).  
 
It is important to understand that primary prophylactic G-CSF is more effective in reducing 
neutropenia and neutropenia-related hospitalization occurrence than secondary prophylaxis, and even 
more so than therapeutic use of G-CSF. Neutropenia, neutropenia hospitalization occurrence and 
neutropenia-related mortality are highest in the first two cycles of chemotherapy (Chen-Hardee, 2006; 
Chrischilles, 2002; Armitage 1984; Gomez, 1998; Shayne, 2007); also, occurrence of neutropenia 
during the first cycle of chemotherapy increases neutropenic events in later cycles (Timmer-Bonte, 
2006). Thus primary prevention in the very first cycle has a synergistic effect on future preventions. 
Studies also show that primary prophylactic G-CSF reduces repeat neutropenia hospitalization, and 
secondary and therapeutic prophylaxis have a lesser effect on recurrent neutropenia incidence and 
hospitalization (Chrischilles, 2002; Scott, 2003). Secondary prophylaxis is often too late to prevent 
and reduce neutropenia and related outcomes, and evidence for the clinical and cost effectiveness of 
secondary prophylaxis are low (Gridelli, 2007). Therapeutic G-CSF benefits have also not been 
consistently established in previous literature (Gridelli, 2007; Berghmans, 2002; Clark, 2005; 
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Hartmann, 1997; Garcia-Carbonero, 2001; Lyman, 1998; Lyman 2004a). Moreover, treatment costs 
of G-CSF use as therapeutic agent are much higher than treatment cost of G-CSF use as a 
prophylactic agent, thereby reducing the cost-effectiveness of therapeutic use (Lyman, 1993).  
  
2.7 Need for evidence of primary prophylactic G-CSF effectiveness in the elderly female breast 
cancer patients 
 
Several clinical trials have been conducted on the efficacy of primary prophylactic G-CSF in 
reducing neutropenia occurrence, neutropenia hospitalization, frequency of infections, febrile 
neutropenia, early mortality and infection related-mortality (Table 2). Although a few of these studies 
show no effect on infection related mortality and early mortality (Crawford, 1991; Pettengell, 1992; 
Zinzani, 1997; Bui, 1995; Gatzemeier, 2000; Gisselbrecht, 1997), most studies demonstrate a 
statistically significant reduction in the occurrence of neutropenia, infections due to neutropenia, and 
febrile neutropenia (Kurderer, 2007; Crawford, 1991; Trillet-Lenoir, 1993; Fossa, 1998; Lyman, 
2001). However, these studies lack external validity as their sample participants were selected from 
local healthcare facilities. Also these studies do not focus on elderly female breast cancer patients as 
they predominantly involve patients suffering from other solid cancers and lymphomas, such as small 
cell lung cancer and Non-Hodgkins Lymphoma (Kurderer, 2007).  
 
From an economic perspective the cost-effectiveness of primary prophylactic G-CSF 
administration has also not been unambiguously established in clinical trials, and the studies have 
determined that the treatment is cost effective only for patients with a greater than 20% risk of febrile 
neutropenia occurrence after chemotherapy (Lyman, 2004; Lyman, 1998). Hence the American 
Society of Clinical Oncology (ASCO) established clinical guidelines (Table 3), with 
recommendations for use of primary prophylactic G-CSF for only those patient groups that benefited 
from primary prophylactic G-CSF use (risk of febrile neutropenia >20%), based on the finding of 
these clinical trials (Gridelli, 2007).  
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Nevertheless, some recent studies established that the incidence and costs of adverse effects 
of chemotherapy for breast cancer patients are under-reported in clinical trials, thereby casting doubt 
on the toxicity-related costs estimated by these trials (Hassett, 2006; Russo, 2006; Du, 2002). A study 
estimated that younger (<65 years) female breast cancer patients receiving chemotherapy incurred 
$1,271 more per year in costs for medical expenses and $17,617 more per year in costs for 
ambulatory care than female breast cancer patients not receiving chemotherapy, due to chemotherapy-
induced toxicity, and that predicted incremental expenditure due to chemotherapy toxicity could reach 
$45 million per year (Hassett, 2006). Chemotherapy-induced toxicity might lead to higher costs than 
predicted by the clinical trials because rates of chemotherapy-induced toxicity could be different at 
the population level versus in the clinical trials due to the following reasons: 
 
1. Patient socio-demographic characteristics like education, income and age are different 
between clinical trial participants and the general population, often due to strict enrollment 
criteria for clinical trials, thus limiting the external validity of the trials. The restrictions due 
to age and comorbidities lead to the exclusion of the older individuals from the clinical trials 
(Holmes, 2003; Muss, 1994). Under-representation of elderly is a problem for estimating 
toxicity-related costs for elderly patients (Aapro, 2005; Britton, 1999; Bugeja, 1997; Adams-
Campbell, 2004; Gross, 2005; Murthy, 2004; Simon, 2004; Talarico, 2004; Goodwin, 1988), 
more so in case of age-related tumors like breast cancer (Hutchins, 1999) requiring cytotoxic 
systemic treatments (Balducci, 1997).  
2. The adherence and behavior of the patients in clinical trials are different from the general 
population, thus modifying the treatment effect (Braunholtz, 2001). 
3. Provider behavior is also different during a clinical trial with better adherence to close 
monitoring and follow-up of patients (Du, 2002).  
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4. Clinical trials have, on average, longer duration of primary prophylactic G-CSF 
administration than the duration in practice - 10 to 11 days versus 4 to 7 days respectively 
(Weycker, 2006; Scott, 2003; Chrischilles 2003). Since duration of administration has a 
significant impact on neutropenia occurrence and hospitalization, it is essential to study the 
outcomes of primary prophylactic G-CSF administration outside of trials. 
5. Most providers participating in clinical trials participate at or are affiliated with cancer 
centers, and thus do not necessarily represent all community practice (Chen-Hardee, 2006).  
6. Inadequate reporting of adverse events like chemotherapy toxicities and incomplete 
documentation of reasons for patient discontinuation in case of adverse events affect the 
sensitivity of the trials in detecting the occurrence of these toxicities (Fromme, 2004; 
Ioannidis, 2001; Erban, 2006; Trotti, 2004). Moreover, some clinical trials are not designed 
with the aim to detect toxicities, but have other prognostic outcomes and survival as the 
endpoints of interest, thereby further increasing the inadequate reporting of toxicities (Erban, 
2006).   
7. Given the much smaller sample size in a clinical trial as compared to a nationally 
representative population level data, rare events of toxicity might be inaccurately detected  
(Ladewski, 2003; Hampson, 2002). Also, clinical trials often have insufficient statistical 
power to estimate treatment effects among subgroups of patients with certain demographic 
and clinical characteristics (Chen-Hardee, 2006).  
 
Apart from looking at clinical effectiveness and cost issues it is also important to evaluate the 
effect of primary prophylactic G-CSF administration on sustaining systemic therapy in the elderly. 
Older patients (>65 years) and individuals with higher number of comorbidities are more at risk of 
substantial planned and unplanned dose reductions due to fear of toxicities (Lyman, 2005; Shayne, 
2006; Shayne, 2007). Planned dose reductions before the start of chemotherapy for patients above 65 
years were higher than younger patients, irrespective of an occurrence of toxicity, indicating the 
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physician attitude about administering chemotherapy to older patients (Shayne, 2006). Increase in age 
is significantly positively correlated with early termination of chemotherapy and lower RDI 
(Chrischilles, 2003; Shayne 2006; Shayne 2007; Lyman, 2003b) due to fear of toxicity, which hinders 
recurrence free and overall survival. Thus there is a need for evidence supporting the benefits of 
sustenance of standard RDI chemotherapy administration in the elderly by means of prophylactic 
agents like G-CSF.   
 
Due to under-representation of older women in breast cancer clinical trials (Hutchins, 1999), 
and the unresolved challenges associated with including the elderly with comorbidities in clinical 
trials (Wild, 2003), treatment decisions for elderly women are often based on extrapolations from the 
results of trials on younger individuals, and also on subjective physician opinions with respect to the 
tolerance or suitability of the treatment among the elderly (Bergman, 1992; Yancik, 1989; Fentiman, 
1990). Given the improvement in life expectancy and the aging population in the US, it is important 
that the medical decisions for the older women are made based on direct scientific evidence, thereby 
requiring a careful evaluation of primary prophylactic G-CSF use among older women receiving 
chemotherapy.  There are studies using population level and nationally representative data that 
demonstrate a beneficial effect of primary prophylactic G-CSF on neutropenia, febrile neutropenia, 
and neutropenia hospitalization in both elderly and younger patients (Shayne, 2007; Shayne , 2006; 
Chrichilles, 2003; Scott, 2003; Weycker 2006; Chrichilles, 2002). Only one of these studies 
specifically looks at female breast cancer patients, and even that study does not specifically look at 
elderly patients (Shayne, 2006). Thus there is a dearth of studies on primary prophylactic G-CSF use 
in elderly female breast cancer patients receiving chemotherapy.  
 
The more recent ASCO guideline (2006) made special recommendations with respect to 
primary prophylactic G-CSF use in patients above 65 years of age (Table 3) (Gridelli, 2007). The 
guidelines indicate that primary prophylactic G-CSF should be administered when the risk of febrile 
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neutropenia is greater than 20% in a patient or when dose dense therapy is required. Elderly >65 years 
fall in the category of “special circumstances”, and physicians are advised to consider patients with 
these special circumstances (like age >65 years) when making a decision to administer primary 
prophylactic G-CSF even if the risk of febrile neutropenia is lower than 20%. Yet the guideline also 
stated that age alone cannot be an indication for primary prophylactic G-CSF administration due to 
the lack of studies validating the clinical effectiveness of primary prophylactic G-CSF for older 
individuals, thus clinicians should consider other patient risk factors as well. There are no explicit 
recommendations about whether or not primary prophylactic G-CSF can be administered purely on 
the basis of age >65 years even if the risk of febrile neutropenia is less than 20%.   The administration 
of primary prophylactic G-CSF in the elderly is clearly indicated in only one clinical setting (diffuse 
large cell lymphoma receiving relatively intensive chemotherapy) according to the guidelines.  
 
Due to the limited recommendations of the ASCO guidelines (Table 3), and lack of studies 
ascertaining the actual patient characteristics and risk factors associated with incidence of 
neutropenia, many physicians still consider “watchful waiting” to be a viable option during the first 
cycle of chemotherapy (Lyman, 2003b, Du, 2005). Thus, a population level study verifying the effect 
of primary prophylactic G-CSF on outcomes and costs in elderly patients is an important first step in 
validating the use of the expensive G-CSF in the elderly, and contributing towards ASCO and 
Medicare policies.  
 
2.8 Importance of using population level data for understanding the effect of primary 
prophylactic G-CSF administration 
 
There is a gap in the literature with regards to the effect of primary prophylactic G-CSF 
administration on the occurrence, cost and treatment of neutropenia in elderly female breast cancer 
patients. Thus in order to understand the significance of primary prophylactic G-CSF administration 
for the elderly female breast cancer patients, it is important to use an externally valid, nationally 
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representative, population-based data to estimate the effect of primary prophylactic G-CSF on: (1) 
reducing chemotherapy-induced neutropenia; (2) reducing utilization of neutropenia therapy and 
management such as hospitalization; (3) reducing Medicare expenditure of neutropenia management, 
and overall healthcare expenditure; (4) successful administration of systemic chemotherapy soon after 
breast cancer diagnosis. Population based data can provide externally valid and nationally 
representative estimates of hematologic toxicity rates as compared to clinical trials. Since a 
methodology to accurately identify chemotherapy toxicity is yet to be developed (Wu, 2000), and 
clinical trials under-report the toxicities (Hassett, 2006), claims data offer an inexpensive way with 
better external validity (Du, 2002).  
 
2.9 Conceptual framework 
 
This study looks at the effect of primary prophylaxis on neutropenia related outcomes and 
expenditures. The conceptual framework used in this study is displayed in Figure 3. The use of 
chemotherapy could result in the occurrence of numerous toxicities based on the intensity and type of 
dose administered (Webster, 1996; Perry, 1984; Erban, 2006; Shapiro, 2001; Du 2002). Among these 
toxicities the dose limiting acute hematological toxicity called neutropenia is of a major concern due 
to cost and clinical implications associated with it (Bodey, 1996; Lyman, 2004; Gandhi, 2001). As 
depicted by arrow 1, chemotherapy induces neutropenia occurrence in breast cancer patients, which in 
turn leads to increased health services utilization for neutropenia management and increased cost of 
patient care. Occurrence of neutropenia results in reduction of chemotherapy cycles administered 
after incidence of neutropenia, and change in administration of radiation therapy to prevent further 
worsening of the condition (Shayne, 2006; Chrischilles, 2003; Lyamn, 2004) as depicted by arrow 2. 
This change affects future chemotherapy and radiation therapy outcomes, as reduction in treatment 
intensity adversely affects the prevention of breast cancer recurrence and mortality as depicted by 
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arrow 3 (Chrischilles, 2003; Bouchardy, 2003; Budman, 1998; Bonneterre, 2005; Shayne, 2006; 
Lyman, 2003b; Weycker, 2006; Ozer, 2000).  
 
Neutropenia occurrence, related healthcare utilization and cost could be reduced by the use of 
primary prophylactic G-CSF. G-CSF can be used for primary (arrow 4a) and secondary prevention 
(arrow 4c), and treatment of neutropenia (arrow 4b), and can thus sustain future chemotherapy dose 
intensities (Table 2).  
 
Baseline characteristics like patient socio-demographic characteristics, clinical characteristics 
including tumor characteristics, and other therapies administered to the patient affect: 
1. The administration and dose intensity of chemotherapy (Hassett, 2006; Shayne, 2006; 
Shayne, 2007; Voelker, 2004; Berrios-Rivera, 2007; Lyman, 2004; Du, 2001; Du 2005a) – 
arrow 5.  
2. Administration of G-CSF (Hershman, 2007; Du, 2005; Chrischilles, 2003) – arrows 6a and 
6b.  
3. Neutropenia related outcomes like neutropenia hospitalization, length of stay for neutropenia 
hospitalization and hospitalization costs (Chrischilles, 2002; Shayne, 2007; Lyman, 2003a; 
Weycker, 2006; Chen-Hardee, 2006; Brooks, 2003; Lyman, 2004; Chrischilles, 2005; Du 
2002) – arrow 7.  
4. Future chemotherapy dose modifications (Chrischilles, 2003; Shayne, 2006; Chrischilles, 
2004; Lyman, 2004; Lyman, 2005) – arrow 8.  
5. Chemotherapy outcomes (Chrischilles, 2003) – arrow 9.  
  
 
CHAPTER 3 
Methods 
 
3.1 Dataset and rationale for the choice of the dataset 
 
Accomplishing the specific aims and ensuring external validity at the national level requires a 
nationally representative dataset that enables the identification of primary prophylactic G-CSF 
administration, along with the identification of chemotherapy administration, neutropenia occurrence, 
level of healthcare service utilization, Medicare expenditures, administration of other therapies, and 
patient socio-demographic and clinical characteristics. Population data improve the identification of 
chemotherapy-related toxicities, like neutropenia, by overcoming the under-reporting issues of 
clinical trials. The data also facilitate the estimation of actual healthcare utilization and Medicare 
expenditures at the population level. The population-based SEER linked to Medicare claims meets 
these requirements.    
 
This study uses the SEER-Medicare data containing newly diagnosed breast cancer cases 
from 1994 to 2002, linked to Medicare claims through 2003. The linkage of SEER and Medicare files 
are a collaborative effort between the National Cancer Institute (NCI), the SEER registries and the 
Centers for Medicare & Medicaid Services (Warren, 2002).  
 
The 17 geographic areas from which the SEER data are collected account for 25% of the US 
population. The data have been collected by NCI annually since 1973. Comparisons of SEER cancer 
mortality rates with those of the entire US population suggest that the SEER data are predominantly 
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representative of the national population (Warren, 2002). SEER data are very similar to the US 
population in terms of socio-demographic variables like age and gender, but the data have a higher 
proportion of non-whites, and more urban and affluent individuals. The data are valid, high quality 
and complete in terms of cancer incidence and diagnosis reporting in the United States (Warren, 
2002). The data contain information on the patient’s demographic characteristics (age, race, gender, 
marital status, education, income, geographic location), date of diagnosis, tumor characteristics 
(stage, grade, histology, size, lymph node positivity and hormone receptor status), presence of other 
malignancies, whether the cancer of interest is the first or a later malignancy, type of surgical 
treatment and radiation therapy recommended or provided within four months of diagnosis, follow-up 
of vital status, and cause of death. Thus, they provide sufficient information about variables known to 
influence primary prophylactic G-CSF administration and its clinical and cost effectiveness. Also, 
since the date of diagnosis is available in the SEER data it is easy to distinguish between prevalent 
versus incident cases, which is not possible with just the claims data.  
 
Medicare claims data are available for 97% of the US population 65 years and above, and 
include health service claims for care provided by physicians, inpatient hospital stays, hospital 
outpatient clinics, home health care agencies, skilled nursing facilities, hospice programs, and durable 
medical equipment suppliers. The inpatient (part A) claims are available from the year 1986. The part 
B physician service claims and outpatient services are only available from the year 1991. Also, since 
it was made mandatory under the National Claims History System from 1991 to include the diagnosis 
codes in the physician claims, diagnosis codes are present in all physician claims only from that year. 
Medicare claims can be used to construct co-morbidity indices for the patients, to identify any service 
utilization, and costs (Charlson, 1987; Romano, 1993; Deyo, 1992; Klabunde, 2000; Klabunde, 
2007). 
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Linking the Medicare claims to the SEER data provides a unique database to study cancer 
control, prevention, treatment, healthcare service utilization, and Medicare expenditures for patients 
above the age of 65 years. The SEER-Medicare data are an efficient and cost effective source of 
information on large heterogeneous, patient populations, unlike the geographically limited clinical 
trials (Potosky, 1993). These observational data include all women residing in a community setting, 
and biases such as volunteer bias in clinical trials and recall bias are also reduced.  Also, since SEER 
data have been collected from medical charts and pathology reports, they contain a wealth of 
information on cancer histology, type, stage and extent of spread. Medicare data have the advantage 
of being longitudinal, and also provide the ability to identify tests and procedures more accurately; 
claims data have higher sensitivity for tests and procedures than chart audits (Nattinger, 2002). The 
two datasets complement each other as they combine the details during initial diagnosis from chart 
review, with a lifetime of utilization and cost data from claims.  
 
Since the SEER Medicare database is large, it provides an opportunity to study the 
occurrence of neutropenia in breast cancer patients receiving chemotherapy with higher statistical 
power. It has been established that chemotherapy use in women above 65 years of age, rates of 
hospitalization for chemotherapy-induced toxicity (including neutropenia), and administration of G-
CSF can be identified using SEER Medicare data (Du, 2002; Earle, 2001; Schrag, 2001, Du, 2001a; 
Du, 2001b).  Chemotherapy and G-CSF are covered by Medicare and thus can be identified using the 
claims. Also, the validity and reliability of Medicare claims to identify chemotherapy administration 
has been successfully documented by previous studies (Warren, 2002; Du, 2005). Medicare has a 
high sensitivity for detecting the receipt of chemotherapy, which is around 88% for breast cancer. The 
claims code for the actual chemotherapy drug delivered, if present, is in high agreement with the drug 
as reported by comparative chart reviews in case of breast cancer. 
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One limitation of the data is that the chemotherapy drug is often not indicated in the claims in 
case of breast cancer. The sensitivity to identify specific chemo agents for breast cancer are 52.5% 
(Methotrexate), 76.2% (Cyclophosphamide) and 79.2% (5-FU). The sensitivity of other agents has 
not been verified (Warren, 2002). If the administrative data cannot be used to identify the specific 
agent, then it is difficult to identify the agent as breast cancer chemotherapy involves numerous 
agents. Also, frequency of the claims do not necessarily determine the frequency or duration of the 
chemotherapy since some providers bill Medicare for multiple administrations using just one claim. 
However, this is an issue only if we want to identify the actual chemotherapy drug, and we do not aim 
to accomplish that in this study. Claims data are very sensitive in identifying the chemotherapy 
administration itself.  
 
3.2 Characteristics of the population of interest 
 
The following criteria were used to select observations for the analysis sample: 
1. Age – Only those individuals with age at diagnosis of 66 years or above were included in 
order to obtain observations with at least one year of Medicare claims prior to diagnosis. The 
complete Medicare claims for a person start at the age of 65 years and at least one year of 
claims prior to diagnosis is required to construct the Charlson comorbidity index. 
2. Gender - Male breast cancer patients were excluded because on an average only .8% of new 
breast cancer cases every year occur in men in the US and their patho-physiology and 
treatment protocols are different from women (American Cancer Society, 2005).  
3. Time period – Only patients with date of diagnosis of the first primary breast cancer between 
the years 1994 to 2002 were included. The G-CSF HCPCS codes were introduced only in 
1994, hence G-CSF administration before that year cannot be identified. Thus, years prior to 
1994 were excluded.   
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4. Insurance - Individuals who are not enrolled in both Medicare part A and B, or who are 
enrolled in an HMO one year before and one year after the breast cancer diagnosis, were 
excluded as their claims records are usually incomplete. The time window for a year before is 
chosen because the modified Charlson comorbidity index is created for a year before 
diagnosis/chemotherapy administration. The upper limit is a year after because all breast 
cancer patients who received chemotherapy within six months of diagnosis were included, 
and any health outcome following the chemotherapy administration for at least up to six 
months was looked into. Hence insurance status one year after diagnosis is crucial for the 
analyses.  
5. Chemotherapy receipt – Breast cancer patients who receive the first cycle of the 
chemotherapy course within 6 months of diagnosis were included. Patients who do not get 
chemotherapy in the first 6 months but receive it after 6 months of diagnosis might be 
individuals who have had a recurrence of the disease. Chemotherapy in that case is not 
administered for the primary tumor but for the recurrence, and treatment protocol and 
prognosis are different for recurrence as compared to that for the primary tumor. Hence, 
patients who do not receive any chemotherapy or receive it after the first six months were 
excluded.  
6. Stages of cancer – Breast cancer therapy predominantly depends on the stage of breast cancer 
(Table 1). Hence the stages were narrowed down to I to III in this study to focus on patients 
who receive chemotherapy as a curative therapy with the aim of reducing recurrence and 
mortality. For stage I to III breast cancer patients, adequate dose intensity has the highest 
benefit in terms of disease free survival.  In stage IV breast cancer, chemotherapy is used just 
as a form of palliation to prolong and improve life. Physician attitude towards adherence and 
prescription of standard dose intensity is very different when treatment is used as palliation in 
stage IV cases. Delays and dose reductions are more common among stage IV cancer patients 
compared to patients at earlier cancer stages (Shayne, 2007), and extent of adherence to 
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standard chemotherapy dose is often a subjective decision between patients and physicians 
(Gridelli, 2007). Stage 0 cancer patients typically do not receive chemotherapy.  
7. Neutropenia diagnosis - All patients with a neutropenia diagnosis code before the first date of 
chemotherapy administration were excluded. Neutropenia diagnosis before the administration 
of chemotherapy could be a coding error, or a true but uncommon occurrence of neutropenia 
from some other cause. In that case the neutropenia diagnosis confounds the analysis, as it is 
difficult to tease out whether or not the later occurrences of neutropenia are chemotherapy-
induced. Since it is impossible to differentiate a coding error from a true occurrence of 
neutropenia before chemotherapy, these cases were excluded.  
8. End-stage renal disease - Individuals above 65 years of age with end-stage renal disease 
(ESRD) were excluded.  
9. Other Cancers - All patients with other cancers before the diagnosis of the first breast cancer 
were included. An indicator was developed to capture any prior occurrence of other cancers 
before the first breast cancer diagnosis.  
10. HIV/AIDS - Individuals diagnosed with HIV/AIDS were excluded as the physiological 
condition of their bone marrow is much different, and their complications are predominantly 
due to immuno-suppression as a result of HIV.  
11. Bone marrow and stem cell transplantation - All patients with bone marrow and stem cell 
transplantation one year before and after the first chemotherapy administration were 
excluded. Stem cell or bone marrow transplantation is often performed to enhance the 
hematopoietic process of the patient. A successful transplantation restores the blood cell 
production thereby preventing neutropenia irrespective of the administration of primary 
prophylactic G-CSF. On the other hand, stem cell or bone marrow transplantation is often 
performed in patients with a predisposition to leukopenia problems. Thus such a procedure 
could be indicative of a higher possibility of neutropenia in the patients until the 
transplantation becomes effective.  
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The result of these inclusions/exclusions and the remaining observations in the analytic data 
are shown in figure 4. The individuals of interest in the SEER-Medicare data based on these 
demographic and clinical characteristics were 10524 (337 treated individuals). Exclusion of missing 
variables leads to a sample size of 10441 (337 treated individuals), which is 99.21% of 10524. 
Matching based on all characteristics reduced the analytical sample size to 1760 (337 treated 
individuals). Matching in this study selects untreated observations closest to the treated observations 
and discards untreated observations that do not have appropriate matches among the treated. Treated 
observations are not discarded in this study. 
 
The decrease in the sample size from 10441 to 1760 after matching raises concerns about the 
statistical power of the study. However, it is important to remember that the decrease in the sample 
size is due to the small number of treated observations (337). There is diminishing gain in power if 
more untreated observations are added to the sample keeping the treated observations constant. On 
the other hand retaining untreated observations that do not have comparable matches will reduce the 
balance after matching and decrease the benefits of the matching process.  
 
3.3 Matching technique to account for non-random treatment assignment in primary 
prophylactic G-CSF administration  
 
Estimation of the treatment effects of primary prophylactic G-CSF ideally aims to estimate 
the difference in the occurrence of outcomes if there is a primary prophylactic G-CSF administration 
versus if there isn’t a primary prophylactic G-CSF administration for the same individual, at a given 
point in time. In the equation (A) below, yi1 denotes the outcome for a person if she obtains the 
primary prophylactic G-CSF at time t, and yi0 denotes the outcome for the same person if she does not 
obtain the primary prophylactic G-CSF at the same time t. The most commonly used estimator to 
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compute the effect of primary prophylactic G-CSF (treatment) on the outcome is the mean difference 
in yi1 and yi0 also known as the average treatment effect (ATE).  
 
ATE = E(yi1 – yi0)    (A) 
 
Here subscript i denotes each individual in the sample/population. In case of a randomized controlled 
trial this mean difference can be estimated by computing the mean difference in the groups having 
received primary prophylactic G-CSF and not having received primary prophylactic G-CSF. 
However, due to lack of randomization and selection into receiving the treatment, average treatment 
effect in observational studies are not simple to estimate.  
 
In case of observational studies, one is able to observe only yi0 or yi1 for an individual at a 
particular time t, because an individual observed at a point in time has either obtained the treatment or 
not obtained the treatment. The unobserved outcome for each individual is called the counterfactual 
outcome. As a result, the estimation faces the problem of missing data in terms of one missing 
outcome variable for each individual. If the treatment assignment is indicated by variable di, such that 
di=1 when the individual is administered primary prophylactic G-CSF and di=0 when the individual is 
not, then one observes yi0 for individual with di=0 and yi1 for individuals with di=1. Thus the outcome 
variable observed in the sample is: 
 
yi = (1-di)yi0 + di yi1     (B) 
 
One way to find the difference in effect, or the ATE is by using: 
 
ATE’ = E(yi|di=1) – E(yi|di=0) = E(yi1 |di=1) – E(yi0|di=0) (C) 
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where yi is the observed outcome of the individuals in the sample. ATE is equal to ATE’ only 
when the act of administering the treatment is independent of the outcome (Rosenbaum, 1983), and 
there is no selection involved in treatment administration, which is the case in randomized control 
trials. In other words when:  
 
ATE’ = E(yi1 |di=1) – E(yi0|di=0) = E(yi1) - E(yi0) = ATE   (D) 
 
where the second equality is true only when di  ||  (yi1, yi0). However, this independence does 
not exist in observational data because the administration of primary prophylactic G-CSF is not 
random. The administration depends on the physician’s judgment about the patient’s need for 
neutropenia prevention and baseline patient characteristics. Individuals who receive the treatment 
might be inherently different from individuals who do not, and hence their neutropenia related and 
chemotherapy related outcomes might be different even at the baseline. For instance individuals 
clinically at a higher risk of neutropenia, like individuals with higher co-morbidity indices, might 
have a higher likelihood of primary prophylactic G-CSF administration. In such cases, randomization 
of the treatment to patients is ideal because it balances all variables (observed and unobserved) except 
the outcome (yi) and treatment (di) across the two groups of treated and untreated patients.    
 
This problem could be partially solved by conditioning on observed variables Xi, where Xi 
are patient characteristics that determine the selection of the treatment by the physician as well as the 
outcome. Once these are controlled for, the outcome may become independent of the treatment. In 
other words di  ||  (yi1, yi0) | Xi. The conditional independence assumption is also called the 
ignorability of treatment assumption or no omitted variable bias assumption. The ignorability 
assumption implies that even if E (yi|di) =|=  E(yi), E (yi|di, Xi) = E(yi|Xi), and that the bias in 
treatment effect is predominantly contributed by observed variables ‘Xi’ (overt bias). The ignorability 
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assumption does not hold if there are unobservable variables (hidden bias) affecting the treatment 
assignment and outcomes.   
 
3.3.1 The implication of (yi1, yi0)  || di | p(Xi) 
It is important to understand that (yi1, yi0)  || di | p(Xi) or (yi1, yi0)  || di | Xi, implies that the 
correlation between the outcome yij (where j =1 for treated and 0 for untreated patients) and treatment 
administration di  is zero given Xi (The reverse is also true if 0 < P(d=1) < 1 – Lee, 2005). However, 
COR (yij, di | Xi) =0 does not imply COR (yi, di | Xi) =0, because the later means that the average 
treatment effect is zero (or primary prophylactic G-CSF has no effect on the outcome in case of this 
study) once the covariates are controlled for. Even if COR (yij, di | Xi) =0, E(yidi | Xi) is not equal to 
E(yi | Xi )E(di | Xi): 
 
E(yidi | Xi) = E{[di (di yi1 + (1- di) yi0 )] | Xi } = E(yi1di | Xi)  
 
E(yi1di | Xi) = E(yi1 | Xi) E(di | Xi)  (because COR (yij, di | Xi) =0)  
 
However E(yi1 | Xi) E(di | Xi)  =|=  E(yi | Xi) E(di | Xi)        
 
In other words the ignorability of the treatment assumption given the Xi does not imply that 
the average effect of the treatment on the outcome is zero give the Xi. It only means the selection of 
treatment assignment based on expected outcomes disappears conditional on Xi. On the other hand, 
the absence of a treatment effect on the outcome after controlling for the covariates does not imply 
that the ignorability assumption is true (Lee, 2005).  
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3.3.2 Preprocessing using matching to better control for Xi 
 
Most social science research uses different parametric or semi-parametric methods to control 
for covariates Xi that influence both the treatment and the outcome. Controlling for these observed 
covariates could make the assignment of treatment independent of the outcome, and hence make the 
observational data as close to a randomized control trial as possible. This independence holds only if 
two conditions are true – all variables affecting both outcome and treatment assignment are controlled 
for (no omitted variable bias), and the parametric or semi-parametric model/specification used to 
estimate the treatment effect is an unbiased estimator.  Thus, the estimator used should not only be 
robust to the omitted variable bias, but also robust to the model dependence. Analysis of 
observational data is often not robust to model dependence because of lack of common support 
between the treated and untreated units with regards to the covaraites (Xi). There are untreated units 
far outside the range of treated units and vice versa, and this requires extrapolations in ranges where 
there are no treated or untreated observations in order to compute the average treatment effects. These 
extrapolations in the sample are dependent on the model specifications and might not be true for the 
population (King, 2006). Imai, King and Stuart also demonstrate mathematically that in a randomly 
collected sample representative of the population, the source of errors is mostly due to the imbalance 
in the covariates between the treated and the untreated group (Imai, 2008).  
 
Preprocessing data by matching on the observed covariates, before using any 
model/specification to estimate a treatment effect, reduces the model dependence as illustrated by Ho 
(2007). Preprocessing data by matching brings the treated observations as close as possible to the 
untreated observations with regards to Xi, such that comparisons in the outcome are only made in the 
area of common support of Xi. It also breaks the link between the treatment variable and other 
covariates, and thus renders any parametric adjustment of Xi irrelevant or less important. Moreover, 
preprocessing using matching is a nonparametric method and hence the preprocessing itself is not 
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model/specification dependent. Preprocessing could also partially control for omitted variable bias. If 
unobserved heterogeneity between the treated and untreated observations are correlated with the 
observed variables, matching on the observed variables balances the unobserved variables to a certain 
extent.  
 
Preprocessing should however be followed by the parametric analysis in our case, since the 
matching performed is not exact, and residual imbalance remains. The subsequent parametric analysis 
will not be model dependent in theory due to the preprocessing, and also be doubly robust in terms of 
the treatment effect estimation (Robins, 2001). Although preprocessing involves dropping 
observations Ho and colleagues (2007) demonstrate how the process does not compromise the 
efficiency of the estimates and improves mean squared error. Matching not only reduces bias in the 
estimated treatment effect by ensuring that only two (or more) similar individuals are compared for 
computing treatment effects, it also reduces the variance of the treatment effect estimates in many 
situations. This reduction occurs because the variance of the coefficient on the treatment variable is 
directly proportional to the size of the correlation between the treatment variable and other covariates 
in the model. Since matching reduces this correlation, the variance drops. However, there is a trade-
off and dropping too many observations to improve the balance can offset this reduction in variance 
as the power of the analysis reduces. This is discussed in section 3.3.6.  
 
3.3.3 Matching based on a single propensity score versus the entire covariate vector 
 
Matching the patients on the observed characteristics is one way of conditioning on Xi. A 
completely non-parametric method of matching is covariate matching, and matching based on 
Mahalanobis distance is the most common method of covariate matching. The Mahalanobis distance 
is defined as: 
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md(Xi,Xj) = {(Xi – Xj)’ S-1 (Xi – Xj)}1/2      (E) 
 
S is the sample variance-covariance matrix of vector X. Untreated observations falling within 
a certain md() (in equation E) of the treated are matched with the treated. The difference between 
Mahalanobis matching and a simple covariate matching (that minimizes the Euclidian distance) is that 
the distance measure used to maximize the balance in covariates is standardized using the variance-
covariance matrix in case of the Mahalanobis matching. As a result of the standardization the scale of 
each variable becomes irrelevant. The Mahalanobis technique also takes into consideration the 
distribution of each variable and this is very essential for a statistically significant balance. 
 
Covariate matching poses a dimensionality problem especially if the vector of covariates is 
large. This can be resolved by matching on just a one-dimensional function of Xi, called the 
propensity score, instead of the entire vector. The propensity score, as defined by Rosenbaum and 
Rubin, “is the conditional probability p(Xi) (of treatment receipt) assigned to each observation, given 
a vector of observed covariates Xi”.  
 
Theoretically, if Zi are the factors that determine the choice of treatment di, along with some 
unobservable variables Ui, then based on the patient’s utility function, Vi = γ (Zi, Ui), a physician 
chooses di=1 if Vi >V*, where V* is the reservation utility/benefit for the patient. Similarly, outcomes 
are determined by: yi1 = γ1 (Wi, Ui1) and yi0 = γ0 (Wi, Ui0). Xi denotes the set of variables that are 
common for both the Zi and Wi.  
 
The propensity score matching  uses the assumption that controlling for a function of the Xi-
vector (which is probability p(Xi) in case of the propensity score matching) makes yij and di 
independent (Rosenbaum, 1983). This implies: 
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(yi1, yi0)  || di | p(Xi) (This is an extension of the ignorability of treatment assumption or no omitted 
variable bias assumption) 
 
In addition to this, Rosenbaum and Rubin make an additional assumption for propensity score 
matching, which is: 0 < P(di=1|p(Xi)) < 1. Thus the function p(Xi) does not perfectly predict the 
choice of treatment. This assumption is required because if there is perfect prediction then the 
possibility of finding matches between the treated and untreated groups with similar propensity scores 
will not be possible and the ATE becomes incomputable by a matching technique. This condition 0 < 
P(di=1|p(Xi)) < 1 can be ensured by not controlling for all variables in Zi to avoid perfect prediction, 
and this is achieved by using only those variables that are common to Zi and Wi (Heckman, 2004). 
Since covariates in Zi not in present Wi do not affect yi, there is no omitted variable bias. If the two 
assumptions (ignorability of treatment and 0 < P(di=1|p(Xi)) < 1) are satisfied, then propensity score 
matching will account for the selection problem (overt bias) and aid in the estimation of unbiased 
treatment effects. 
 
Using propensity score does have its cons. The propensity to receive treatment by an 
observation is never known and has to be estimated. The unbiased estimation of the propensity score 
depends on the model used to estimate it. Since estimation is not perfect in all cases, relying just on 
the propensity score for matching might not lead to the achievement of the best balance in covariates 
between treated and untreated observations.      
 
3.3.4 Types of matching techniques and options 
 
Multiple types of standard matching estimators exist: 
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1. Exact matching – A treated unit is matched to all possible untreated units that have the exact 
same value for each of the covariates as the treated unit itself. The downside to this type of 
matching is that most social science research involves multiple covariates, and exact 
matching on each one will lead to deletion of many treated (untreated) observations due to the 
lack of untreated (treated) observations with exact values for all the covariates.  
2. Nearest neighbor matching – The nearest untreated observation(s) for each treated 
observation is chosen. The matching could be limited with the use of a caliper measure. The 
caliper defines the maximum difference between the characteristics (covariates) of the treated 
and untreated observations for them to be matched. If no matches within the caliper are found 
the observation is discarded. The difference in magnitude of the propensity score is a type of 
caliper. The matching could also be limited on the basis of number of untreated matches per 
treated. If only one of the nearest matches is chosen for each treated observation, then it is a 
one-on-one matching. Multiple untreated observations could also be matched with one treated 
observation. 
3. Stratification or interval matching – The treated and untreated individuals are sorted into 
strata based on a function of the covariates, for example pre-specified ranges of the 
propensity score. 
4. Kernel matching – A counterfactual is generated for each treated observation using all 
untreated observations but the untreated observations are weighted differently based on the 
similarity in the matching measure e.g. the propensity score. For instance the untreated 
observation with the closest propensity score value as the treated observation will receive the 
highest weight.   
 
Typically the choice of the matching technique is not made ex-ante but is decided based on 
the degree of balance in Xi achieved by the matching technique (Ho, 2007; Lee, 2005). Balance looks 
at the similarity of distribution of Xi in the treated versus the untreated group. The matching 
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technique that balances the covariates the most is chosen to construct the matched data for further 
parametric analysis. The aim is to reduce the baseline difference between treated and untreated 
observations as much as possible and form pairs as close as possible.   
 
Other choices have to be made in order to bring the treated group as close to the untreated 
group as possible (Lee, 2005; Morgan, 2007; Ho, 2007). These choices involve decisions based on 
number of matches of untreated patients per treated patient, whether or not the number of matched 
untreated patients should be same or different for each treated patient, selection of untreated matches 
for each treated patient with and without replacement, whether or not a limit should be imposed on 
the magnitude of similarity in the propensity score between the treated and untreated observation (e.g. 
caliper), and whether or not the treated (untreated) patient should be dropped from the analytical 
dataset if no close matches exist. These choices are also made based on the nature of the data. For 
instance if the data have a larger number of untreated observations as compared to treated 
observations, matching each treated observation with multiple untreated observations, provided the 
matching is close enough, will increase the efficiency of the estimates. On the other hand if very few 
untreated observations exist compared to the treated observations then matching with replacement is 
recommended (Morgan, 2007; Ho, 2007). The primary aim while choosing among these techniques 
should be to reduce any imbalance between the treated and untreated groups.  
 
3.3.5 Automated algorithm for choosing the best matches and improving balance – Genetic 
Matching 
 
Balance between treated and untreated observations can be improved manually by testing 
different types of matching techniques and selecting the technique that achieves the maximum 
balance. Given the variety of matching options available achieving the most optimal balance 
manually is a tedious process. An automated search algorithm has been developed by Diamond and 
Sekhon (2006) to optimize balance while matching and to replace manual trial and error methods for 
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optimizing balance. The algorithm also combines the benefits of both propensity score matching and 
matching on the complete covariate vector (covariate matching).    
 
In order to obtain optimal balance in each one of the variables in X, the matching should be 
equal percentage bias reducing (EPBR). Traditional matching methods, based on propensity scores or 
Mahalanobis distance covariate matching, are EPBR if the covariates have an ellipsoidal distribution 
(normal/t-dist) (Rubin, 2006). When matching is EPBR for X, then the percent reduction in the biases 
(discrepancy between treated and untreated observations) of each of the matching variables is the 
same (Rubin 1976). If EPBR property does not hold, matching could increase the bias or not reduce 
the bias in some covariates, while reducing the bias for some others. Therefore, one of the chief 
reasons why good balance is not always obtained by matching observational data is because, given 
the nature of the variables in the data and their relationship to the treatment variable, the matching is 
not equal percentage bias reducing. 
 
EPBR rarely holds in real social science data, because even if a covariate is ellipsoidally 
distributed in the population, a given finite sample may have departures from the distribution. 
Moreover, binary/categorical variables are not ellipsoidally distributed. If pretreatment variables are 
not ellipsoidally distributed in a sample, then EPBR holds only if the true propensity score model is 
known. Also, traditional matching methods give equal weight to each coordinate/covariate of X while 
reducing bias (in case of covariate matching), or base the bias reduction on the specification of the 
propensity score (in case of propensity score matching). Thus, under traditional matching methods 
EPBR will only hold if the functional forms of the covariates used in covariate matching, or 
specification of the propensity score are correct.  
 
To overcome this issue and to automate the tedious process of optimizing the balance in 
covariates between the treated and untreated observation, a new matching algorithm called Genetic 
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matching has been introduced (Diamond, 2006; Sekhon, 1998). Genetic matching has been shown to 
dominate other matching methods both when EPBR holds and when it doesn’t (Sekhon, 2006; 
Diamond, 2005). This matching is non-parametric and is a mathematical generalization of the 
propensity score and Mahalanobis distance matching.  
 
The basic intuition of the algorithm is to search over the entire space of distance metrics 
(which includes the Mahalanobis distance metric) and obtain a distance metric that achieves the best 
possible balance. A generalized distance metric is represented as: 
 
d(Xi,Xj) = {(Xi – Xj)’ (S-1/2)’ WS-1/2 (Xi – Xj)}1/2    (F) 
 
where W is a weight matrix with non-zero parameters only in the main diagonal, and S1/2 is the 
Cholesky decomposition of the sample variance-covariance matrix S. Genetic matching estimates the 
appropriate weight for each coordinate of X by allowing the data to state the appropriate weight for 
each covariate while matching, without assuming equal weights for each X or matching based on a 
single parametrically estimated propensity score.  
 
The estimated propensity score or the linear predictor of the propensity score estimator 
should be included along with other pretreatment variables in the X vector (Sekhon, 2008). The 
importance of including the estimated propensity score is that if the propensity estimation 
specification is correct, and if indeed the propensity score matching ensures the best balance between 
the treated and untreated observations, then the algorithm will assign all the weight to the propensity 
score coordinate of X, and other pretreatment variables will have a weight of zero. On the other hand, 
the algorithm will converge to the Mahalanobis covariate matching if that is the appropriate distance 
measure for the best balance; all parameters of W will be ‘one’ except the weight corresponding to 
the propensity score (which will be zero). This method eliminates the need to re-perform matching 
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every time the post-matched data exhibits poor balance of X between treated and untreated 
observations by incorporating the balance optimization into the matching procedure.   
 
  The algorithm attains best optimal balance using the data by minimizing a measure of the 
maximum observed discrepancy in any coordinate of X between the treated and the untreated groups. 
The measure of discrepancy is in the form of p-values of paired t-tests for the covariates in the treated 
and untreated observations and Kolmogorov-Smirnov (KS) tests, or any other user defined measure. 
The KS test is equivalent to a t-test for binary variables. The statistics are just a measure of balance 
and are not used to conduct formal hypothesis testing, and the objective is to maximize balance 
between the two groups without bounds (Sekhon, 2008). Hence, the algorithm does not stop if the p-
values for the difference between the covariates in the treated group and untreated group becomes 
statistically insignificant (>0.05), but continues to optimize without limit until the best possible 
balance is reached.  
 
The balance in pretreatment variables between treated and untreated observations should be 
maximized without bounds because hypothesis testing to check balance between treated and untreated 
groups is theoretically incorrect. The aim is to achieve balance in the given data and not to test the 
expected balance in a super-population or population from which the sample is hypothetically or 
actually drawn. Balance in a sample is required to avoid extrapolation bias and should be tested 
directly in a sample without having to average over populations and super-populations. Moreover, 
hypothesis test between two groups are affected by other factors apart from balance, like the 
remaining sample size after discarding observations due to matching. Hence the test statistics are not 
monotone functions of balance. Ideally, the joint empirical distribution of all the pretreatment 
variables between the treated and untreated groups should be tested. Lower dimensional measures 
like t-test and KS test can be used, but they should be optimized without bounds as well.  
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The algorithm is based on the principles of population genetics (the criteria of “survival of the 
fittest”) and hence called the genetic algorithm. The genetic algorithm (GA) begins with an arbitrary 
population of trial solutions. Each trial solution is a vector of numbers that serve as parameters of the 
function to be optimized. In this case, the algorithm is used to estimate weights for the model 
pretreatment variables in equation B and hence the trial solution is a vector of weights. The GA uses a 
collection of heuristic rules to change one or more of these trial solutions in the current population to 
produce one or more trial solutions for the next set of population with the goal to ultimately construct 
a weight vector (one trial solution in the population of solutions) which achieves the best balance in 
the data. The heuristic rules are genetic operators based on the genetic process of reproduction 
(selecting some trial solutions better satisfying the optimization function and including them in the 
next population), mutation (randomly changing numbers in a population), and crossover and 
inversion (mixing and matching current set of trial solutions to get new ones). The advantage of this 
algorithm is that the function to be optimized need not be continuous and need not have derivatives in 
order for the optimization to work (Sekhon, 1998).    
 
Using a Markov chain method, Nix and Vos (1992) showed that if each population of trial 
solutions represents a state, and the heuristic rules determine the probability of changing from one 
state to the other in order to reach the global optimum, then the system is asymptotic in population 
size and converges to the global optimum with an increase in population size.  Thus the algorithm 
benefits from its asymptotic properties.   
 
3.3.6 Important issues and concerns to be considered  
 
Certain points should be kept in mind before preprocessing the data. First, to make sure that 
matching does not introduce any bias in the treatment effect estimation, all post-treatment variables 
that could be affected by the treatment itself, or that could be affected by the outcome after treatment, 
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should be kept out of the matching equation. Thus, any variable measured after treatment 
administration should not be included. Second, the variance reduction mentioned in section 3.3.2 
could be offset by dropping too many observations that do not have matches. If we desire bias 
reduction using as exact a matching as possible, it could mean lose of many observations (given the 
large size of the covariate vector X) and thus an increase in variance. Thus, exact matching is not a 
good option for our observational data. Third, variables that do not affect the treatment assignment 
should be kept out of the matching equation to avoid inefficiencies.  
 
The data analyzed in this study have a very small treated group (337 observations) and a large 
untreated group. Matching was used to discard untreated observations that did not match treated 
observations. The convex hull criterion was used for this purpose and untreated observations outside 
the convex hull of the treated observations were discarded. The convex hull for data is the smallest 
convex set that contains all the k-dimension data points, where k is the number of covariates in the 
data. When treated and untreated observations fall within each other’s convex hull they share a 
common support for all covariates; a technique to verify common convex hull between the treated and 
the untreated observations is a means of identifying common support (King, 2006). In case of one 
covariate, the common support can be identified by plotting a histogram of the covariate for the 
treated and untreated group and eliminating the areas that do not overlap between the two groups. 
This method is not possible if the covariate X vector is multidimensional. Thus the convex hull 
method provides conservative evaluation of common support when multiple variables are involved, 
and using the convex hull method in combination with the matching technique helps achieve the goal 
of reducing extrapolation and interpolation bias, and consequently reduces the model dependence. 
When estimating causal effects, the counterfactual used to estimate the effect should be within the 
convex hull of the observed data, otherwise the analysis leads to extrapolation bias and model 
dependence (King, 2006).   
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Since matching is performed before parametric analysis, it is important to determine the 
standard errors estimation for the average treatment effect estimates from parametric analysis. 
Researchers using non-parametric techniques to estimate ATE use elaborate procedure, to compute 
variance estimates after matching. However, in this analysis, matching is only used for pre-processing 
the data as a function of the observables. This is followed by the parametric estimation, which again 
treats the observables as fixed or exogenous. Thus, as Ho and colleagues have suggested, we use the 
variance and standard error estimates which are part of the parametric estimation (Ho, 2007) thereby 
treating the observables and the entire preprocessing procedure as fixed.    
 
3.4 Estimations and Hypotheses 
 
This study looks at the effect of primary prophylactic G-CSF administered within 5 days of 
chemotherapy initiation (Figure 1) on the occurrence of chemotherapy-induced neutropenia 
hospitalization and length of stay; Medicare expenditures due to neutropenia management, and 
overall expenditure in the first year after the start of chemotherapy; and successful administration of 
systemic cancer therapy that could otherwise be hindered by occurrence of neutropenia. The 
conceptual framework behind the hypotheses is illustrated in figure 3.  
 
3.4.1 Determinants of primary prophylactic G-CSF administration  
 
The likelihood of primary prophylactic G-CSF administration based on patient socio-
demographic characteristics, clinical characteristics, and type of chemotherapy and other therapies 
administered, was estimated using a logistic regression model. The analysis aimed to identify the 
determinants of primary prophylactic G-CSF administration in elderly female breast cancer patients 
receiving chemotherapy. The predicted value of the dependent variable for each individual from this 
logistic model, denoted by p(Xi), was used as the propensity score for that individual.   
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The following equation was analyzed for ascertaining the likelihood of primary prophylactic 
G-CSF administration: 
 
P1(di=1| Xi) = F1(λi, φi, ρi, τi, ε1i)                    (1) 
 
• The treatment, di, is a variable indicating the administration of primary prophylactic G-CSF 
within the first five days of the first course chemotherapy initiation (the very first cycle). 
Administration of primary prophylactic G-CSF was identified by procedure codes for all the 
commercially available G-CSF drugs - Filgrastim, Pegfilgrastim, Lenograstim and 
Sargramostim, from the Medicare Claims. Since G-CSF is administered both as a 
prophylactic as well as a therapeutic drug for neutropenia, it is hard to distinguish if the G-
CSF was administered prophylactically or in response to some neutropenic symptoms, using 
claims data. In order to prevent misclassification of therapeutic or secondary prophylactic use 
of G-CSF as primary prophylaxis, we have restricted the primary prophylactic G-CSF 
administration window to just 5 days after the first course chemotherapy initiation which is in 
line with other claims based studies (Weycker 2006; Chrischilles, 2002). Primary 
prophylactic G-CSF is administered at least 24 hours after the first chemotherapy cycle, but 
mostly within 2-3 days of administering a cycle of chemotherapy. Neutropenic symptoms 
begin within a week after chemotherapy administration and peak after two weeks (Perry, 
1984; Shapiro, 2001). Thus, any administration of G-CSF within 5 days of chemotherapy 
initiation is not therapeutic. Moreover, studies also show that primary prophylactic 
administration of G-CSF after the first five days of chemotherapy initiation are less effective 
in preventing neutropenia (Crawford, 1997; Kuderer 2007), and hence a 5-day window 
following the first chemotherapy cycle for primary prophylactic G-CSF administration is a 
crucial period to analyze. 
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• λi denotes patient socio-demographic characteristics comprising of age, race, marital status, 
socio-economic status (primarily education and income), geographic area of residence and 
urbanicity. These patient socio-demographic characteristics are obtained from the SEER 
records. 
 
• φi denotes patient clinical characteristics comprising of modified Charlson comorbidity index 
(Charlson, 1987; Klabunde, 2002), relevant clinical history one month prior to chemotherapy 
initiation (including occurrence of infection, administration of antibiotics, and 
hospitalization), presence of other primary cancers before the first breast cancer diagnosis, 
and tumor characteristics (stage, tumor grade, tumor size, lymph node involvement, and 
hormone receptor status).  Patient clinical characteristics are obtained from the SEER records 
as well as the Medicare Claims.    
 
• ρi denotes the group of variables representing breast cancer therapy administered to the 
patient, which includes chemotherapy characteristics, and administration of other therapies 
like surgery and radiation therapy before primary prophylactic G-CSF administration. 
Provision of other therapies like surgery and radiation therapy are obtained from both the 
SEER and Medicare databases. Chemotherapy characteristics include - whether or not the 
first chemotherapy cycle was anthracycline based, the number of drugs in the first cycle, and 
the duration between the first and second cycle. These indicators were obtained from the 
claims data. Anthracycline drug regimen has a higher probability of toxicity and hence needs 
to be controlled for (Lyman, 2003c; Lyman 2004). The number of drugs and the duration 
between the cycles are a measure of chemotherapy intensity. All characteristics for 
chemotherapy are measured only in the first cycle (not the entire first course). G-CSF is 
administered within five days after the first cycle (which is the start of the first course) and 
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hence the other chemotherapy characteristics after the first cycle are post-treatment variables, 
which could be influenced by the treatment itself, and so should not be controlled for.  
 
• Time trends are controlled by using indicator variables for each year (τi). The indicator 
variables were based on year of chemotherapy administration and were obtained from the 
Medicare data containing chemotherapy claims.  
 
• Xi denotes all the independent variables controlled for in the model, namely λi, φi, ρi, τi.  
 
• ε1i was the error term in this model.  
 
The probability distribution F1 was assumed to be logistic for equation (1), and hence a 
logistic regression was used to estimate the propensity score in this study. Once the propensity score 
was computed and the analytic dataset with matched treated and untreated patients was created using 
genetic matching, all the below-mentioned hypotheses (sections 3.4.2 to 3.4.5) are tested. Different 
specifications and higher order terms were evaluated before arriving at the final model estimating the 
probability of primary prophylactic G-CSF administration.   
 
3.4.2 Effect of primary prophylactic G-CSF on neutropenia prevention 
 
The initial aim of this study was to estimate the effect of primary prophylactic G-CSF 
administration on reducing the occurrence of neutropenia, for elderly female breast cancer patients 
receiving chemotherapy.  The occurrence of clinical neutropenia (marked by a drop in the neutrophil 
count in the blood below 2000/microL) without hospitalization cannot be identified using claims data, 
since many cases of mild neutropenia go unreported. Also, in practice the ICD-9-CM diagnosis code 
used to identify neutropenia (288.0x) is used while filing claims for all G-CSF administrations, even 
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if no neutropenia has occurred and G-CSF is administered as a preventive therapy for neutropenia. 
These practices compromise the sensitivity and specificity of using claims to identify neutropenia 
alone. However, if a patient is serious enough to be hospitalized due to very low neutrophil count or 
febrile neutropenia (fever with neutrophil drop) then the diagnosis code recoded as the cause of 
hospitalization is definitely indicative of a neutropenia occurrence. Thus, in order to measure the 
treatment effect of primary prophylactic G-CSF administration on neutropenia prevention, 
neutropenia hospitalization was used as the dependent variable of interest. 
 
 
The following hypothesis was tested: 
 
Hypothesis 1: Administration of primary prophylactic G-CSF reduces the occurrence of 
neutropenia hospitalization following initiation of chemotherapy for elderly female breast cancer 
patients.  
 
Three indicators for the first neutropenia hospitalization were developed for three different 
time periods after the start of first course chemotherapy using the claims data. The first indicator 
captures whether or not a neutropenia hospitalization occurred during the first month after 
chemotherapy initiation. The other two indicators are used to capture the same indicator for a time 
window of three and six months after chemotherapy initiation, respectively. Neutropenic symptoms 
begin within a week after chemotherapy administration and peak after two weeks (Perry, 1984). Thus, 
the first month captures the immediate effect of primary prophylactic G-CSF administration on 
neutropenia occurrence. The time periods 3 and 6 months capture the entire period of first course 
chemotherapy, which lasts from about 3 to 6 months after chemotherapy initiation.  
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The following equation was analyzed for ascertaining the likelihood of neutropenia 
occurrence: 
 
P2(Yi=1|di, Xi) = F2(di, λi, φi, ρi, τi, ε2i)                    (2) 
 
where the dependent variable Yi is an indicator denoting the occurrence of the first neutropenia 
hospitalization (within one, three or six months) and di is the indicator for administration of primary 
prophylactic G-CSF. The other independent variables controlled for (λi, φi, ρi, τi) are the same as 
mentioned above. F2 was assumed to be a logistic distribution and a logistic regression model was 
used to assess the occurrence of neutropenia hospitalization.  
 
3.4.3 Effect of primary prophylactic G-CSF on neutropenia-related healthcare utilization 
 
After a neutropenia hospitalization, a patient is not usually discharged until she recovers from 
fever and associated infections, and her neutrophil count improves. Thus, healthcare utilization 
(measured by length of stay due to neutropenia hospitalization) is an indicator for severity of the 
neutropenia. In order to estimate the effect of primary prophylactic G-CSF on the neutropenia-related 
healthcare utilization in elderly female breast cancer patients receiving chemotherapy, the following 
hypothesis was tested: 
 
Hypothesis 2: Administration of primary prophylactic G-CSF reduces the duration of 
neutropenia hospitalization, for elderly female breast cancer patients receiving chemotherapy  
 
The length of stay for the first neutropenia hospitalization was measured using the Medicare 
in-patient files. Since three different time-periods were observed to develop the indicator for the first 
neutropenia hospitalization, three corresponding variables with lengths of stay were developed.  
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The equation used for the analysis was: 
 
E (LOSi | Yi =1, di, Xi) = F3(di, λi, φi, ρi, τi, ε3i)                     (3) 
 
Here LOSi  represents the duration of hospitalization for neutropenia. An ordinary least square 
regression model was used to assess the effect of primary prophylactic G-CSF on the duration of 
hospitalization for the management of neutropenia. Xi ‘s comprised of the same independent variables 
referred to above (λi, φi, ιi, ρi, τi).  
 
A logarithmic form for the lengths of stay variables was used during the least square 
regression because the lengths of stay were skewed to the right thereby creating a possibility that the 
error terms in the model are not normally distributed. A graphical examination of the lengths of stay 
demonstrated that the dependent variables have a lognormal distribution. However, since this is the 
distribution of the unconditional dependent variable, it is not indicative of the distribution of the error 
term that depends on the distribution of the dependent variable conditional on the covariates. In order 
to conclusively decide the model specification a Box-Cox test was performed which supported the 
use of a logged dependent variable for the lengths of stay.  
 
3.4.4 Effect of primary prophylactic G-CSF on Medicare Expenditures 
 
G-CSF is expensive, and thus it was interesting to see if cost savings are associated with 
primary prophylactic G-CSF administration. Neutropenia, especially in the presence of infections and 
fever, requires immediate hospitalization for evaluation and aggressive administration of empiric 
broad-spectrum antibiotics to control the infection. The largest share (62% to 82%) of direct 
healthcare costs for cancer patients suffering from neutropenia are expensive hospitalization costs 
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including diagnostic tests and antibiotic administration for treating life threatening systemic infections 
and febrile neutropenia (Kurderer, 2006; Leese, 1993; Dranitsaris, 1995). Most of the hospitalization 
cost is associated with length of stay and level of neutropenia complications. Thus, examining any 
reduction in expenditure of neutropenia hospitalization with primary prophylactic G-CSF 
administration was one important aspect of this cost.  
 
Also, dose reduction and dose delay to control neutropenia hinder the effective administration 
of a planned treatment regimen, diminish the efficacy of chemotherapy and radiation therapy, harm 
patient health outcomes and prognosis, and increase the probability of recurrence and mortality 
(Baquiran, 2001; Webster, 1996; Welte, 1996; Lyman, 2002; Ziegler, 2006).  Hence the overall 
treatment costs might increase due to lose of efficacy of the chemotherapy and radiation therapy 
regimen. Managing recurrence and worse prognosis could also increase the healthcare costs. Thus, 
overall treatment costs during the first year following the chemotherapy initiation (when bulk of the 
curative cancer treatment takes place in stages I to III) might be affected by primary prophylactic G-
CSF. Possible second course chemotherapy administration in the first year due to ineffective first 
course administration, a more spread out but less intense first course chemotherapy, early recurrence 
in the first year, increased hospitalization due to neutropenia, and antibiotic administration for 
managing neutropenia symptoms even in the absence of neutropenia hospitalization could increase 
the costs for patients not receiving G-CSF. 
 
In order to estimate the effect of primary prophylactic G-CSF use on neutropenia-related 
Medicare expenditures, and overall Medicare expenditures during the first year after chemotherapy 
initiation in elderly female breast cancer patients, the following hypothesis was tested: 
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Hypothesis 3: Administration of primary prophylactic G-CSF reduces the neutropenia 
hospitalization expenditure, and the first year’s Medicare expenditures following the initiation of 
chemotherapy in elderly female breast cancer patients.  
 
Two groups of variables for Medicare expenditures were developed: 
 
1. Three expenditure variables corresponding to the three different time periods used for 
observing the first neutropenia hospitalization were developed. Neutropenia hospitalization 
expenditures in the Medicare inpatient files associated with the first neutropenia 
hospitalization were used to estimate these variables. 
2. Overall healthcare expenditure for breast cancer patients in the first year after the initiation of 
chemotherapy.  
 
The neutropenia hospitalization expenditure associated with the first neutropenia 
hospitalization was recorded from the Medicare inpatient files. Inpatient, outpatient and physician 
office claims are used to construct the overall healthcare expenditures during the first year after the 
start of primary prophylactic G-CSF.  
 
The equation used for estimation of the difference in neutropenia hospitalization expenditures 
(NHE) with and without primary prophylactic G-CSF is: 
 
E (NHEi | Yi =1, di, Xi) = F4(di, λi, φi, ρi, τi, ε4i)                      (4) 
 
The equation used for estimation of the difference in overall Medicare expenditures (ME) in 
one year following chemotherapy initiation with and without primary prophylactic G-CSF is: 
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E (MEi | di, Xi) = F5(di, λi, φi, ρi, τi, ε5i)                      (5) 
 
An ordinary least square regression was used to estimate the affect of primary prophylactic 
G-CSF on expenditures for female breast cancer patients receiving chemotherapy. A logarithmic form 
for the expenditure variables was used during the least square regression because the expenditures 
were skewed to the right thereby creating a possibility that the error terms in the model are not 
normally distributed. A graphical examination of the expenditures demonstrated that the dependent 
variables have a lognormal distribution. However, since this is the distribution of the unconditional 
dependent variable, it is not indicative of the distribution of the error term that depends on the 
distribution of the dependent variable conditional on the covariates. In order to conclusively decide 
the model specification a Box-Cox test was performed which supported the use of a logged dependent 
variable for the expenditures.  
 
3.4.5 Effect of primary prophylactic G-CSF on systemic therapy 
 
The most noteworthy contribution of primary prophylactic G-CSF has been in sustaining 
systemic therapy administration that are otherwise hindered due to neutropenia occurrence (Webster, 
1996; Lyman, 1998; Shayne, 2006). Both chemotherapy and radiation therapy are aimed at inhibiting 
cancer cell growth. Since both therapies are systemic in nature they also have an effect on other 
normally dividing cells in the body, like the bone marrow cells. Thus, further chemotherapy and 
radiation therapy could worsen the drop in neutrophil count, and hence the systemic therapies are 
stopped, delayed or reduced in intensity to manage neutropenia. Prevention of neutropenia ensures 
adherence to standard treatment protocols, and continued administration of systemic therapy 
throughout the initial breast cancer treatment period.  
 
  57
The following hypotheses are tested in order to examine the effect of primary prophylactic G-
CSF in sustaining systemic therapy: 
 
Hypothesis 4: Administration of primary prophylactic G-CSF increases the probability of 
administering radiation therapy during the first course of chemotherapy.  
Hypothesis 5: Administration of primary prophylactic G-CSF increases the number of 
chemotherapy cycles administered during the first course. 
 
A logistic regression model was used to estimate the probability of administration of radiation 
therapy after initiation of chemotherapy, and probability of administering more than five cycles of 
chemotherapy during the first course using the following equation: 
 
P6(STi=1|di, Xi) = F6(di, λi, φi, ρi, τi, ε6i)                    (6) 
 
 where STi represents the indicator for administration of radiation therapy after chemotherapy 
initiation and the indicator for administering more than five chemotherapy cycles during the first 
course.  
 
Indicators were developed to measure the administration of chemotherapy and radiation 
therapy after the start of the first course chemotherapy. The two main indictors were: 
1. Administration of any radiation therapy during the first course. 
2. Administration of more than five cycles of chemotherapy during the first course.  
 
The reason why more than five cycles during the first course was used as a marker for 
clinically adequate chemotherapy was because an average first course has around 6 cycles (or more). 
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3.5 Measures 
 
The SEER-Medicare dataset provides good measures of most variables required for the 
analysis. Table 4 gives the variable name, the source (Medicare claims versus SEER data), the claims 
codes used and the time period for which the variable was constructed, if applicable.  
 
3.5.1 Dependent Variables 
 
3.5.1.1 Neutropenia Hospitalization  
 
Three indicators for the first neutropenia hospitalization following the start of chemotherapy 
were developed for three different time periods after the start of chemotherapy using the claims data. 
The first indicator captures whether or not a neutropenia hospitalization occurred during the first 
month after first course chemotherapy initiation. The other two indicators are used to capture the 
same indicator for a time window of three and six months after chemotherapy initiation, respectively. 
 
3.5.1.2 Neutropenia Hospitalization Length of Stay 
 
Length of stay due to neutropenia hospitalization is an indicator for severity of the 
neutropenia, and was measured from the length of stay reported in the Medicare in-patient files after 
the first neutropenia hospitalization. Since three different time-periods were observed to develop the 
indicator for the first neutropenia hospitalization, three variables with corresponding lengths of stay 
were developed. A logarithmic form for the lengths of stay variables was used during the least square 
regression because the lengths of stay were skewed to the right thereby creating a possibility that the 
error terms in the model are not normally distributed. A graphical examination of the lengths of stay 
demonstrated that the dependent variables have a lognormal distribution. However, since this is the 
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distribution of the unconditional dependent variable, it is not indicative of the distribution of the error 
term that depends on the distribution of the dependent variable conditional on the covariates. In order 
to conclusively decide the model specification a Box-Cox test was performed which supported the 
use of a logged dependent variable for the lengths of stay.  
 
3.5.1.3 Expenditures 
 
Two groups of variables for Medicare expenditures were developed: 
 
1. Three expenditure variables corresponding to the three different time periods used for 
observing the first neutropenia hospitalization were developed. Neutropenia hospitalization 
expenditures in the Medicare inpatient files associated with the first neutropenia 
hospitalization were used to estimate these variables. 
2. Overall healthcare expenditure in the first year after the initiation of chemotherapy.  
 
The neutropenia hospitalization expenditure was recorded from the Medicare inpatient files, 
associated with a neutropenia hospitalization. Inpatient, outpatient and physician office claims are 
used to construct the overall healthcare expenditures during the first year after the start of 
chemotherapy.  
 
A logarithmic form for the expenditure variables was used during the least square regression 
because the expenditures were skewed to the right thereby creating a possibility that the error terms in 
the model are not normally distributed. A graphical examination of the expenditures demonstrated 
that the dependent variables have a lognormal distribution. However, since this is the distribution of 
the unconditional dependent variable, it is not indicative of the distribution of the error term that 
depends on the distribution of the dependent variable conditional on the covariates. In order to 
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conclusively decide the model specification a Box-Cox test was performed which supported the use 
of a logged dependent variable for the expenditures.  
 
3.5.1.4 Systemic cancer therapy variables 
 
Indicators were developed to measure the administration of chemotherapy and radiation 
therapy after the start of the first course chemotherapy. The two main indictors were: 
 
1. Administration of any radiation therapy during the first course. 
2. Administration of more than five cycles of chemotherapy during the first course.  
 
The reason why more than five cycles during the first course was used as a marker for 
clinically adequate chemotherapy was because an average first course has around 6 cycles (or more).  
 
3.5.2 Independent Variables 
 
3.5.2.1 Primary prophylactic G-CSF administration and duration 
 
Administration of primary prophylactic G-CSF was identified by procedure codes in the 
outpatient and physician claims for all the commercially available G-CSF drugs - Filgrastim, 
Pegfilgrastim, Lenograstim and Sargramostim. G-CSF begun within 5 days of the first chemotherapy 
administration was considered primary prophylaxis. Since primary prophylactic G-CSF is 
administered to prevent chemotherapy induced neutropenia occurrence, and chemotherapy induced 
neutropenia can occur from the very first week of chemotherapy initiation, primary prophylaxis 
should be started soon after the first course chemotherapy. As mentioned above, the earliest G-CSF 
can be given is after 24 hours of chemotherapy administration. Also, studies show that prophylactic 
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administration of G-CSF after the first five days of chemotherapy initiation are less effective in 
preventing neutropenia (Crawford, 1997; Kuderer 2007), and hence a 5-day window period is 
important for evaluating “primary” “prophylactic” G-CSF administration. 
  
In order to understand the G-CSF administration claims, it is important to know the following 
facts. 
 
1. Commercially available G-CSFs are Filgrastim, Pegfilgrastim, Lenograstim and 
Sargramostim, with Filgrastim being the most commonly used product (86% of primary 
prophylactic use in this study) (Welte, 1996). Lenograstim is rarely used in the United States 
and is not present in the Medicare files used in this study. Pegfilgrastim is not present for the 
time period examined in this study – 1994 to 2002.  
2. Sargramostim is also referred to as granulocyte-macrophage colony stimulating factor (GM-
CSF), and in this study both G-CSF and GM-CSF are referred to as G-CSF, as some other 
authors had done previously (Hershman, 2007).  
3. Filgrastim is usually administered intravenously or subcutaneously at 5 micrograms per 
kilogram per day, 24-hours after chemotherapy administration, and continued for up to 2 
weeks or till the neutrophil count exceeds the 10,000/microL (Package insert – Amgen; Ellis, 
2002; Baquiran, 2001; Du, 2005).  
4. Empirical studies show that if primary prophylactic G-CSF is administered, the first dose of 
G-CSF is given after 24-hours, and most often within three days of a chemotherapy cycle. 
The primary prophylaxis is definitely administered by the first five days of a chemotherapy 
cycle. The 24-hour wait period after a chemotherapy cycle administration is to prevent 
cytotoxic changes in the stem cells stimulated by G-CSF from the still active 
chemotherapeutic drugs. Rarely some physicians initiate primary prophylactic G-CSF after 
seven to 10 days following a chemotherapy cycle administration. Also, in practice the entire 
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prophylactic course is given for less than a week in breast cancer patients receiving 
chemotherapy (Weycker, 2006).  
5. Pegfilgrastim (pegylated filgrastim) is a relatively new drug, and its use in community 
practice has just begun. It has been shown to be more cost effective and clinically efficacious 
than filgrastim or lenograstim in various clinical trials (Kuderer, 2007; Kuderer, 2005). 
Pegfilgrastim, due to the pegylation, is longer lasting and hence requires administration only 
once per chemotherapy cycle (2-3 weeks). Filgrastim, on the other hand, needs to be given 
every day for 1 to 2 weeks after its start.   Therefore Pegfilgrastim is ideal for higher dose 
dense or more frequently administered chemotherapies (every 2 weeks; regular chemotherapy 
is every 3 weeks), as it can be injected into the patient whenever she comes for her 
chemotherapy cycle, and the patient need not visit the provider everyday just for receiving a 
shot of G-CSF. 
 
Duration of the primary prophylactic G-CSF is the number of consecutive days the primary 
prophylactic G-CSF is administered. It is important to keep in mind that the duration is different for 
Pegfilgrastim, as it is not meant to be administered everyday. However, Filgrastim was the most 
common drug encountered in claims (86% of primary prophylactic use in this study). Pegfilgrastim 
was FDA approved only on January 2002 and did not appear in the claims for the years under study 
(1994-2002).  
 
Claims data have some limitations in determining the duration of G-CSF administration. G-
CSF is administered as an outpatient or in the physician’s office. If the patient is admitted, then the 
inpatient claims do not indicate G-CSF administration. In most cases, if the G-CSF is started with 
chemotherapy and then the patient gets hospitalized, G-CSF administration is continued, but the 
duration cannot be established while the patient is an inpatient.  
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Another reason why G-CSF duration cannot be accurately measured is because G-CSF is 
reimbursed by Medicare only if patients obtain it under physician supervision; if G-CSF is self-
administered then the patient has to pay for it out of pocket and the administration does not show up 
in Medicare claims. Most patients do obtain it at the physician’s office or as outpatients, due to the 
high cost of G-CSF, which makes out of pocket payments unaffordable. However, if the patients have 
supplementary insurance or are located at a considerable distance from the nearest provider, they 
might choose to self-administer at least part of the G-CSF course. The patients might obtain the initial 
shots at the doctor’s office, and once they are confident of the administration technique, they could 
self-administer it. In such cases claims data are inadequate to measure G-CSF duration.  
 
However, the main variable of interest in this study was the dummy variable for whether or 
not primary prophylactic G-CSF was administered. Unlike its effect on measuring duration, the 
choice to self-administer G-CSF had very little effect on the sensitivity to identify a primary 
prophylactic G-CSF administration. Primary prophylactic G-CSF, as defined in this study, is 
administered for the first time to the patient soon after the first cycle of the first course. The first few 
administrations occur predominantly at the physician’s office and are reimbursed by Medicare.  
 
Three variables were developed to capture primary prophylactic G-CSF administration: 
 
1. An indicator for whether or not G-CSF was administered within the first five days of the start 
of chemotherapy. This was the chief variable of interest. 
2. A continuous variable for the number of days primary prophylactic G-CSF was administered.  
3. An indicator variable for whether or not the number of days primary prophylactic G-CSF was 
administered for was greater than or equal to five. Empirical studies show that although G-
CSF administration duration is recommended for 10-14 days, in practice prophylactic G-CSF 
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is administered only for 4-7 days (Weycker, 2006). Thus, five days were considered to be the 
lower limit for a clinically adequate primary prophylactic G-CSF administration.  
 
3.5.2.2 Patient socio-demographic characteristics 
 
An increase in age is significantly correlated with early termination of chemotherapy, lower 
RDI, G-CSF administration and all other clinical outcomes (Chrischilles, 2003; Shayne 2006; Shayne 
2007; Lyman, 2003b; Du, 2005; Chen-Hardee, 2006), thus it is important to control for this variable. 
Since the study period does not span more than 12 to 18 months after diagnosis, age at diagnosis was 
used in the analyses instead of current age. Age at diagnosis is present in both the SEER data and 
Medicare Enrollment Database (EDB). The study relies on Medicare EDB data for age because social 
security information on age is considered to be highly accurate (Bach, 2002). 
  
Race has been shown to be correlated with chemotherapy administration, G-CSF 
administration, and other clinical outcomes (Du, 2001; Du, 2005; Lyman 2004). The race indicator 
present in the data is reliable for blacks and whites and has a high agreement between SEER and 
Medicare records. A recent validation of Medicare showed that Asians and native Americans have a 
very low sensitivity, though a high specificity (Arday, 2000). The indicator for Hispanics is 
inconsistent between the SEER and Medicare, since in the Medicare files it is classified as a type of 
race, which is identified by an individual’s social security application, and in SEER it is a type of 
ethnicity identified using algorithms for Spanish last names. Thus the SEER algorithm often 
misclassifies Hispanic women. Nevertheless, the SEER ethnicity variable is more sensitive than the 
Medicare variable (Bach, 2002). The most commonly used Race/Ethnicity variable in statistical 
analysis is the Race Recode B variable in the SEER data, which combines the race and the Hispanic 
ethnicity information in the SEER-Medicare. The “Race Recode B” variable was used in this study. 
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Since the number of observations in the minority races was very low, a single indicator for white was 
used.  
 
Marital status predicts both chemotherapy receipt and G-CSF administration (Du, 2001; Du, 
2005); the presence of a spouse may encourage adherence to treatment protocols. An indicator for 
marital status is available in the SEER data. A single indicator for whether or not the person is 
married was used.  
 
Socioeconomic status (SES) variables are important covariates in the analysis because they 
affect the administration of chemotherapy and G-CSF, and overall clinical outcomes (Du, 2005; 
Shayne 2006; Shayne 2007). The only individual level SES variable in the data is the state buy-in 
(SBI) variable, which indicates that the individual is low income as she receives Medicaid 
Supplemental Insurance (MSI). However, the MSI variable is specific but not sensitive to poverty as 
most poor individuals do not apply for SBI. Due to privacy concerns, education and income are 
aggregate measures at a census tract level or Zip code level. Some aggregations are further broken 
down by race and age group.  
 
The aggregate measures, however, are that they are noisy at an individual level. They have 
construction validity issues as they often end up capturing neighborhood related health effects instead 
of SES related health effects. Studies comparing the aggregate measures with the original individual 
measures stated that the aggregate measures had much lower power and poorer predictive capacity 
compared to individual measures (Greenwald, 1994). A study showed that further stratifying SES 
variables based on race or rural and urban location increased the validity of the aggregate measure, 
but stratifying did not necessarily improve the aggregate measures in all cases (Bach, 2002).  
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The individual level income variable is highly correlated with the aggregate measure; it was 
found that a self-reported income variable was well correlated with aggregate income variable 
irrespective of the level of aggregation (Bach, 2002). On the other hand, for the education variable, 
the census tract level aggregation was believed to be more predictive than the ZIP code level 
aggregation.   
 
The variables used to control for in this study are: 
 
1. Four education variables, stratified by race, measuring percentage of adults above 25 years in 
the residential census tract for each of the four education categories – Less than high school, 
High school diploma, Some college, At least four years of college. The race specificity 
reduces the noise in the aggregate variable.  
2. One variable measuring the median income in the residential census tract for the breast 
cancer patient.  
 
Geographic variation in treatment administration, healthcare utilization, and healthcare 
expenditures have long been established in the literature (Wennberg 1975; Wennberg, 2005; 
Wennberg, 2008). A recent study also found that there is significant geographic variation in the 
administration of G-CSF (Du, 2005). Geographic variation was controlled for using the SEER 
registry area variable.  Urban/rural area influences healthcare access for the patients and was 
controlled for using an indicator for urban residence.  
 
3.5.2.3 Patient clinical characteristics 
 
Comorbidities are very important predictors of treatment administration and outcome. 
Previous literature has established that comorbidities are important determinants of administration 
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and duration of both chemotherapy and G-CSF (Voelker, 2004; Du, 2001b; Hershman, 2007; Du, 
2005; Berrios-Rivera, 2007; Shayne, 2006). Comorbidities also affect the occurrence of neutropenia 
and other chemotherapy-related outcomes (Scott, 2003; Chrischilles, 2002; Chrischilles, 2005; 
Lyman, 1998; EBCTCG, 1998) Comorbidities are a significant determinant of length of stay 
(Chrischilles, 2002) and so need to be controlled for in both length of stay and cost estimations. Older 
women with breast cancer are a very heterogeneous group with respect to their comorbidities. The 
number of comorbidities increases with age and comorbidities have a greater role in the prognosis of 
older patients with breast cancer (Diab, 2000; Satariano, 1994). If comorbidities are not captured in 
the analysis then the resultant confounding may make age appear to be correlated with worse 
prognosis (Chrichilles, 2003). Renal and heart disease, and anemia are specific comorbidities which 
need to be controlled for due to their direct association with chemotherapy effectiveness and 
neutropenia related outcomes (Chrischilles, 2005; Chrischilles, 2002; Voelker, 2004; Scott, 2003). 
The modified Charlson comorbidity index is one of the most commonly used measures in previous 
research (Chrischilles, 2002; Chrischilles, 2005; Du, 2001; Hershman, 2007; Du, 2005). This study 
uses the Romano and Deyo modified Charlson comorbidity index, which has been further modified 
for cancer patients by the SEER-Medicare research group. The algorithm for the modified 
comorbidity index is available in the official SEER-Medicare website.   
 
Since we are considering the first primary occurrence of breast cancer without excluding 
patients who suffered from other cancers previously, it is important to take the presence of other 
cancers before the breast cancer diagnosis into account. This was captured by an indicator for absence 
of any cancer diagnosis before the breast cancer under study.  
 
History of infection, antibiotics use and hospitalization one month before the start of 
chemotherapy are controlled for using an indicator variable each. Each of these clinical factors could 
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affect the susceptibility of a patient to neutropenia and hospitalization and also affect the probability 
of prophylactic G-CSF administration.    
 
Tumor characteristics like stage, tumor grade, tumor size, lymph node involvement, and 
estrogen and progesterone receptor status are important determinants of chemotherapy and G-CSF 
administration, and also the occurrence of neutropenia and other clinical outcomes (Voelker, 2004; 
Du, 2001; Hershman, 2007; Du, 2005; Scott, 2003; Chrischilles, 2002; Chrischilles, 2005; 
Chrischilles, 2003). Thus these factors are controlled for.  
 
3.5.2.4 Therapeutic characteristics 
 
Surgery could be performed before or after chemotherapy administration as illustrated in 
Figures 1 and 2. Thus indicators are developed to capture whether or not the surgery was performed 
and if it was before or after the chemotherapy. Performance of Lymph node dissection before and 
after the chemotherapy was also controlled for. Administration of radiation therapy before the start of 
chemotherapy was also controlled for. 
 
Chemotherapy in breast cancer is characterized by the types of drugs administered, the dose 
of these drugs, the number of drugs administered and the duration between cycles in a chemotherapy 
course. Since not all types of drugs can be identified for each administration, an indicator was 
developed for whether or not anthracycline was administered in the first cycle because anthracycline 
based drugs are known to have a higher probability of chemotherapy toxicity as compared to other 
drugs (Lyman, 2003c; Lyman 2004), and their administration can be identified using claims (Warren, 
2002). Dosage cannot be measured from claims data. The other chemotherapy characteristics that are 
controlled for include the number of drugs administered in the first cycle, and the duration (in days) 
between the first and second cycle. Chemotherapy characteristics after the first cycle were not 
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controlled for because the treatment (primary prophylactic G-CSF) is administered immediately after 
the first cycle and controlling for post-treatment characteristics is inappropriate given that the 
treatment itself might influence the chemotherapy characteristics (like duration, and number of 
drugs).       
 
3.5.2.6 Time trend 
 
Controlling for year of chemotherapy dose administration and toxicity occurrence is essential. 
Studies show that the overall cost associated with neutropenia hospitalization and management has 
been reduced over time due to the shifting of care from in-patient setting to out patient setting 
(Lyman, 2003a). Also, the treatment protocols, the type of drugs used and their effectiveness have 
been changing, thereby making the year of chemotherapy and primary prophylactic G-CSF 
administration an important parameter. Time trends also control for, changes due to guideline 
updates, practice changes due to multiple G-CSF effectiveness studies published after the year 2002, 
and the increased use of dose dense chemotherapy regimen in the recent years.  
  
 
Chapter 4 
Results 
 
The SEER incidence data from 1986 to 2002 had 310835 observations with breast cancer 
diagnosis (Figure 4). Based on the inclusion and exclusion criteria discussed in section 3.2, 10524 
were observations of interest. The insurance criteria (presence of both part A and B, and being a non-
HMO enrollee an year before and after diagnosis) led to the largest number of exclusions. After 
dropping observations due to missing values and individuals residing in Rural Georgia who did not 
receive any treatment, the total number of observations left was 10441. 337 patients out of 10441 
received G-CSF as primary prophylaxis within five days of chemotherapy initiation.  
 
4.1 Determinants of primary prophylactic G-CSF administration - Descriptive statistics 
 
The data were divided into women who received primary prophylactic G-CSF (treated group) 
and women who did not (untreated group), and differences in their socio-demographic characteristics, 
clinical (including tumor) characteristics, and type of procedures performed were investigated. With 
regards to socio-demographic characteristics it was found that younger women, whites, and women 
from certain SEER regions (especially of California) were more likely to receive primary 
prophylactic G-CSF (Table 5). Clinically, women who received primary prophylactic G-CSF were 
more likely to have tumor stage III, have a larger sized tumor, be lymph node positive, have a history 
of recent (one month before start of chemotherapy) antibiotic administration, and receive 
anthracycline as part of the chemotherapy regimen during the first cycle. As expected primary 
prophylactic G-CSF administration is more common in the recent years than earlier years.  
  71
 
The variables with the largest difference in the means for the treated and untreated group 
were SEER registry region and anthracycline administration during the first cycle (Figure 5 and 6). 
Figure 5 shows that the SEER registries in California, Louisiana, and Connecticut have the highest 
administration rates for primary prophylactic G-CSF, and Hawaii, Kentucky, Iowa, Atlanta and Utah 
have some of the lowest rates. Rural Georgia has no patient receiving prophylactic chemotherapy. 
 
In summary younger women, whites, women living in SEER regions of California, Louisiana 
and Connecticut, and diagnosed at a later year were more likely to receive primary prophylactic G-
CSF. Clinically, women with more advanced tumor stage, larger tumor size, and node positivity had a 
higher probability of receiving primary prophylactic G-CSF. History of antibiotic use in the recent 
past and anthracycline administration in the first cycle of chemotherapy were also significantly 
correlated with use of primary prophylactic G-CSF.  
 
4.2 Determinants of primary prophylactic G-CSF administration – Parametric estimation of 
propensity score  
 
In order to estimate the propensity of receiving primary prophylactic G-CSF for each 
observation a logistic regression was performed as depicted in equation 1, and the results are 
presented in table 6. The analysis revealed that SEER region and anthracycline based chemotherapy 
are the most significant predictors of receipt of chemotherapy, as demonstrated by the descriptive 
statistics previously. Since the SEER region with the highest proportion receiving primary 
prophylactic G-CSF, San Francisco, was used as the reference category for the region variables, all 
regional coefficients are negative in magnitude. The regional variables were jointly statistically 
significant.  
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Race is another significant predictor with whites having a higher probability of primary 
prophylactic G-CSF receipt. The year variables were also jointly statistically significant, such that the 
individuals diagnosed in later years had a higher probability of getting primary prophylactic G-CSF. 
Chemotherapy characteristics like number of drugs administered during the first cycle, and shorter 
duration between the first and second cycle are also highly correlated with primary prophylactic G-
CSF administration.  
 
In summary, race, geographic region, year of diagnosis and chemotherapy characteristics are 
the primary variables which are statistically correlated with primary prophylactic G-CSF 
administration. After controlling for chemotherapy, age and most other clinical characteristics are not 
significantly correlated with primary prophylactic G-CSF administration in the multivariate analysis.   
 
4.3 Comparison between longer duration versus shorter duration of primary prophylactic G-
CSF administration  
 
Studies in non-Hodgkin’s Lymphoma patients show that “duration” of primary prophylactic 
G-CSF administration is an important factor in improving neutropenia-related outcomes (Weycker, 
2006; Weycker 2004; Scott 2003; Chrichilles 2003). Thus, some descriptive statistics and parametric 
analysis were performed to understand the determinants as well as effects associated with duration of 
G-CSF administration in patients who received primary prophylactic G-CSF.  
 
In this study the number of days of primary prophylactic G-CSF receipt ranged from 1 to 43. 
However 90% of the patients who received primary prophylactic G-CSF got it for 10 days or less, 
with both the mean and median days of administration being around 5 days. This study looked at the 
duration of primary prophylactic G-CSF administration both as a continuous variable, with one day as 
the unit of analysis, and as a categorical variables with two categories - less than five days of 
administration (inadequate duration) and five or more days of administration (adequate duration).  
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Scott and colleagues using medical records data classified shorter (inadequate) duration as 
less than seven days and longer (adequate) duration as seven or more days (Scott, 2003) for non-
Hodgkin’s Lymphoma patients, since the mean number of days of G-CSF administration was 9.5 
days in their study. Weycker et al’s study used claims data and a continuous measure for G-CSF 
duration (in days); the mean duration of G-CSF administration was 6 days for breast cancer patients 
in their study. Studies looking at the effectiveness of G-CSF in NHL and breast cancer patients are 
consistent in their finding about the mean duration of G-CSF administration, which is shorter (5-6 
days) in breast cancer patients compared to NHL patients (7-10days) (Webster 1996; Scott, 2003; 
Weycker, 2006; Chrischilles, 2003). In this study the mean and the median duration of administration 
was 5 days and hence the categorical variable was constructed accordingly. 
 
A descriptive look (table 5) at the differences between patients receiving adequate primary 
prophylactic G-CSF versus inadequate primary prophylactic G-CSF, among the 337 patients who 
receive primary prophylactic G-CSF, revealed that being white and more educated increased the 
probability of receiving adequate primary prophylactic G-CSF. Race (being black versus white) had 
one of the largest differences in terms of proportion of patients receiving adequate primary 
prophylactic G-CSF (Figure 7). Unlike administration of primary prophylactic G-CSF the duration is 
not influenced by geographic variation.  
 
Past history of other cancers, recent infections, larger tumor size and lymph node positivity 
increase the probability of adequate primary prophylactic G-CSF administration. Chemotherapy 
characteristics like anthracycline regimen (Figure 6), more number of drugs administered in the first 
cycle and shorter duration between first and second cycle are also highly correlated with adequate 
primary prophylactic G-CSF administration. In summary, based on the univariate analysis the chief 
determinants of duration of primary prophylactic G-CSF administration are race, education, diagnosis 
  74
of another cancer before the first primary breast cancer diagnosis, recent history of infections, larger 
tumor size, lymph node positivity, and all chemotherapy characteristics. 
 
A logistic regression on the indicator for adequate primary prophylactic G-CSF 
administration, and an ordinary least square on the actual number of days primary prophylactic G-
CSF was administered, indicated that chemotherapy characteristics like anthracycline regimen, more 
number of drugs administered in the first cycle and shorter duration between first and second cycle 
were significant predictors for a longer duration of primary prophylactic G-CSF administration (Table 
6). Past history of other cancers and recent infections also increase the duration of primary 
prophylactic G-CSF administration. Recent antibiotic use reduced the duration of primary 
prophylactic G-CSF administration. In summary, chemotherapy characteristics and patient’s recent 
clinical history are the chief predictors of duration of primary prophylactic G-CSF administration.   
 
4.4 Outcomes – Descriptive analysis  
 
Outcome variables such as – Neutropenia hospitalization, length of stay and expenditure 
associated with Neutropenia Hospitalization, overall Medicare expenditure, and provision of systemic 
therapy during the first course – were compared for women who received primary prophylactic G-
CSF and those who did not. Comparisons were also made for women who received adequate (>5 
days) primary prophylactic G-CSF versus women who received less than five days of primary 
prophylactic G-CSF.  
 
4.4.1 Neutropenia Hospitalization  
 
The descriptive analysis showed that neutropenia hospitalization was more common among 
individuals who received primary prophylactic G-CSF compared to individuals who did not (Table 
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7). This result was statistically significant for hospitalization within a month of chemotherapy 
initiation. However, patients with longer duration of primary prophylactic G-CSF administration had 
lower mean hospitalization compared to patients with shorter (inadequate) duration and this was 
statistically significant for both hospitalizations after 1 month and 3 months of chemotherapy 
initiation (Table 7). Figure 8 illustrates this effect, where irrespective of the time window used to 
measure the first neutropenia hospitalization after chemotherapy initiation, individuals receiving 
primary prophylactic G-CSF had higher hospitalization rates than individuals not receiving primary 
prophylactic G-CSF. On the other hand as shown in figure 9 individuals receiving a longer duration 
of primary prophylactic G-CSF (>=5 days) consistently have lower rates of hospitalization as 
compared to individuals receiving a shorter/inadequate duration of primary prophylactic G-CSF, 
irrespective of the time window used to measure neutropenia hospitalization.  
 
On further analyzing the affect of longer duration of primary prophylactic G-CSF on 
neutropenia hospitalization, a very interesting trend was observed. The longer duration seemed to 
matter more in cases of more advanced and severe cancer, than a less severe one. Figure 10 illustrates 
the rate of neutropenia hospitalization with respect to the three breast cancer stages under study for 
individuals with and without primary prophylactic G-CSF administration. Here the stage of cancer 
does not really make a difference in the rate of hospitalization with and without primary prophylactic 
G-CSF, and people receiving primary prophylactic G-CSF have a higher neutropenia hospitalization 
rate. However, as illustrated by figure 11 the longer duration of primary prophylactic G-CSF 
administration has lower hospitalization rates in patients with higher stages of breast cancer (stage II 
and III). As shown in figures 12 to 15, this trend repeats itself when the cancer is classified based on 
grade (such that grades 3 and 4 have lower hospitalization rates for individuals receiving longer 
duration of primary prophylactic G-CSF versus shorter duration of primary prophylactic G-CSF) and 
size (patients with tumor size above 2 cms have lower hospitalization rates with higher G-CSF 
duration).  In summary, duration of primary prophylactic G-CSF seems to have a positive correlation 
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with lower probability of neutropenia hospitalization based on simple descriptive statistics, and more 
so in case of more advanced cancer.  
 
4.4.2 Neutropenia Hospitalization – Length of stay  
 
Patients receiving primary prophylactic G-CSF have a lower length of stay due to neutropenia 
hospitalization on an average (Table 7 and Figure 16). However, the difference was not statistically 
significant. The duration of primary prophylactic G-CSF administration does not seem to have an 
effect on the length of stay once hospitalized (Table 7 and Figure 17), although it was associated with 
lower neutropenia hospitalization rates as described above. The means of logarithmic length of stay 
are also presented in table 7 since the parametric analysis is performed on logarithm of length of stay.   
 
4.4.3 Neutropenia Hospitalization – Expenditure  
 
Patients receiving primary prophylactic G-CSF have a lower expenditure due to neutropenia 
hospitalization on an average (Table 7 and Figure 18). Longer duration of primary prophylactic G-
CSF administration was also associated with lower expenditure due to neutropenia hospitalization 
(Table 7 and Figure 19). However, neither of these differences was statistically significant. The 
means of logarithm of the expenditure are also presented in table 7. 
 
4.4.4 Overall Medicare Expenditure for a year after chemotherapy initiation 
 
The descriptive analysis of the overall Medicare expenditure for a year after initiation of 
chemotherapy showed that for patients receiving primary prophylactic G-CSF the expenditures were 
on an average higher than patients not receiving primary prophylactic G-CSF (Table 7 and Figure 
20). This trend continued among patients receiving a longer duration of primary prophylactic G-CSF 
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(Table 7 and Figure 21), such that the patients receiving 5 days or more of primary prophylactic G-
CSF had a higher overall Medicare expenditure for a year after chemotherapy initiation compared to 
patients receiving less than 5 days of primary prophylactic G-CSF. These differences were 
statistically significant.  
 
4.4.5 Systemic therapy administration 
 
Both the administration of primary prophylactic G-CSF and longer duration of primary 
prophylactic G-CSF administration increase the average number of chemotherapy cycles 
administered during the first course (Table 7, Figure 22 and 23). The probability of any 
administration of radiation therapy during the first course is higher in patients receiving primary 
prophylactic G-CSF versus patients not receiving primary prophylactic G-CSF (Figure 23). However, 
duration does not seem to be associated with radiation therapy administration (Figure 23). This seems 
to suggest that appropriate primary prophylaxis might actually improve systemic therapy 
administration in breast cancer patients.  
 
4.5 A closer look at primary prophylactic G-CSF duration and outcomes  
   
Parametric analysis was done to examine the effect of “duration” of primary prophylactic G-
CSF administration on neutropenia hospitalization, expenditure and systemic chemotherapy 
administration. The covariates controlled for in these analyses were the same as those used for other 
parametric analysis examining the effect of primary prophylactic G-CSF on these outcomes, namely – 
age, race, marital status, education, income, urban residence, SEER region, relevant clinical history, 
tumor characteristics, chemotherapy characteristics and other therapies administered. This analysis 
was not preceded by any form of matching, but was performed using the 337 observations who 
received primary prophylactic G-CSF. The analysis was done using the continuous variable for 
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number of primary prophylactic G-CSF days as well as the categorical variable for primary 
prophylactic G-CSF administration for 5 or more days.  
 
Performing two analyses using two different dependent variable specifications (a continuous 
and a categorical variable) showed that higher duration of primary prophylactic G-CSF administration 
reduced the rate of neutropenia hospitalization after chemotherapy initiation, and improved the rates 
of systemic therapy administration (Table 10). Table 12 shows the marginal effects computed by the 
average of probabilities method. The average of probability method was used in this study because it 
is easy to interpret for binary variables like administration of primary prophylactic G-CSF and does 
not ignore the distribution of the marginal effects in the data (Norton, 2004).  
 
The adequate administration of primary prophylactic G-CSF for five or more days reduces 
the probability of neutropenia hospitalization by seven percentage points, nine percentage points, and 
four percentage points in the first month, first three months, and the first six months after 
chemotherapy initiation respectively. Each additional day of primary prophylactic G-CSF 
administration reduces the probability of neutropenia hospitalization by one percentage point in the 
first month and first three months respectively. The adequate administration of primary prophylactic 
G-CSF for five or more days, versus less than five days, increases the probability of radiation therapy 
administration and adequate (more than 5 cycles) chemotherapy administration during the first course 
by one percentage point each (Table 12).   
 
The overall Medicare expenditure for a year after chemotherapy initiation were higher for 
patients receiving primary prophylactic G-CSF for a longer duration. Receiving 5 or more days of 
primary prophylactic G-CSF administration increased the overall expenditure by 19.62%, and 
increase in primary prophylactic G-CSF administration by one day increased the overall expenditure 
by 1.74% (table 12). Analyses on neutropenia length of stay and neutropenia related hospitalization 
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expenditures could not be performed as the number of patients hospitalized for neutropenia, among 
those who received primary prophylactic G-CSF, were too low to perform any parametric analyses. 
Among the 337 patients who received primary prophylactic G-CSF, 15 were hospitalized within the 
first month of chemotherapy initiation, 20 were hospitalized within the first 3 months, and 25 were 
hospitalized within the first 6 months of chemotherapy initiation. A sample size of 15-25 observations 
was not an adequate for the parametric analysis.      
 
Since the decision to develop a categorical variable for 5 or more days (versus less than five 
days) was based on clinical practice patterns in the claims data (since five days was the mean and 
median duration in this study and other similar studies), and did not have any scientific basis, similar 
analyses were also performed by creating categorical variables for 7 or more days of administration, 
and 10 or more days of administration. It was interesting to note that both 7 or more days and 10 or 
more of administration did not have a statistically significant benefit in reducing neutropenia 
hospitalization rates, though there were some effects on improving adherence to systemic therapies.   
 
4.6 Parametric analysis after genetic matching 
 
Before performing the parametric analysis to determine the effect of primary prophylactic G-
CSF on probability of neutropenia hospitalization, length of stay, expenditures, and provision of 
systemic therapy, the 337 treated individuals were matched with untreated individuals closest to them 
in terms of the covariates. Genetic matching technique was used for selecting the appropriate 
matches. The propensity score was included as one of the variable to be matched on, as discussed in 
section 3.3.5.  
 
In order to make the matching process as flexible as possible to ensure optimal matching and 
also abiding by the choice limitations of the software, several choices were made. Since there were 
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only 337 treated observations among the 10441 observations, discarding treated observations while 
matching might compromise the power of the study. Given that there were 10104 untreated 
observations finding appropriate matches for all the 337 treated observations will not be challenging. 
On the other hand all the10104 untreated observations might not have an appropriate match among 
the 337 treated observations. Thus, discard options were set to remove untreated observations that 
did not match with the treated observations and at the same time preserve all the 337 treated 
observations.  
 
Matching was performed with replacement so that the treated observations matched later are 
not forced to match with untreated observations which are not optimal matches; this often happens 
when the matching is done without replacement and the pools of untreated and treated observations 
shrink in size as each pair is formed. Since treated observations are not discarded the treated 
observations matched later will have to be paired with leftover untreated observations even if the 
match is poor. Thus, matching with replacement was preferred. 
 
There are concerns about variance estimation in the case of matching with replacement 
because the assumption of independent and identically distributed observations is violated as the same 
observation is matched multiple times. However, in case of this analysis this assumption is not 
violated because matching is used to construct the analytic data but is not directly used to estimate the 
treatment effects. Once the analytic data are constructed the parametric estimation is performed as it 
would be with any other data. The untreated units matched with replacement are not counted twice 
during the analysis. Thus matching with replacement does not have any implications on variance 
estimation in case of this analysis. 
 
Since the ratio of untreated to treated was very high, each treated observation could 
potentially have more than one match. The software requires that the user specify the number of 
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matches for each treated. The number of untreated to be matched with treated was set at six. The 
number of untreated observations to be matched should not be too low, especially in this sample, 
since only 337 observations were treated. Having only one to two untreated matches for each treated 
might severely compromise the power of the sample. On the other hand increasing the untreated 
matches, keeping the treated observations constant, has diminishing returns for the power, and might 
also lead to poor forced matches. Multiple matches were performed by specifying 4 to 8 untreated 
matches with each treated observation. It was found that, due to the matching with replacement option 
the untreated observations in the matched sample did not increase much when more than six untreated 
were matched with treated. Moreover, the descriptive statistics showed that the matches became 
poorer with more statistical difference in the control variables of the treated versus untreated 
observations as the number of matches were increased beyond six. Thus, the number of untreated 
matches per treated were specified as six. It is important to note that the final matched sample will not 
have a 1:6 ratio of treated to untreated due matching with replacement; some untreated observations 
will be matched with more than one treated observation.  
 
Options were also set for specific genetic matching parameters. The population size for the 
number of solution sets (number of sets of weights in this case) was set at 5000. This implies that the 
algorithm begins with 5000 sets of 57 weights required in this optimization (there are 56 control 
variables and one propensity score), tries them out on the sample, and accordingly performs the 
genetic operations of reproduction, mutation, crossover and inversion to come up with the next set of 
trial solutions of 5000 weights vectors. This process is continued till the most optimal set of weights 
are selected such that they cannot be further improved. The higher the population size the better the 
optimization. In order to decide when the optimal solution is achieved the “wait.generation” option is 
set, which is the maximum number of generations of population until which, if the solution is not 
improved by the genetic operations, the algorithm stop. The wait.generation was set to 25 in this 
optimization. If the genetic operations are unable to improve the solution within 25 generations, then 
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the last best solution is considered optimal. Another important option used was the memory matrix 
option. This option preserves all the previously tried solution vectors and ensures that the newly 
generated solutions are not redundant. This option however compromised the speed of the algorithm. 
The optimization was aimed at minimizing the statistical difference in control variables between the 
treated and untreated by maximizing the p-values associated with each variable.  
 
After discarding untreated observations which did not match treatment observations 1760 
observations were left. The treated to untreated ration was 1:4.223 approximately.  
 
The descriptive statistics of means and statistical differences of control variables between the 
treated and untreated group for the final matched sample is presented in table 8. The descriptive 
statistics before matching are also presented for the purpose of comparison. The statistically 
significant differences in covariates that existed before matching were no longer present after 
matching. However, three variables, past history of cancer, history of infection a month before 
chemotherapy initiation, and receipt of radiation therapy before chemotherapy initiation, became 
significantly different, which was not the case previously. These variables were not statistically 
correlated with administration of primary prophylactic G-CSF before – both based on descriptive 
statistics and the logistic regression – hence the algorithm assigned smaller weights to these variables 
during the matching process. Thus their balance was compromised while ensuring good balance in 
variables which were significant determinants of primary prophylactic G-CSF administration. 
Performing the matching multiple times with different specifications did not make any difference and 
imbalances still remained. Since parametric analysis will be performed to control for the remaining 
imbalances, further analysis was performed on this matched pool even though minor differences in 
the treated and untreated existed.  
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Table 9 shows the comparative statistics for the dependent variables, and the results illustrate 
that the statistically significant differences between women who received primary prophylactic G-
CSF and who did not remained the same after matching. This is because the matching process did not 
involve any balancing of the dependent variables. Although there were few statistically significant 
changes in the dependent variables after matching some new trends emerged. The proportion of 
individuals hospitalized due to neutropenia during the first three and six months after the start of 
chemotherapy was higher in the untreated individuals than the treated individuals after matching. This 
was a reverse trend as compared to the trend before matching, although not statistically significant 
both before and after matching. The mean difference in the length of stay and expenditures due to 
neutropenia hospitalization increased, such that they were higher in the untreated individuals as 
compared to the treated individuals. The trends were same as before but just more pronounced in 
magnitude. However, they were not statistically significant. Most other differences remained similar.     
 
Table 10 presents the regression coefficients with standard deviations in the parenthesis after 
parametric analysis. Post-matching primary prophylactic G-CSF administration seems to have a 
statically significant affect in lowering the probability of neutropenia hospitalization, for the first 
neutropenia hospitalization within three and six months of chemotherapy initiation. Women receiving 
primary prophylactic G-CSF have a one percentage-point lower risk of being hospitalized as 
compared to women who did not receive primary prophylactic G-CSF, both during the three month as 
well as the six month window (Table 11). This trend did not exit before matching. For the first month 
after chemotherapy initiation, however, primary prophylactic G-CSF did not have any statistically 
significant effect on neutropenia hospitalizations post-matching.  
 
The average length of stay and neutropenia hospitalization expenditures were lower in 
magnitude for women receiving primary prophylactic G-CSF both before and after matching. These 
effects are not statistically significant. However, it is interesting to note that the magnitude of 
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difference in length of stay and neutropenia hospitalization expenditures become more prominent 
after matching such that the average length of stay and neutropenia hospitalization expenditures are 
higher in women not receiving primary prophylactic G-CSF as compared to those receiving it. The 
lack of statistical significance in spite of an increase in magnitude of the effect of primary 
prophylactic G-CSF on length of stay and expenditures is probably because of the reduction in sample 
size of hospitalized individuals post-matching.  
 
The analysis for the reduction in hospitalization length of stay and expenditure during the 
first month after the initiation of chemotherapy could not be performed as the number of observations 
was far too low post-matching (48 patients hospitalized during the first month in both treated and 
untreated women put together). Since logarithm of length of stay and expenditure was used the 
marginal effects are computed using the Kennedy transformation method (Kennedy, 1981).  
 
Overall expenditures within one year of chemotherapy initiation were consistently higher for 
women who received primary prophylactic G-CSF versus who did not both before and after matching 
(Table 11). In the analysis post-matching the overall expenditures were 57.25 percent higher in 
women receiving primary prophylactic G-CSF (Table 11). G-CSF prophylaxis also significantly 
increased the probability of radiation therapy administration and administration of chemotherapy for 
more than 5 cycles during the first course by 8%-points and 6%-points respectively (Table 11).  
 
4.7 Analysis without controlling for therapeutic modalities 
 
The previous analysis controlled for all the breast cancer therapies provided before and at the 
start of chemotherapy first course (the first cycle). Primary prophylactic G-CSF administration occurs 
two to five days after the administration of first cycle of chemotherapy first course and hence the 
therapy variables were pretreatment and were included in the analyses.  
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However, physicians often plan the short-term treatment protocol for a breast cancer patient 
soon after her diagnosis based on the tumor characteristics and other clinical characteristics. Type of 
surgery to be performed and type of radiation therapy and chemotherapy to be administered might be 
decided simultaneously. In addition, primary prophylactic G-CSF administration is often decided 
based on the type of chemotherapy regimen planned. Thus, treatment administered during the first 
few months after diagnosis could be a joint decision along with the decision to administer primary 
prophylactic G-CSF, and the treatment variables controlled in this study, although administered 
before primary prophylactic G-CSF (pre-treatment variables), might be correlated to the decision to 
administer G-CSF. A sensitivity analysis was performed by excluding all the treatment variables to 
see if the treatment protocols associated with the decision to administer primary prophylactic G-CSF 
(and not just the primary prophylaxis itself) were associated with better health outcomes overall. 
 
The descriptive statistics after matching on only the socio-demographic, clinical and tumor 
characteristics are provided in table A1. The sample size after matching was 2046 with ratio of treated 
to untreated being 1:5.07. The balance in control variables between treated and untreated observations 
was well achieved, with statistically significant differences only in anthracycline use in the first cycle 
of the first course chemotherapy. The descriptive statistics for the outcome variables post-matching, 
and the results of the parametric analysis are presented in tables A2 and A3 respectively. It is 
important to remember that the results before matching in table A3 are different from results before 
matching in table 10 because the analysis in table A3 does not control for the therapy variables before 
matching even though the observations used are the same as in table 10. 
 
An important difference in the results in table 10 versus table A3 was the lack of effect of 
primary prophylactic G-CSF on probability of neutropenia hospitalization when treatment variables 
are not controlled for. Primary prophylactic G-CSF reduced the probability of neutropenia 
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hospitalizations in the first three and six months after the start of chemotherapy in the analysis 
controlling for pre-treatment therapies (table 10 and 11). However, as can be seen in table A3 and A4 
there was no statistically significant effect of primary prophylactic G-CSF on neutropenia 
hospitalizations if the analysis did not control for pre-treatment therapies. Similar to the analysis 
controlling for treatment variables, G-CSF prophylaxis significantly increased the probability of 
radiation therapy administration and administration of chemotherapy for more than 5 cycles during 
the first course by 4%-points and 8%-points respectively (Table A4). The overall expenditures were 
70.47 percent higher in women receiving primary prophylactic G-CSF (Table A4). The trends in the 
effect of primary prophylactic G-CSF duration on the key outcome variables were mostly not 
statistically significant when pre-treatment variables were not controlled for (Table A5). The positive 
effect of primary prophylactic G-CSF duration on adequate chemotherapy administration during the 
first course was the only effect significant at the 5% level.  
 
Since neutropenia occurrence is associated more with systemic therapy administration, the 
surgery performed might not be endogenous to the administration of G-CSF but the type of 
chemotherapy and radiation therapy administered before the start of G-CSF might be associated with 
the plan to start primary prophylactic G-CSF administration. Hence the analysis was re-performed by 
just excluding the chemotherapy and radiation therapy variables instead of all the treatment variables.  
 
The sample size after matching on all socio-demographic, clinical and tumor characteristics, 
and surgery performed was 2090 with the ratio of treated to untreated being 1:5.2. The balance in the 
covariates was well achieved, with statistically significant differences only in the history of antibiotic 
use before start of G-CSF and anthracyline use as part of the first cycle in chemotherapy (Table A6). 
The trends were similar to the previous analysis performed without controlling for any treatment 
variable (table A8). Both administration of primary prophylaxis and adequate duration of 
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administration were positively correlated with the expenditures in the first year and improved 
systemic therapy provision (Table A9 to A10). No other effects were statistically significant.  
  
 
Chapter 5 
Discussion 
 
5.1 Determinants of primary prophylactic G-CSF administration   
 
One of the chief aims of this study was to establish the clinical and socio-demographic 
determinants of primary prophylactic G-CSF administration and to better understand the factors 
underlying a physician’s decision to administer G-CSF prophylactically in an actual clinical setting. 
The study found that race, geographic region, year of diagnosis and chemotherapy characteristics are 
the primary variables which are statistically correlated with primary prophylactic G-CSF 
administration; SEER region and anthracycline based chemotherapy are the major predictors of 
receipt of primary prophylactic G-CSF.  
 
5.1.1 Chemotherapy characteristics as predictors of a physician’s decision to administer 
primary prophylactic G-CSF   
 
Past studies show that younger age, and numerous clinical characteristics like extent of breast 
cancer disease spread, advanced tumor stage, tumor size, node positivity and lower comorbidity index 
are significant clinical predictors of G-CSF administration in Non-Hodgkin’s Lymphoma patients 
(Chrischilles, 2003) and breast cancer patients (Hershman, 2007; Du, 2005). One study expressed 
concern that physicians should administer primary prophylactic G-CSF to younger women and 
women with lower comorbidity index even though older and sicker women are more vulnerable to 
chemotherapy toxicity (Du, 2005).  
 
  89
Initial univariate comparisons in this study did indicate similar trends in age and clinical 
characteristics, but the trends disappeared in multivariate analysis. Further sensitivity analysis with 
different multivariate specifications revealed that including chemotherapy characteristics in the 
multivariate analysis made the correlation of age and other clinical characteristics with primary 
prophylactic G-CSF administration insignificant. The past studies did not control for chemotherapy 
characteristics.  
 
This finding suggests that physicians first decide the chemotherapy regimen (type of drugs, 
doses, frequency and intensity) based on patient clinical characteristics, and then decide the need for 
primary prophylactic G-CSF administration based on the risk of toxicity of the chemotherapy 
regimen. Younger and healthier patients (with lower co-morbidity index) are more tolerant of intense 
chemotherapy, and patients with higher extent of cancer spread (measured by advanced stage, larger 
size and node positivity) require a more intense chemotherapy. Hence, these patients receive a more 
intense chemotherapy and are also administered primary prophylactic G-CSF to counter the high risk 
of chemotherapy induced neutropenia. Thus, it is not the cancer characteristics and patient 
demographics, but the risk associated with chosen chemotherapy regimen that directly determines the 
physician’s decision to administer primary prophylactic G-CSF. 
    
Since anthracycline-based chemotherapy regimen, more number of drugs used in the first 
cycle, and more frequent cycles have a higher risk of toxicity, it is not surprising that these 
individuals are more likely to receive primary prophylactic G-CSF (Lyman, 2003c; Lyman 2004). 
 
5.1.2 Temporal Variation in the use of a new drug  
 
Temporal variation in the probability of primary prophylactic G-CSF administration is similar 
to variation in a previous study which looked at general hematopoietic factors administration (Du, 
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2005). Significant temporal variation is not surprising given that primary prophylactic G-CSF was 
introduced in 1991 and the data include administrations from 1994 to 2002. G-CSF administration as 
prophylaxis is often a provider’s decision; hence, awareness and beliefs of the providers are important 
determinants of whether or not the patient gets the drug. Since the drug was introduced relatively 
recently, it will take some time for the physicians to become aware of the drug, and the awareness 
will steadily increase with time, therefore patients diagnosed in the later years are more probable of 
receiving the drug. Practice guidelines also have an effect on how soon the physicians come to know 
about the drug and adopt it in their practice. Incorporation of recommendations for primary 
prophylactic administration of G-CSF in the ASCO guidelines since 1994 definitely contributed 
towards the awareness and use of the drug in clinical practice. The use of G-CSF in the general 
population experienced the maximum increase after the year 1999.  
 
5.1.3 Unexplained racial and regional disparities   
 
Racial and regional disparities in the administration of primary prophylactic G-CSF are a 
concern. Regional differences chiefly indicate geographic variations in practice patterns. Many 
studies have been published since early 1970s documenting significant geographic variations in 
different treatment modalities especially by the research group at The Dartmouth Institute (Wennberg 
1975; Wennberg, 2005; Wennberg, 2008). These variations are attributed primarily to variations in 
practice styles and provider beliefs about treatment effectiveness. Given that G-CSF is a recently 
introduced preventive agent, geographic variations might be more pronounced as it will take 
physicians some time to incorporate the use of G-CSF in their practice. Different physicians will 
adopt the drug at a different rate, and the adoption will also be heavily influenced by practices of 
colleagues, thereby making the difference appear very regional. Also, since no strict guidelines exist 
for the administration of G-CSF as a prophylactic agent in the elderly breast cancer patients, the 
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administration often depends on the discretion of the provider thereby increasing the variations in 
practice patterns.  
 
Figure 5 shows that the SEER registries in California, Louisiana and Connecticut have the 
highest administration rates for primary prophylactic G-CSF, and Hawaii, Kentucky, Iowa, Atlanta, 
and Utah have some of the lowest rates. Rural Georgia has no patient receiving prophylactic 
chemotherapy. Past studies using the SEER-Medicare data demonstrate that Los Angeles, 
Connecticut and Utah have higher rates of G-CSF administration, and Hawaii, New Mexico, Seattle 
and Detroit had the lowest in Non-Hodgkin’s Lymphoma patients (Chrischilles, 2003).  For breast 
cancer patients in the SEER data California, Detroit and Atlanta had a higher probability of receiving 
general G-CSF (not just primary prophylaxis) (Du, 2005).  
 
Since regional variations are one of the most significant in determining the probability of G-
CSF administration, a more detailed descriptive analysis was performed to understand the possible 
factors that might be driving the trend. Table 13 illustrates the number of women who received G-
CSF in each region, sample size in each region, the total number of unique physician identifier 
associated with the chemotherapy claims in each region (indicating the total number of physician in 
the data for that region), the number of physicians who administered G-CSF to all their patients, and 
the number of physicians who never administered G-CSF to their patients. The regions are arranged 
in a descending order of the rate of primary prophylactic G-CSF administration.  
 
Certain regions could have higher rates either because few physicians who believe in the 
merits of the drug drive its use in that region, or because the proportion of physicians administering 
the drug in that region is higher. Table 13 illustrates that only about 10% of physicians on an average 
administer the drug prophylactically. Clearly a higher proportion of physicians administer the drug in 
regions with higher rates of G-CSF administration. Physicians in the regions with higher rates of G-
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CSF administration do administer G-CSF to a higher proportion of the patients on an average, but this 
trend is not consistent. The trends suggest that higher percentage of physicians administering the drug 
in each region is probably driving the overall rates more than the higher rates of drug administration 
per physician. A higher proportion of providers seem to be aware of G-CSF and support its use in 
areas with higher rates of administration. There was no evidence that certain physicians were 
involved with unusually high rates of G-CSF administration or overuse in regions of high rates. 
Moreover, there are very few patients under each physician in a region and so physician specific 
statistical trends are not easy to interpret using the SEER data for these years.   
 
Change in regional trends with time was also descriptively examined, but no significant 
temporal differences between regions were observed in the rate of administration of the drug.   
 
5.2 Determinants of duration of primary prophylactic G-CSF administration 
 
Few studies look at the determinants of duration of primary prophylactic G-CSF. The study 
looking at NHL patients showed that previous radiation therapy use, older age (>75 years) and later 
years of cancer diagnosis (after 1997) were associated with lower duration of primary prophylactic G-
CSF administration (<7 days) (Chrischilles, 2003). These findings were very different from our study 
looking at breast cancer patients. This study found that past history of cancer, recent infections, and 
chemotherapy characteristics influence the duration of primary prophylactic G-CSF administration. 
History of recent antibiotics administration reduced the duration of primary prophylactic G-CSF 
administration.  
 
Interestingly, regional differences that were statistically significant in predicting the 
administration did not play any role in predicting the duration of primary prophylactic G-CSF. This 
could be because the decision to administer primary prophylactic G-CSF is predominantly provider 
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dependent and once the providers decide to administer primary prophylactic G-CSF, they intend to 
administer it for at least a week, which is the typical standard practice. However, the duration of 
administration is dependent on patient’s convenience and treatment adherence. Thus the duration is 
affected more by patient characteristics and clinical needs, and not significantly affected by provider 
practice styles that are captured as regional trends. 
 
Past history of other cancers and recent infections increase the probability of adequate (>5 
days) primary prophylactic G-CSF administration. These correlations are indicative of higher 
compliance among patients with previous bad health experiences, and provider’s insistence on better 
adherence due to patient’s susceptibility to infections. Chemotherapy characteristics are, as discussed 
before, an important determinant of both primary prophylactic G-CSF administration and its duration. 
This significant effect of chemotherapy is due to the direct impact of the chemotherapy regimen on 
the severity of neutropenia occurrence.  
 
An interesting finding is that antibiotics use reduces primary prophylactic G-CSF duration. 
Some physicians use antibiotics as partial substitutes for the expensive G-CSF prophylaxis to prevent 
febrile neutropenia and other neutropenia related infections, although the substitution is not clinically 
recommended (Dr. Gary Lyman, personal communication). These physicians, anticipating a higher 
risk of neutropenia occurrence, start their patients on prophylactic antibiotics a few days before the 
administration of chemotherapy, and might not be administering primary prophylactic G-CSF long 
enough due to the intended substitution.  
 
5.3 Effect on neutropenia hospitalization probability 
 
The beneficial effect of prophylactic G-CSF in the form of reduction in the risk of 
hospitalization has been demonstrated by other clinical trials and studies as well (Chrischilles, 2002; 
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Glaspy, 1993; Engelhard, 1994; Dranitsaris, 1995; Heil, 1997; Moore, 1997; Weycker, 2004). 
However, none of these studies involved breast cancer patients or focused on the elderly patient 
population. This study found a reduction in risk of hospitalization among elderly breast cancer 
patients receiving primary prophylactic G-CSF. Women receiving primary prophylactic G-CSF have 
a one percentage-point lower risk of being hospitalized as compared to women who did not receive 
primary prophylactic G-CSF, both during the three month [95%CI: -1.2 to -0.5%-points] as well as 
the six month [95%CI: -1.8 to -0.6%-points] window post-matching (Table 11). The effect of primary 
prophylactic G-CSF for the first month was not statistically significant. These findings support the 
first hypothesis that primary prophylactic G-CSF reduces the occurrence of neutropenia 
hospitalization in elderly female breast cancer patients receiving chemotherapy. 
 
The lack of any beneficial effect of primary prophylactic G-CSF in the first month might be 
due to two reasons. First, in the first month neutropenia occurrence might not be severe enough to 
require hospitalization. Since we are looking only at neutropenia hospitalization and not the incidence 
of neutropenia, it might be hard to detect the benefits. Second, the benefits of primary prophylactic G-
CSF could be additive because occurrence of neutropenia in the first month increases the probability 
of neutropenia occurrence and severity in the later months (Timmer-Bonte, 2006). Also, the women 
who receive primary prophylactic G-CSF might be more likely to receive the drug at a later date 
during the course of chemotherapy (along with the later cycles) thereby further improving better 
toxicity tolerance throughout the first course (which lasts for three to six months after the start of 
chemotherapy).  
 
It is important to note that positive correlation of primary prophylactic G-CSF and 
neutropenia hospitalization rates before matching is strongly suggestive of endogeneity; primary 
prophylactic G-CSF is often administered to women who have a higher risk of neutropenia. Post-
matching, this trend reverses possibly because matching ensures comparison between women with 
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very similar clinical characteristics and risk of neutropenia. Thus, in women with similar neutropenia 
risk, administering primary prophylactic G-CSF reduces neutropenia hospitalization risk.  
 
Some clinical trials have also looked at the effect of G-CSF on occurrence of neutropenia and 
febrile neutropenia and find a beneficial effect of G-CSF, especially the drug Filgrastim (Gridelli, 
2007; Oyama, 1990; Crawford, 1991; Pettengell, 1992; Anderson, 1991; Havemann, 1991; Kotake, 
1991; Trillet-Lenoir, 1993; Gerhartz, 1993; Kaku, 1993; Gebbia, 1993; Gebbia, 1994; Eguchi, 1994; 
Rampling, 1994; Bui, 1995; Bergmann, 1995; Muhonen, 1996; Jones, 1996; Zinzani, 1997; 
Gisselbrecht, 1997; Moore, 1997; Bassan, 1997; Fossa, 1998; Feng, 1998; Hidalgo, 1998; Lyman, 
2002; Osby, 2003; Scott, 2003; Kuderer, 2005; Timmer-Bonte, 2005; Vogel, 2005; Shayne, 2007; 
Kuderer, 2007).  
 
Other studies find no effect of primary prophylactic G-CSF on neutropenia occurrence or 
hospitalization (Shaffer, 1993; Bunn, 1995; Woll, 1995; Weiss, 1996; Fridrik, 1997; Dunlop, 1998; 
Steward, 1998; Doorduijn, 2003). These studies predominantly looked at Sargramostim (GM-CSF) 
and Lenograstim administration. Filgrastim, which is the most commonly used G-CSF in the 
Medicare patients (86% of primary prophylactic use in this study), is usually found to be very 
clinically effective by most of the clinical trials and meta-analyses (Kuderer, 2007).  
 
Adequate duration of primary prophylactic G-CSF administration has been found to be 
effective in reducing neutropenia incidence and neutropenia hospitalizations in non-Hodgkin’s 
lymphoma patients (Weycker, 2004; Chrischilles, 2003; Scott, 2003). These studies show that longer 
duration was associated with lower incidence of febrile neutropenia (Scott, 2003), and lower risk of 
hospitalization and infection (Weycker, 2006; Weycker 2004). Weycker (2004) found significant 
differences between patients receiving primary prophylactic G-CSF for less than five days, and for 
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five or more days. Chrischilles and colleagues also show that lower duration of prophylactic G-CSF is 
associated with higher risk of neutropenia hospitalization (Chrischilles, 2003). 
 
This study, which for the first time looked at elderly breast cancer patients, found that 
adequate (or longer) duration of primary prophylactic G-CSF reduced the probability of neutropenia 
hospitalization. The adequate administration of primary prophylactic G-CSF for five or more days 
reduces the probability of neutropenia hospitalization by 7 %-points [95%CI: -15 to -1 %-points], 
9%-points [95%CI: -15 to -3 %-points], and 4%-points [95%CI: -8 to -0.3 %-points] in the first 
month, first three months, and the first six months after chemotherapy initiation respectively (Table 
12).  
 
It was interesting to note that adequate duration of primary prophylactic G-CSF 
administration particularly lowered the probability of neutropenia hospitalization in women suffering 
from more severe cancer like – higher stages, higher grade, and larger size (Figures 11, 13 and 15), 
and these reductions were statistically significant. One reason why adequate duration lowered 
neutropenia hospitalization in more severe cases, but did not have much effect in the less serious 
cases, could be because the severe cases are more likely to receive intense chemotherapy with a 
higher risk of neutropenia, thus neutropenia prophylaxis is more beneficial in such cases. This trend 
of better effectiveness of adequate primary prophylactic G-CSF (versus less than 5 days of G-CSF) in 
severe cases is not observed in patients who receive any primary prophylactic G-CSF (versus those 
who do not) (Figures 10, 12 and 14).   
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5.4 Effect on neutropenia hospitalization length of stay  
 
A reduction in the length of stay due to G-CSF has been documented by many studies 
previously (Kaplan, 1991; Glaspy, 1993; Moore, 1997; Chrischilles, 2002; Maher, 1994; Gerhatz, 
1993; Zagonel, 1994; Dranitsaris, 1995). There have also been studies in which the beneficial effects 
of G-CSF on length of stay have been statistically insignificant (Bunn, 1995; Woll, 1995; Dunlop, 
1998). In this study there is no statistically significant effect of primary prophylactic G-CSF on the 
length of stay once patient is hospitalized probably due to the small sample size of women who were 
hospitalized. Thus, the second hypothesis could not be corroborated. In addition, the effect of 
duration of primary prophylactic G-CSF administration on neutropenia hospitalization length of stay 
could not be assessed due to the small sample size of the women receiving primary prophylactic G-
CSF as well as getting hospitalized. 
 
5.5 Effect on Medicare expenditures 
 
In order to test hypothesis three the expenditures associated with the first neutropenia 
hospitalization within the first, third and sixth month after the start of chemotherapy were examined. 
The trends in magnitude were very similar to the findings from length of stay, which further 
emphasizes the fact that length of stay is one of the chief determinants of Medicare costs associated 
with a hospitalization (Lyman, 2004). None of the effects were statistically significant, probably 
because of the small sample size of women who get hospitalized, hence the first part of the hypothesis 
three could not be corroborated as well. The effect of duration of primary prophylactic G-CSF 
administration on neutropenia hospitalization expenditures could not be assessed due to the small 
sample size of the women receiving any primary prophylactic G-CSF as well as getting hospitalized.  
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The second part of hypothesis three looks at the effect of primary prophylactic G-CSF on 
overall Medicare Expenditures for one year after the start of chemotherapy. The initial aim was to see 
if primary prophylactic G-CSF administration prevented early recurrence and other worse outcomes, 
and hence lowered the cost of breast cancer management and treatment in the first year after the start 
of chemotherapy. The study, however, found reverse trends. Women who received primary 
prophylactic G-CSF had higher mean overall expenditure and this effect was statistically significant. 
In the post-matching analysis the overall expenditures were 57.25% higher in women receiving 
primary prophylactic G-CSF (Table 11). Women receiving a higher duration of primary prophylactic 
G-CSF also had higher overall Medicare expenditure during the first year after start of chemotherapy. 
Receiving 5 or more days of primary prophylactic G-CSF increased the overall expenditure by 
19.62%, and increase in primary prophylactic G-CSF by one day increased the overall expenditure by 
1.74% (Table 12). 
 
There could be multiple reasons for higher overall expenditure in spite of effective primary 
prophylaxis. The administration of primary prophylactic G-CSF increased the successful 
administration of the first course of chemotherapy and radiation therapy (as discussed in the next 
section). Since the bulk of these therapies are administered in the first year, increased adherence to 
these therapies will increase the Medicare expenditure in the first year. It is also important to 
understand that G-CSF is expensive, and the costs for prophylactic G-CSF administration during the 
entire first course chemotherapy could range between $5,000 to $30,000. This considerable cost could 
offset cost reductions due to reduced neutropenia management and hospitalization costs. In order to 
understand the main driving factors behind higher first year expenditure in women receiving primary 
prophylactic G-CSF a descriptive analysis was performed to identify different components of these 
overall costs (Table 14).  
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In the matched data the average G-CSF expenditure in the first year for women who received 
the drug as primary prophylaxis was $7914 versus $1369 for women who did not receive the drug as 
primary prophylaxis (but received it later). The maximum expenditure of G-CSF for women who 
received primary prophylaxis was $44204 and was below $20,000 for 95% of the women receiving 
primary prophylaxis. On the other hand the expenditure was below $8,000 for 95% of the women not 
having received primary prophylaxis, with the maximum expenditure being $24927. Seventy percent 
of women who did not receive primary prophylactic G-CSF had no G-CSF expenditure in the first 
year.  
 
Chemotherapy expenditures were twice as high for women receiving primary prophylactic G-
CSF. Fifty percent of women who did not receive primary prophylaxis had less than $4,000 of 
chemotherapy expenses in the first year, and 50% of the women having received G-CSF had more 
than $10,000 of chemotherapy expenses in the first year with a maximum of $61,705. Given both the 
difference in the expenditure due to G-CSF and chemotherapy, it is not surprising that women having 
received primary prophylactic G-CSF have high expenditures in the first year in spite of any cost 
reductions due to reduced neutropenia management and hospitalization costs. It is also important to 
note that in women receiving primary prophylactic G-CSF, G-CSF accounts for nearly 30% of the 
overall costs in the first year and is almost as big a contributor to overall costs as chemotherapy (at 
40%).   
 
Previous studies predominantly look at neutropenia hospitalization and immediate care costs 
and have ambiguous findings in terms of the cost reduction due to G-CSF. These past studies are 
broadly of three types - some directly estimate the expenditures associated with neutropenia 
hospitalization; some develop cost models to estimate the threshold above which prophylaxis of 
neutropenia becomes cost-effective;  and some estimate the reduction in hospitalization costs and 
other neutropenia related costs due to G-CSF administration. 
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Studies that just look at the cost of neutropenia hospitalization have found that cost of care 
and inpatient care is around 1.5 to 2 times higher in women experiencing neutropenia (Weycker, 
2006; Gandhi, 2001) and the neutropenia hospitalization cost could range from $10,000 to $30,000 
(Eldar-Lissai, 2007; Kuderer, 2006; Weycker, 2007; Weycker 2006; Brooks, 2003). Studies also find 
that the cost of care for neutropenia predominantly depends on the patient’s baseline clinical status 
like cancer stage and existence of other comorbidities (Chrischilles, 2005).  
 
Studies looking at cost-effectiveness of G-CSF using cost-models have demonstrated that 
primary prophylactic G-CSF is cost-reducing and cost effective in patients with high risk of 
developing neutropenia, febrile neutropenia or neutropenia hospitalization (>20% risk according to 
the currently accepted model by ASCO) (Eldar-Lissai, 2007; Uyl-de Groot, 1996; Lyman 2004; 
Lyman, 1993). Uyl-de Groot and colleagues show that G-CSF is cost effective in terms of reducing 
hospitalization and antibiotic administration costs in patients receiving chemotherapy, especially for 
patients with higher risk of infections (Uyl-de Groot, 1996). These cost-effectiveness models only 
include direct healthcare costs and do not include out-of-pocket costs, indirect costs (due to 
caregiver’s time and any other form of loss of pay), intangible costs and quality of life considerations. 
Lyman and colleagues suggest that prophylactic G-CSF should be administered even if the risk is less 
than 20% in patients with possibly complicated or prolonged course of management such as the 
elderly patients (Lyman, 1998). 
 
Studies looking at reductions in costs due to neutropenia are mostly clinical trials and 
retrospective chart reviews with low external validity (Glaspy, 1993; Zagonel, 1994; Dranitsaris, 
1995; Bassan, 1997). These studies have mixed findings. Some studies reveal a drop in costs, on 
average, in patients receiving primary prophylactic G-CSF compared to those not receiving the 
prophylaxis (Glaspy, 1993; Zagonel, 1994), while some reveal no change in costs (Dranitsaris, 1995; 
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Bassan, 1997).  Two studies found that although the neutropenia hospitalization length of stay was 
reduced in patients receiving G-CSF, the cost reduction was offset by the initial cost of G-CSF 
administration (Dranitsaris, 1995; Bassan, 1997).  
 
5.6 Effect on systemic therapy provision 
 
This study found that primary prophylactic G-CSF administration was associated with higher 
probability of radiation therapy administration during the first course and higher probability of 
administration of more than 5 cycles of chemotherapy during the first course, thereby supporting 
hypotheses four and five. Primary prophylactic G-CSF increased the probability of radiation therapy 
administration and administration of chemotherapy for more than 5 cycles during the first course by 
8%-points [95%CI: 1 to 14 %-points] and 6%-points respectively [95%CI: 0.1 to 12 %-points] (Table 
11). Also, women receiving a higher duration of primary prophylactic G-CSF also had higher 
probability of radiation therapy administration during the first course and higher probability of 
administration of more than 5 cycles of chemotherapy during the first course. The adequate 
administration of primary prophylactic G-CSF for five or more days leads to a 1%-point increase in 
both the probability of radiation therapy administration [95%CI: 0.1 to 1.6 %-points] and the 
probability of adequate chemotherapy administration (more than 5 cycles) [95%CI: 0.1 to 2.0 %-
points] during the first course (Table 12).   
 
These findings are crucial from the point of view of the providers. Not reducing systemic 
therapy intensities ensures complete cure from breast cancer, prevents recurrence and reduces 
mortality. One of the prime incentives for physicians to administer primary prophylactic G-CSF is to 
sustain dose intensity, adhere to preplanned chemotherapy regimen, and avoid reduction or stopping 
of systemic chemotherapy which might lead to worse future prognosis (Bonneterre, 2005; Budman, 
1998; Webster, 1996; Shayne, 2007).  
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Past clinical trials and other studies do find that primary prophylactic G-CSF administration 
increased adherence to preplanned chemotherapy regimens without reductions, successful 
administration of adequate chemotherapy dose intensities, or ability to increase the dose intensity 
based on patient needs (Jost, 1990; Kaplan, 1991; Kotake, 1991; Ardizzoni, 1994; Engelhard, 1994; 
Miles, 1994; Zagonel, 1994; Hansen, 1995; Woll, 1995; Webster, 1996; Jones, 1996; Heil, 1997; 
Fridrik, 1997; Fukuoka, 1997; Hidalgo, 1998; Steward, 1998; Stoger, 1998; Pfreundschuh, 2001; 
Lyman, 2002; Kuderer, 2005; Shayne, 2006; Kuderer, 2007). Two clinical trials also found no 
beneficial effect of chemotherapy on sustaining chemotherapy does intensity (Shaffer, 1993; 
Logothetis, 1995), but these two studies looked only at Sargramostim (GM-CSF) and not the 
Filgrastim, the more commonly used G-CSF. To the best of the author’s knowledge, none of the 
studies looked at the effect of primary prophylactic G-CSF on future radiation therapy administration; 
hence the positive effect of primary prophylactic G-CSF in sustaining radiation therapy during the 
first course is a new finding in this study.  
 
5.7 Analysis without controlling for the type of treatment  
 
Physicians often plan the short-term treatment protocol for a breast cancer patient soon after 
her diagnosis based on the tumor characteristics and other clinical characteristics. Type of surgery to 
be performed and type of radiation therapy and chemotherapy to be administered might be decided 
simultaneously. In addition, primary prophylactic G-CSF administration is often decided based on the 
type of chemotherapy regimen planned. Thus, treatment administered during the first few months 
after diagnosis could be a joint decision along with the decision to administer primary prophylactic G-
CSF, and the treatment variables controlled in this study, although administered before primary 
prophylactic G-CSF (pre-treatment variables), might be correlated to the decision to administer G-
CSF. 
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A sensitivity analysis was performed by excluding all the treatment variables to see if the 
treatment protocols associated with the decision to administer primary prophylactic G-CSF (and not 
just the primary prophylaxis itself) were associated with better health outcomes overall. As can be 
seen from table A4, A5 and A6 most effects are similar to the previous parametric analysis performed 
after controlling for the type of pre-treatment therapies (table 10-12), except for hypothesis one. The 
important difference was that there was no effect of primary prophylactic G-CSF administration on 
neutropenia hospitalization probability. Since the reduction in neutropenia hospitalizations is the main 
finding of this study, the difference between analyses controlling for and not controlling for the type 
of treatments administered is interesting.  
 
This lack of neutropenia hospitalization risk reduction could be because of the following 
factors: 
 
1. The treatment variables are acting as indirect measures for unobserved heterogeneity in 
clinical characteristics that providers are aware of but are not reported in the observational 
data (like laboratory values for baseline blood cell counts and co-morbidities not recorded in 
the Medicare claims). Thus, patients receiving similar therapy are closer to each other in 
terms of their clinical characteristics and neutropenia susceptibility. Not controlling for these 
treatment characteristics increases the unobserved heterogeneity and makes unbiased 
estimation of treatment effect difficult.  
 
2. The treatment (especially chemotherapy) variables are the main source of neutropenia risk. 
Since neutropenia and neutropenia hospitalization are induced by chemotherapy (and 
worsened by other systemic therapies like radiation therapy), not controlling for these leads to 
the comparison of patients with different risks of neutropenia occurrence. As established 
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before in this study patients receiving primary prophylactic G-CSF receive more intense 
chemotherapy and hence are inherently at a higher risk of neutropenia occurrence. Thus, not 
controlling for difference in type of treatment increases the baseline risk of patients receiving 
G-CSF and biases the treatment effect estimate towards zero.   
 
The same lack of effect on neutropenia hospitalization is observed when surgery variables are 
controlled for but chemotherapy and radiation therapy are not (since these are more directly related to 
neutropenia risk and G-CS administration) (Tables 9 to 11), emphasizing the fact that neutropenia risk 
is determined by systemic therapy and not controlling for the treatments makes the treated group 
different from the untreated group in terms of baseline neutropenia risk.  
 
5.8 Policy Implications 
 
5.8.1 Implications for Providers and ASCO policies 
 
One of the main aims of the study is to provide evidence for the benefits of primary 
prophylactic G-CSF administration, address gaps in the literature, and contribute towards ASCO 
policies with regards to the appropriateness of the primary prophylaxis in elderly female breast cancer 
patients. The study found that primary prophylactic G-CSF is clinically beneficial in elderly breast 
cancer patients receiving chemotherapy as it reduces the probability of neutropenia hospitalizations 
and improves adherence to provision of systemic therapy (both radiation and chemotherapy).  
 
Standardized and unambiguous ASCO guidelines for primary prophylactic G-CSF 
administration in the elderly could help reduce unexplained racial and regional disparities currently 
observed in the population. It is not surprising that unexplained regional disparities exist in the 
administration of a recently introduced drug since it takes time for providers to become aware of a 
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new drug. The extent to which they change their treatment protocols to incorporate the new drug 
depends on unambiguous standard medical guidelines supporting its use and the extent to which their 
colleagues adopt the drug successfully and realize its benefits. Clear ASCO guidelines for the primary 
prophylactic G-CSF use in the elderly patients, and publication of scientific evidence supporting 
primary prophylaxis, will help reduce subjective judgment and promote standardization of care. 
 
ASCO recommendation for appropriate primary prophylactic G-CSF administration should 
address various aspects including successful identification of high risk patients, appropriate window 
for primary prophylaxis, duration of administration and concerns about any side effects or counter-
indications.  
 
1. Risk Identification:  
Factors that increase the risk of neutropenia occurrence include older age, presence of 
comorbid conditions (especially those that impede the body’s ability to maintain and excrete the 
chemotherapeutic agents like – renal disease, live disease, bone marrow disease), more advanced 
cancer stage, previous anemia, abnormal leukocyte counts, recent infection and chemotherapy 
characteristics (Chrischilles, 2002; Shayne, 2007; Lyman, 2003a; Weycker, 2006; Chen-Hardee, 
2006; Brooks, 2003; Lyman, 2004; Chrischilles, 2005; Du 2002). Many of the comorbidities, and 
conditions like anemia and abnormal leukocyte counts are assessed by the providers using the latest 
blood tests. Since blood levels are not present in these data, the study could not verify if the providers 
were indeed using this information while deciding to administer primary prophylactic G-CSF. The 
study did establish that chemotherapy characteristics determined the administration of G-CSF. The 
providers use the clinical information to determine the intensity of the chemotherapy regimen and 
based on the risk of the chosen regimen they decide to administer prophylactic G-CSF.  
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In order to standardize the risk identification process ASCO guidelines should be more 
explicit and specific about comorbidities, blood tests and chemotherapy characteristics that increase 
the risk of neutropenia while making recommendations for administering prophylactic G-CSF. The 
guidelines state risk rates above which primary prophylaxis is recommended but do not explicitly 
state the clinical causes for these high-risk rates and the extent to which these causes affect the risk 
rates (ASCO, 2006). This ambiguity needs to be addressed. The guidelines do provide incidence rates 
for neutropenia with different chemotherapy regimen, which is probably why physicians decide G-
CSF administration based on the regimen.   
 
2. Appropriate window for primary prophylaxis: 
This study establishes the benefits of primary prophylaxis administered within the first five 
days of the start of first course chemotherapy, i.e. within five days of the very first cycle. However, 
this study does not provide evidence for a broader definition of primary prophylactic G-CSF. 
According to the clinical definition, any administration after the start of chemotherapy but before the 
first incidence of neutropenia constitutes primary prophylaxis. Since neutropenia is an acute 
complication and can occur any time after a week of starting the chemotherapy, most providers 
suspecting a patient’s higher susceptibility administer the drug within the first two to three days of 
starting chemotherapy. Sometimes, given the cost of the drug some providers might decide to wait for 
few days (or cycles) and administer the drug in case the blood counts worsen. For example if the 
patient had an Absolute Neutrophil Count (ANC) of 5000 cells/mm3 before the start of chemotherapy 
and it dipped to 4000 cells/mm3 after three cycles of the first course chemotherapy, the patient is still 
not neutropenic (normal ANC is 1500 to 8000 cells/mm3 and neutropenia starts below 1500 
cells/mm3). If the provider starts the G-CSF soon after the third cycle, due to the drop in ANC, it will 
still be primary prophylaxis. This study does not account for such late but justifiable starts in primary 
prophylaxis.  
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On the other hand, it is important to emphasize that 50% of neutropenia cases occur soon 
after the first cycle, and the first occurrence significantly increases the likelihood of later occurrences 
(Chen-Hardee, 2006; Chrischilles, 2002; Armitage 1984; Gomez, 1998; Shayne, 2007; Timmer-
Bonte, 2006). Thus the 5-day window following the first cycle for primary prophylactic G-CSF 
administration is an important time frame because administration during that time prevents the initial 
neutropenia after first cycle and reduces the probability of future neutropenia occurrences. ASCO 
recommends prophylactic administration within 24 to 72 hours of administration of chemotherapy but 
does not indicate if the patient should start receiving it with the very first cycle. Since primary 
prophylaxis started after 5 days is difficult to identify using claims data, it is hard to establish if an 
earlier start of primary prophylaxis is better than administrations at later dates/cycles in this study. 
However, an earlier start does seem to be beneficial in itself as per the findings in this study.  
 
3. Duration of administration:  
Given the findings in this study adequate administration of primary prophylactic G-CSF 
seems to be very important. Provider’s awareness about the importance of duration and explicit 
guidelines about the duration are important to ensure consistent practices across all providers. ASCO 
guidelines recommend continuation of G-CSF until ANC returns to 2000 to 3000 cells/mm3 but the 
guidelines do not state a minimum duration until which the drug should be administered. Thus, there 
is no guidance for primary prophylactic G-CSF administration where the ANC is normal at the start 
of the prophylactic administration.  
 
A sensitivity analysis was done in this study to see if five or more days of administration was 
particularly beneficial in reducing neutropenia hospitalization compared to a different cut off for the 
duration – 7 or more days and 10 or more days. It was interesting to note both 7 or more days and 10 
or more of administration did not have a statistically significant benefit in reducing neutropenia 
hospitalization rates, though there were some effects on improving adherence to systemic therapies. 
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This lack of effect probably suggests a diminishing return to increasing duration. If administering the 
drug for at least five days has better overall outcome in the population then it is important that ASCO 
recommend a minimum duration for G-CSF administration accordingly. More research with different 
cancers, age groups, and population subsets needs to be done in order to establish a scientifically 
valid minimum duration for primary prophylactic G-CSF administration in all cases.  
 
4. Concerns about side effects:  
Although none of the reported or hypothesized side effects have been scientifically evaluated 
through population based studies or clinical trials, long-term safety of G-CSF has not been 
established. The most common concern is occurrence of Acute Myeloid Leukemia or 
Myelodysplastic Syndrome (Hershman, 2007). Chemotherapy often causes mutation in blood cells at 
an early stage of their development. Typically, these mutated cells destroy themselves, but the G-CSF 
administration saves them from destruction, thereby leading to their developing into blood cancer 
cells. G-CSF also has some direct mutant effects on the blood cells. The National Surgical Adjuvant 
Breast and Bowel Project (NSABP) conducted a study by pooling data from six clinical trials in order 
to look at the possible occurrence of Acute Myeloid Leukemia or Myelodysplastic Syndrome due to 
G-CSF administration (Smith, 2003). Due to small sample sizes the study could not establish 
statistically significant correlations or causality but reported the findings as hypothesis generating. 
Another study using the SEER Medicare data reported statistically significant increase in the 
occurrence of Acute Myeloid Leukemia or Myelodysplastic Syndrome in patients receiving G-CSF, 
however causality could not be established.  
 
Bone and muscle pain is another concern. Bone pain occurs due to rising pressure within 
bone marrow by increased granulocytes, edema within bone marrow by histamine release, and 
increased level of bradykinin due to the biochemical effect of G-CSF. Studies report the incidence to 
be about 1-5% in patients receiving G-CSF (Ogata, 2005; Kuderer, 2005). Most other symptoms are 
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related to the subcutaneous mode of administration of G-CSF leading to redness, irritation or other 
inflammatory symptoms of the injection.  
 
The side effects are predominantly temporary discomforts and have very low incidence rates, 
and studies state that the benefits far outweigh these side effects (Hershman, 2007). However, these 
possible risks could deter some providers from using the drug. It is important that the ASCO 
guidelines explicitly outline the nature and incidents of these side effects in light of the benefits in 
order to alleviate any concerns about the use of this drug.  
 
5.8.2 Implications for Payers and Medicare Policies  
 
1. Implications for cost: 
Cost effectiveness has not been unambiguously established for primary prophylactic G-CSF, 
and some studies show that any cost reduction due to reduction in neutropenia hospitalization are 
often offset by the initial cost of G-CSF administration (Dranitsaris, 1995; Bassan, 1997). However, 
these studies do not account for quality of life issues associated with reduction of neutropenia 
complications and indirect costs to the patient and family due to hospitalizations and neutropenia 
management.  
 
The cost of G-CSF administration is not trivial. Each shot costs $250. Since one course of 
primary prophylaxis is administered for 5 to 10 days, a course costs $1,250 to $2,500. If G-CSF is 
administered after every cycle in the first course chemotherapy, and the first course has 4 to 12 cycles 
on an average, the costs could range from $5,000 to $30,000. This is almost the same as the cost of 
the first course chemotherapy itself. In this study neutropenia hospitalization costs are lower for 
patients receiving G-CSF but the difference is not statistically significant. Overall costs are 
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significantly higher for patients receiving G-CSF, hence cost saving is not apparent in this study and 
primary prophylaxis is justifiable only on the basis of clinical and therapeutic benefits.  
 
2. Implications for coverage:  
This study found adequate primary prophylactic G-CSF administration to be vital for 
improving the clinical benefits. The stipulations associated with Medicare coverage of G-CSF have a 
significant effect on the duration of G-CSF administration. Medicare only covers G-CSF 
administration if the drug is administered in the physician’s office. Since the drug is very expensive if 
bought out-of-pocket for self-administration, and traveling to the physician’s office everyday for a 
week or more might not be feasible for all patients, many patients find it hard to comply with the 
adequate duration. Expanding coverage to include self-administration as long as it is approved by the 
physician is an important step to ensure adequate drug administration.  
 
5.8.3 Implications for patients  
 
1. Awareness about the importance of duration:  
The decision to administer G-CSF is clearly the provider’s decision, but adequate uptake of 
G-CSF is also determined by patient’s ability to comply with the recommended duration. The study 
found that the determinants of duration of administration are more patient specific instead of factors 
like geographic location that are associated with provider beliefs in the region. It is important to 
ensure that patients understand the significance of duration and improve their compliance.  
 
2. Awareness about side effects: 
Side effects could deter patients from complying with the adequate administration of G-CSF. 
Patient awareness about the side effects, especially possible bone and muscle pain, and other effects 
associated with subcutaneous administration will help the patient be mentally prepared and avoid 
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unnecessary panic. It is also important to explain the low occurrence and easy medical management 
of these symptoms and precautions the patients can take to avoid or alleviate these symptoms.   
 
5.9 Limitations  
 
1. Non-Random treatment assignment:  
Providers decide whether or not to administer primary prophylactic G-CSF based on patient 
characteristics, thus the treatment assignment is not random in this study and estimation of unbiased 
treatment effect is not straightforward. The physician administers primary prophylactic G-CSF to 
patients at a higher neutropenia risk, hence the baseline outcomes for patients receiving G-CSF are 
different from the baseline outcomes for patients not receiving G-CSF. This issue is partially 
addressed by controlling for patient clinical characteristics and using a matching technique to reduce 
bias. This technique, however, does not account for unobserved differences in patients who receive 
G-CSF versus who don’t.  
 
2. Narrow primary prophylactic G-CSF window 
Since G-CSF is administered both as prophylactic and therapeutic drug for neutropenia, it is 
hard to distinguish using claims data if the G-CSF was administered prophylactically or in response 
to some neutropenia symptom. In order to prevent misclassification of therapeutic use of G-CSF as 
prophylaxis, we have restricted the primary prophylactic G-CSF administration window to just 5 days 
after the first chemotherapy administration similar to other claims based studies (Weycker 2006; 
Chrischilles, 2002). The sample size issues and small post-matching sample were due to the low 
number of patients receiving primary prophylaxis within the first 5 days of the start of chemotherapy.  
 
A descriptive analysis was done to look at the number of women receiving G-CSF at different 
time periods after the start of chemotherapy. 475 (476 on including rural Georgia) women received 
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G-CSF within a week of the start of chemotherapy compared to 337 (none in rural Georgia) women 
who received it within the first five days. 1699 (1700 on including rural Georgia) women receive G-
CSF within the first month after start of chemotherapy, 2719 (2723 on including rural Georgia) 
women receive it within three months and 3066 (3072 on including rural Georgia) women receive it 
within six months of the start of chemotherapy. Increasing the window after the start of chemotherapy 
considerably increases the number of patients receiving any G-CSF. Some of these administrations 
could be primary prophylactic and might have been misclassified due to the restrictive 5-day window. 
This leads to the estimation of the treatment effects of primary prophylaxis to be biased towards zero, 
thus the estimates would be more conservative than in the actual population.  
 
The effects of primary prophylaxis administered during the 5 day window is however 
important to look at because 50% of neutropenia occur soon after the first cycle and the first 
occurrence significantly increases the later occurrences (Chen-Hardee, 2006; Chrischilles, 2002; 
Armitage 1984; Gomez, 1998; Shayne, 2007; Timmer-Bonte, 2006). The prophylaxis administered 
during the first five days of chemotherapy initiation prevents the initial neutropenia after first cycle 
and reduces the probability of future neutropenia occurrences.  
 
3. Inability to estimate chemotherapy dose intensity:  
Dose of chemotherapy cannot be observed in the claims data. Dose intensity of chemotherapy 
(amount of dose and frequency of the cycle) is the direct determinant of neutropenia risk (Shayne, 
2007), but could not be controlled for in this study. This is partially addressed by controlling for the 
type and number of drugs administered in the first cycle, and the duration between the first and the 
second cycle. 
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4. External validity issues  
Matching helps compare treated patients (receiving G-CSF) with untreated patients closest in 
their socio-demographic and clinical characteristics and helps reduce model dependence and baseline 
differences in observed characteristics. In this analysis many untreated observations were dropped 
due to the small size of the treated group and the inability to find an appropriate treated match for 
each of the untreated patients. This does not compromise the power of the study as there is very little 
improvement in power if the untreated group is increased keeping the treated group constant. 
Dropping these observations might reduce the generalizability of the study. However, it is important 
to understand that the untreated observations that were dropped do not have treated observations to 
compare against. Hence using them to estimate treatment effects requires extrapolating treated 
observations in areas were the common support is lacking, thus leading to model dependence. Any 
lose in generalizability due to dropping unmatched untreated observations is a limitation of the data 
and not the matching technique. It is also important to note that there were no covariate (observed 
variable) categories which were eliminated from the analysis (except rural Georgia) due to discarding 
observations while matching.  
   
5.10 Future research and next steps 
 
Future research is required to explore some areas which could not be examined in this study, 
and also to further corroborate the findings in this study: 
 
1. Analysis with the more recent SEER-Medicare data with patients diagnosed after 2002:  
Examining some of the trends revealed in this study using the more recent SEER Medicare 
data will be interesting. Since G-CSF has been around for a while it will be interesting to see if 
unexplained regional disparities reduce with time. Regional trends with time were examined in this 
data and it was observed that primary prophylactic administration rates were increasing with time in 
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all regions, but regional disparities existed even in the later years.  However, due to the small number 
of patients receiving primary prophylactic G-CSF (337) in this sample, regional trends with time 
could not be statistically evaluated. 
 
Addition of the recent SEER-Medicare data will provide more observations and statistical 
power to look at the effect of primary prophylactic G-CSF on neutropenia hospitalization length of 
stay and expenditures, and to examine the effects of duration of primary prophylactic G-CSF 
administration on these neutropenia related outcomes.  
 
2. Evaluating the effects of primary prophylaxis in younger breast cancer patients: 
It will be interesting to see if the beneficial effects of primary prophylactic G-CSF on 
neutropenia hospitalization rates and systemic treatment adherence exist in the younger population, as 
compared to the elderly patients, using the Market Scan data.  
 
3. Evaluating the effects of primary prophylaxis in other cancer patients:  
Since this study only looks at breast cancer patients receiving chemotherapy, it is important to 
assess these effects in other cancers requiring chemotherapy – like Pancreatic Cancer, Leukemia, and 
Non-Hodgkin’s Lymphoma, in order to further contribute evidence towards the ASCO guidelines.  
 
4. Comparing the effectiveness between different G-CSF drugs – Filgrastim versus Sargramostim:  
Since Medicare patients predominately receive Filgrastim (86% in this analysis), and studies 
examining Sargramostim (used in VA patients) often reveal a lower effectiveness of G-CSF, it will be 
interesting to use VA claims to compare the effectiveness of Filgratsim with Sargramostim.  
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5. Detailed cost-effectiveness study:   
This study could not establish any changes in cost due to administration of primary 
prophylactic G-CSF. However, a comprehensive cost study requires examination of all types of cost 
associated with neutropenia. It is also important to determine the perspective form which the cost 
analysis will be performed. This study evaluated costs from the payer’s perspective and only looked 
at actual expenditure to Medicare. Given the quality of life, out of pocket and indirect cost issues 
involved with primary prophylaxis it is also important to conduct cost-effectiveness analyses from the 
patient’s or societal perspective by incorporating direct, indirect and intangible costs to the subject. 
 
6. Analysis using other clinical data: 
One of the limitations of the study was the inability to control for relevant laboratory values 
used as markers by providers to decide the need for administration of primary prophylactic G-CSF 
(Blood cell counts, and markers for bone marrow, liver and renal functioning). Using clinical data 
that include these parameters might help develop better propensity models for determinants of G-CSF 
administration.    
  
 
Chapter 6 
Conclusion 
 
Primary prophylactic G-CSF is aimed to prevent chemotherapy related toxicities and sustain 
dose intensity in cancer patients requiring chemotherapy. This study looks at the effect of primary 
prophylactic G-CSF in preventing neutropenia hospitalization, length of stay and expenditure 
associated with neutropenia hospitalization, overall Medicare expenditures in the first year after start 
of chemotherapy, and ability to administer adequate systemic therapies (chemotherapy and radiation 
therapy) during the first course chemotherapy in elderly breast cancer women. The study also 
examines the determinants of primary prophylactic G-CSF administration in these patients.  
 
The study found that the key determinants of primary prophylactic G-CSF in the elderly 
patients receiving chemotherapy were – Race, SEER region, Year of diagnosis/chemotherapy 
initiation and Characteristics of the chemotherapy regimen. Unexplained and significant variations in 
primary prophylactic G-CSF administration based on race and region are a concern. The study also 
found that primary prophylactic G-CSF reduced the probability of neutropenia hospitalization and 
improved the probability of adequate chemotherapy and radiation therapy provision during the first 
course chemotherapy. Primary prophylactic G-CSF patients also had significantly higher overall 
Medicare expenditures during the first year after the start of chemotherapy (which is the time when 
bulk of the cancer related therapies are provided). The study also found that along with the 
administration of primary prophylactic G-CSF the number of days G-CSF is administered was very 
crucial for these outcomes. The study calls for changes in ASCO and Medicare policies and clear 
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guidelines for administration of primary prophylactic G-CSF and duration of G-CSF administration in 
the elderly.  
  
 
 
TABLES 
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Table 1 Extent of disease spread and standard treatment protocol by breast cancer stage 
 
Stage  Extent of disease spread Standard Treatment Protocol 
Stage 0 Carcinoma in situ. The precancerous 
stage with no tumor or disease spread. 
• Observation with regular mammograms 
• In some cases surgery with or without 
radiation  
• In some adjuvant Hormonal therapy.  
• In some stand alone Hormonal therapy 
Stage I Tumor size < 2 cm, no axillary lymph 
nodes or other body parts involved. 
• Surgery with or without radiation  
• Adjuvant Systemic Chemotherapy with or 
without Hormonal therapy 
• Adjuvant Radiation therapy 
• Adjuvant Hormonal therapy 
Stage IIA No tumor and axillary lymph nodes 
involved. 
Or Tumor size <2 cm and axillary 
lymph nodes involved.  
Or Tumor size 2-5 cm and no axillary 
lymph nodes involved. 
• Surgery with or without radiation  
• Adjuvant Systemic Chemotherapy with or 
without Hormonal therapy 
• Adjuvant Radiation therapy 
• Adjuvant Hormonal therapy 
Stage IIB Tumor size 2-5 cm and axillary lymph 
nodes involved (< 4 axillary nodes) 
Or Tumor size > 5 cm and no axillary 
lymph nodes involved.  
• Surgery with or without radiation  
• Adjuvant Systemic Chemotherapy with or 
without Hormonal therapy 
• Adjuvant Radiation therapy 
• Adjuvant Hormonal therapy 
Stage IIIA No tumor and cancer is found in the 
axillary lymph nodes that are attached 
to each other or to other structures. 
Or Tumor size 2-5 cm with 4 or more 
axillary nodes are attached to each 
other or to other structures 
Or Tumor size > 5 cm and axillary 
lymph nodes involved.   
 
• Surgery with or without radiation  
• Adjuvant Systemic Chemotherapy with or 
without Hormonal therapy 
• Adjuvant Radiation therapy 
• Adjuvant Hormonal therapy 
Stage IIIB Tumor has penetrated chest wall or 
skin, and may have spread to < 10 (or 
no) axillary nodes 
• Systemic chemotherapy  
• Systemic chemotherapy followed by 
surgery followed by radiation therapy 
followed by systemic chemotherapy 
Stage IIIC Any tumor size or no tumor with 
involvement of often more than 10 
lymph nodes including the ones in the 
collarbone and neck, and internal breast 
lymph nodes.  
• Surgery with or without radiation  
• Adjuvant Systemic Chemotherapy with or 
without Hormonal therapy 
• Adjuvant Radiation therapy 
• Adjuvant Hormonal therapy 
• In some cases just Systemic 
chemotherapy  
• In some cases Systemic chemotherapy 
followed by surgery followed by radiation 
therapy followed by systemic 
chemotherapy 
Stage IV 
(metastasis) 
The cancer has spread to other organs 
of the body, most often the bones, 
lungs, liver, or brain. 
• Systemic chemotherapy  
• Systemic chemotherapy followed by 
surgery followed by radiation therapy 
followed by systemic chemotherapy 
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Table 2 Findings from previous research exploring the effects of G-CSF administration 
 
 
 Study 
Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
1. Oyama, 1990 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
G-CSF 
G-CSF reduced 
incidence and duration 
of neutropenia induced 
by intensive 
chemotherapy. 
2. Jost, 1990 Germ cell 
tumors 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
GM-CSF 
GM-CSF resulted in a 
significant shortening 
of neutropenia and 
allowed for the timely 
administration of the 
subsequent cycle of 
chemotherapy. 
3. Crawford, 
1991 
Small Cell 
Lung Cancer 
Clinical Trial 31-80 Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
4. Pettengell, 
1992 
Non-
Hodgkin’s 
Lymphoma  
Clinical Trial 
 
16-71 Primary 
Prophylaxis – 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
5. Anderson, 
1991 
Small Cell 
Lung Cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF prevents 
neutropenia.  
6. De Vries, 
1991 
Ovarian 
Cancer 
Clinical Trial 31-66 Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduces the 
severity of neutropenia 
and thrombocytopenia 
after chemotherapy 
7. Havemann, 
1991 
Small Cell 
Lung Cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF does reduce 
neutropenia but has no 
effect on response 
rates and survival.  
8. Kaplan, 1991 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF lead to 
higher mean nadirs of 
the absolute neutrophil 
count, shorter mean 
durations of 
neutropenia, fewer 
chemotherapy cycles 
complicated by 
neutropenia and fever, 
fewer days 
hospitalized for fever 
and neutropenia, fewer 
reductions in 
chemotherapy 
dosages, and less 
frequent delays in 
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 Study 
Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
chemotherapy 
administration. 
9. Kotake, 1991 Urogenital 
cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
G-CSF 
G-CSF reduces 
incidence of 
neutropenia, duration 
of neutropenia and 
accelerates recovery, 
and enables an 
increase in the dose of 
chemotherapy.  
10. Liberati, 1991 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF improved 
neutrophil count after 
chemotherapy 
administration, but had 
side effects.  
11. Trillet-Lenior, 
1993 
Small Cell 
Lung Cancer 
Clinical Trial Unknown Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
12. Lyman, 1993 Any 
malignancy 
Simulation – 
Decision 
Analysis 
(probabilities 
based on 
Crawford, 
1991 study) 
NA Primary 
Prophylaxis 
and 
Therapeutic- 
Filgrastim 
Reduces cost of 
hospitalization if used 
prophylactically. Cost 
effective only if risk of 
neutropenic fever is 
higher than 40% for 
the administered 
chemotherapy 
regimen. Therapeutic 
use is not cost 
effective.  
13. Glaspy, 1993 Small Cell 
Lung Cancer 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
Filgrastim 
Filgrastim had 
significantly fewer and 
less resource-intensive 
hospitalizations. 
Filgrastim minimized 
the total charges, costs 
and Medicare 
payments.  
14. Gerhartz, 
1993 
Non-
Hodgkin’s 
Lymphoma 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduced 
neutropenia, days with 
fever and days of 
hospitalization for 
infection, and 
improved 
chemotherapy 
response.  
15. Kaku, 1993 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial All 
Adults 
Secondary 
Prophylaxis – 
GM-CSF 
GM-CSF prevented 
neutropenia, increased 
granulocyte count and 
reduced the duration of 
low granulocyte 
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 Study 
Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
counts.  
16. Shaffer, 1993 Advanced 
Malignancies 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
GM-CSF 
GM-CSF had no effect 
on neutropenia or dose 
intensity improvement.  
17. Gebbia, 1993 Any 
advanced 
solid tumor 
Clinical Trial 38-66 Primary 
Prophylaxis - 
Lenograstim 
Reduces febrile 
neutropenia. 
18. Gebbia, 1994 Any 
advanced 
solid tumor 
Clinical Trial 40-75 Primary 
Prophylaxis – 
Lenograstim 
Reduces febrile 
neutropenia. 
19. Zagonel, 1994 Non-
Hodgkin’s 
Lymphoma 
Pilot Study 60-70  Primary 
Prophylaxis - 
G-CSF 
G-CSF sustains 
chemotherapy 
administration, 
reduces hospitalization 
days, severe infections 
and mucositis, and 
overall treatment costs 
of cancer patients on 
chemotherapy.  
20. Aviles, 1994 Diffuse large 
cell 
lymphoma 
Clinical Trial  Primary 
Prophylaxis - 
G-CSF 
G-CSF kept leukocyte 
and granulocyte count 
higher, total number of 
days of leukopenia 
shorter, delays in 
treatment and infection 
episodes less frequent.  
Complete response 
was better in patients 
who received G-CSF.  
21. Ardizzoni, 
1994 
Breast Cancer Clinical Trial Adult Primary 
Prophylaxis - 
GM-CSF 
G-CSF helps increase 
chemotherapy dose 
intensity 
22. Eguchi, 1994 Non-small-
cell lung 
cancer 
Clinical Trial < 76 Secondary 
prophylaxis – 
GM-CSF 
GM-CSF reduced the 
duration of 
chemotherapy-induced 
granulocytopenia 
23. Eguchi, 1994 Small-cell 
lung cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
G-CSF 
G-CSF reduced the 
incidence of 
neutropenia.  
24. Engelhard, 
1994 
Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 18-73 Primary 
Prophylaxis – 
GM-CSF 
GM-CSF significantly 
reduced the length and 
nadir of neutropenia, 
the length of fever 
episodes, the 
frequency of all and of 
severe infections, and 
of hospitalization and 
antibiotic 
requirements. There 
was no effect on 
response rate and 
overall survival 
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 Study 
Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
between the GM-CSF 
treatment and control 
groups. GM-CSF 
helped maintain 
chemotherapy dose 
intensity. 
25. Hamm, 1994 Small-cell 
lung cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduces 
chemotherapy-
associated neutropenia 
26.  Maher, 1994 Cancer other 
than myeloid 
leukemia 
Clinical Trial Adults 
>15 years 
Therapeutic 
G-CSF – 
Filgratsim  
Filgrastim accelerated 
neutrophil recovery, 
shortened the duration 
of febrile neutropenia 
and shortened length 
of stay for neutropenia 
hospitalization.  
27. Miles, 1994 Small-cell 
lung cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
G-CSF 
G-CSF significantly 
decreased dose 
reductions due to 
neutropenia 
28. Rampling, 
1994 
Intracerebral 
malignant 
glioma 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduced 
neutropenia 
occurrence and 
increased neutrophil 
count.  
29. Rowe, 1995 Acute 
Myelogenous 
Leukemia 
Clinical Trial 55-70 GM-CSF Reduces the duration 
of neutropenia and 
therapy-related 
mortality and 
morbidity 
30. Dranitsaris, 
1995 
Hodgkin’s 
and Non-
Hodgkin’s 
Lymphoma 
Analysis of 
retrospective 
chart review 
All 
Adults 
Primary 
Prophylaxis – 
G-CSF 
G-CSF use lead to 
fewer hospital days but 
the total net 
cost/patient was 
similar with and 
without G-CSF, such 
that the initial G-CSF 
expenditure is offset 
by reduced 
hospitalization. 
31. Stone, 1995 Acute 
myelogenous 
leukemia 
Clinical Trial  > 65 Primary and 
Secondary 
Prophylaxis 
GM-CSF 
GM-CSF did not seem 
to improve treatment-
related mortality rate 
or the rate of 
remission, though it 
did reduce number of 
neutropenia days. 
32. Chevallier, 
1995 
Inflammatory 
Breast Cancer  
Clinical Trial 23-65 Primary 
Prophylaxis – 
Lenograstim 
No effect on febrile 
neutropenia infection-
related mortality and 
early mortality. 
33. Bui, 1995 Soft Tissue Clinical Trial 21-69 Primary Reduces febrile 
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 Study 
Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
Sarcoma Prophylaxis – 
Lenograstim 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
34. Bajorin, 1995 Germ cell 
tumors 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduced the 
incidence of infections 
in the first cycle of 
chemotherapy, but no 
benefit beyond the 
initial chemotherapy 
cycle was evident.  
35. Bergmann, 
1995 
Non-
Hodgkin’s 
Lymphoma 
Clinical Trial All adults Primary 
Prophylaxis – 
GM-CSF 
The analyses revealed 
a significant reduction 
of neutropenia and 
duration of 
neutropenia in the 
GM-CSF group. 
36. Bunn, 1995 Limited-stage 
small-cell 
lung cancer 
Clinical Trial All adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF 
administration 
‘increased’ the 
frequency and duration 
of life-threatening 
thrombocytopenia, 
toxic deaths, 
nonhematologic 
toxicities, days in 
hospital, incidence of 
intravenous antibiotic 
use, and transfusions. 
GM-CSF increased 
post-chemotherapy 
WBC and neutrophil 
counts, but had no 
effect on the frequency 
of grade 4 leukopenia 
or neutropenia. GM-
CSF had no effect on 
survival and response 
rate.  
37. Chi, 1995 Head and 
neck cancer 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF can 
significantly reduce 
the severity and 
duration of 
chemotherapy-induced 
oral mucositis.  
38. Hansen, 1995 Breast Cancer Clinical Trial Adult Primary 
Prophylaxis – 
GM-CSF 
GM-CSF reduced 
granulocyte nadir 
duration and severity. 
No difference in 
frequency of 
neutropenic fever or 
antibiotic use. GM-
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
CSF improved dose 
intensity and response 
to chemotherapy.  
39. Katano, 1995 Breast Cancer Clinical Trial Adult Primary and 
Secondary 
Prophylaxis – 
G-CSF 
G-CSF can effectively 
treat and prevent 
chemotherapy-induced 
oral mucositis 
40. Logothetis, 
1995 
Urothelial 
tumor 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
GM-CSF 
GM-CSF did not effect 
the dose-intensity or 
incidence of infection.  
41. Seymour, 
1995 
Solid cancer 
or lymphoma 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
Lenograstim 
Dose strength of 
lenograstim had a 
significant effect on 
the duration of 
neutropenia, the 
absolute neutrophil 
count and the time to 
ANC nadir 
42. Woll, 1995 Small Cell 
Lung Cancer 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
Lenograstim 
WBC and neutrophil 
counts were higher in 
G-CSF patients than in 
the control group. No 
significant differences 
in the incidence of 
febrile neutropenia, 
antibiotic or 
transfusion 
requirements, or days 
in hospital. G-CSF 
helped increase dose 
intensity and improve 
2-year survival.   
43. Weiss, 1996 Advanced 
Malignancy 
Clinical Trial >18 Primary 
Prophylaxis – 
GM-CSF 
GM-CSF provides no 
clinically useful 
improvement in 
granulocyte tolerance 
of therapy 
44. Yau, 1996 Lymphoma 
or breast 
carcinoma 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF significantly 
shortens the duration 
of neutropenia and 
readmission only 
during the first course 
45. Uyl-de Groot, 
1996 
Any 
malignancy 
Markov 
Model 
All adults Primary 
Prophylaxis 
and 
Therapeutic - 
Any G-CSF 
Both prophylactic and 
therapeutic G-CSF are 
cost minimizing. 
Prophylactic G-CSF is 
cost minimizing only 
if the chemotherapy 
administered has a 
neutropenic fever risk 
higher than 50%.  
46. Muhonen, Metastasis Clinical Trial 34-65 Primary Reduces occurrence of 
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
1996 Breast Cancer  Prophylaxis - 
Filgrastim 
 
neutropenia.  
47. Webster, 1996 Breast Cancer Pilot study All 
Adults 
Secondary 
Prophylactic 
G-CSF 
Sustains pre-planned 
full dose intensity of 
chemotherapy, and 
reduces chemotherapy 
delays and dose 
reductions.  
48. Jones, 1996 Breast Cancer Clinical Trial Adults Primary 
Prophylaxis – 
Sargramostim 
GM-CSF significantly 
enhanced ANC 
recovery after FAC 
chemotherapy; it 
decreased the 
incidence and duration 
of associated 
neutropenia and 
moderately increased 
the dose-intensity of 
adjuvant 
chemotherapy. 
49. Paterakis, 
1996 
Non small-
cell lung 
cancer, small-
cell lung 
cancer, 
ovarian and 
breast cancer 
Clinical Trial All 
Adults 
Primary 
Prophylaxis – 
GM-CSF  
Positive effect of GM-
CSF on the erythroid 
tissue of patients 
receiving 
chemotherapy for solid 
tumors. 
50. Zinzani, 1997 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 60-82 Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
51. Heil, 1997 Acute 
Myeloid 
Leukemia 
Clinical Trial > 16 Primary 
Prophylaxis - 
Filgrastim 
Filgrastim reduces the 
duration of 
neutropenia, duration 
of fever, parenteral 
antibiotic use, and 
hospitalization. It also 
helps in sustaining 
dose intensity.   
52. Gisselbrecht, 
1997 
Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 15-55 Primary 
Prophylaxis - 
Lenograstim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
53. Moore, 1997 Acute 
Myeloid 
Leukemia 
Clinical Trial Adults 
<60 
Primary 
Prophylaxis  
and 
Therapeutic - 
G-CSF 
Reduces duration of 
granulocytopenia, 
need for 
hospitalization, 
duration of 
hospitalization, and 
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
duration of 
thrombocytopenia 
54. Ganser, 1997 Acute 
Myeloid 
Leukemia 
Literature 
review 
Adults Any G-CSF Reduces duration of 
neutropenia. 
Ambiguous effect on 
complete remission 
rates, event-free 
survival, and overall 
survival 
55. Bassan, 1997 Acute 
lymphoblastic 
leukemia 
Clinical Trial Adults Primary 
Prophylaxis  - 
Filgrastim 
G-CSF limited the 
incidence of severe 
neutropenia and 
related complications. 
Though costs were 
high in the G-CSF 
group chiefly due to 
the cost of Filgrastim 
itself.  
56. Fridrik, 1997 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 18-75 Primary 
Prophylaxis  - 
Filgrastim 
Filgrastim helped 
sustain dose intensity 
but did not affect 
febrile neutropenia 
rates.  
57. Fukuoka, 
1997 
Small-cell 
lung cancer 
Clinical Trial All 
Adults 
Primary 
Prophylaxis - 
G-CSF 
G-CSF helped dose 
intensity increase.  
58. Fossa, 1998 Germ Cell 
Tumor 
Clinical Trial 15-65 Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia and early 
mortality. No effect on 
infection-related 
mortality. 
59. Lyman, 1998 Any 
malignancy 
Decision 
analysis 
model 
All adults Primary 
Prophylaxis - 
Any G-CSF 
G-CSF is cost 
effective only if risk of 
neutropenic fever is 
higher than 20% for 
the administered 
chemotherapy. 
60. Dunlop, 1998 Hodgkin's 
disease 
Clinical Trial Adults Primary 
Prophylaxis – 
Filgrastim 
Filgrastim reduced the 
median duration of 
leucopenia, but had no 
effect on days of 
hospitalization, 
admissions for 
infectious 
complications, 
duration, grade and 
incidence of infections 
and incidence of 
febrile neutropenia.   
61. Feng, 1998 Any 
malignancy 
Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
Prevented neutropenia 
and shortened the 
duration of 
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
(leucomax) neutropenia.  
62. Hidalgo, 1998 Ovarian 
Carcinoma 
Clinical Trial 27-74 Primary 
Prophylaxis – 
G-CSF 
Improved dose 
intensity increment 
and reduced 
occurrence of 
neutropenia.  
63. Steward, 1998 Small Cell 
Lung Cancer 
Clinical Trial 38-75 Primary 
Prophylaxis – 
GM-CSF 
GM-CSF did not 
reduce neutropenia 
related complications 
like febrile 
neutropenia. It did 
help increase dose 
intensity.  
64. Stoger, 1998 Breast Cancer Clinical Trial Adults Primary 
Prophylaxis – 
GM-CSF 
GM-CSF helped 
increase dose intensity. 
65. Gatzemeier, 
2000 
Small Cell 
Lung Cancer 
Clinical Trial 39-75 Primary 
Prophylaxis – 
Lenograstim 
No effect on infection-
related mortality and 
early mortality. 
66. Pfreundschuh, 
2001 
Hodgkin's 
disease 
Clinical Trial 18-60 Primary 
Prophylaxis – 
GM-CSF 
GM-CSF helps 
increase dose intensity.  
67. Lyman, 2002 Any 
malignancy 
Meta-
Analysis 
All adults Primary 
Prophylaxis - 
Any G-CSF 
Reduces risk of febrile 
neutropenia, infection, 
and infection related 
mortality. Sustain dose 
intensity.  
68. Chrischilles, 
2002 
Non-
Hodgkin’s 
Lymphoma 
Primary data 
analysis 
> 18  Primary and 
Secondary 
Prophylaxis – 
Agent not 
specified 
G-CSF use reduced 
neutropenia 
hospitalization and 
duration of 
hospitalization  
69. Osby, 2002 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial > 60 Primary 
Prophylaxis – 
G-CSF 
G-CSF treatment 
efficiently accelerated 
granulocyte recovery 
following 
chemotherapy. 
70. Doorduijn, 
2003 
Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 65-90 Primary 
Prophylaxis - 
Filgrastim 
No effect on febrile 
neutropenia, infection-
related mortality and 
early mortality. 
71. Osby, 2003 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial 60-86 Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on early mortality. 
72. Chrischilles, 
2003 
Non-
Hodgkin’s 
Lymphoma 
Secondary 
data analysis 
(SEER-
Medicare) 
> 65 Primary 
Prophylaxis - 
Filgrastim 
(duration) 
Longer duration of 
Filgrastim 
administration reduces 
neutropenia 
hospitalization and 
increases time to 
hospitalization after 
chemotherapy.  
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
73. Scott, 2003 Non-
Hodgkin’s 
Lymphoma 
Secondary 
data analysis 
All adults Primary and 
Secondary 
Prophylaxis - 
Filgrastim 
Primary prophylaxis 
and longer duration 
(>7 days) secondary 
prophylaxis reduces 
the occurrence of 
febrile neutropenia 
74. Grigg, 2003 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial > 60 Primary 
Prophylaxis - 
G-CSF 
G-CSF reduced 
duration of severe 
neutropenia.  
75. Papaldo, 2003 Early stage 
breast cancer 
Clinical Trial Adults Primary 
Prophylaxis - 
G-CSF 
G-CSF does not 
improve disease free 
and overall survival.  
76. Weycker, 
2004 
Non-
Hodgkin’s 
Lymphoma 
Secondary 
data analysis  
All adults Primary 
Prophylaxis - 
Any G-CSF 
Reduces neutropenia 
hospitalization and 
infection-related 
hospitalization.  
77. Wang, 2004 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial Adult Primary 
Prophylaxis - 
G-CSF 
Use of G-CSF 
prevents leukopenia. 
78. Kuderer, 2005 Non-myeloid  
malignancy 
Meta-
analysis 
All adults Primary 
Prophylaxis - 
Pegfilgrastim, 
Lenograstim 
and Filgrastim 
G-CSF in general 
reduces febrile 
neutropenia, infection-
related mortality and 
increases delivered 
dose intensity. 
79. Timmer-
Bonte, 2005 
Small Cell 
Lung Cancer 
Clinical Trial 36-81 Primary 
Prophylaxis - 
Filgrastim 
Reduces febrile 
neutropenia. No effect 
on infection-related 
mortality and early 
mortality. 
80. Vogel, 2005 Breast Cancer Clinical Trial 21-88 Primary 
Prophylaxis - 
Pegfilgrastim 
Reduces febrile 
neutropenia and early 
mortality. No effect on 
infection-related 
mortality. 
81. Weycker, 
2006 
Non-
Hodgkin’s 
Lymphoma, 
Breast 
Cancer, Lung 
Cancer 
Secondary 
data analysis 
> 18 Primary 
Prophylaxis - 
Filgrastim 
(duration) 
Higher duration of 
Filgrastim 
administration reduced 
neutropenia and 
infection related 
hospitalizations.  
82. Shayne, 2006 Breast Cancer Secondary 
data analysis 
All adults Primary 
Prophylaxis - 
Any G-CSF 
G-CSF helps sustain 
chemotherapy dose 
intensity. 
83. Burton, 2006 Non-
Hodgkin’s 
Lymphoma 
Clinical Trial >60 years Primary 
Prophylaxis – 
G-CSF 
There was no 
significant difference 
in the recurrence-free 
or overall survival 
with the addition of G-
CSF. 
84. Eldar-Lissai, 
2007 
Any solid 
tumor 
Cost-Utility 
analysis 
18-65 Primary 
Prophylaxis - 
Pegfilgrastim was 
more cost-effective as 
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Reference 
Type of 
tumor 
studied 
Type of 
Study 
Age 
Range 
Treatment 
type 
Outcome 
Pegfilgrastim 
and Filgrastim 
well as cost 
minimizing as 
compared to filgrastim 
and no therapy. 
Filgrastim is not cost-
effective as compared 
to no treatment.  
85. Shayne, 2007 Any 
malignancy 
Analysis of 
Prospectively 
collected 
data 
> 70 Primary 
Prophylaxis - 
Any G-CSF 
Use of G-CSF reduced 
the occurrence of 
Severe and Febrile 
Neutropenia.  
86. Kuderer, 2007 Any 
malignancy 
Meta-
analysis 
All adults Primary 
Prophylaxis - 
Pegfilgrastim, 
Lenograstim 
and Filgrastim 
G-CSF in general 
reduces febrile 
neutropenia, infection-
related mortality and 
early mortality. G-CSF 
improves 
chemotherapy dose 
intensity.  
87. Sung, 2007 Any 
malignancy 
Meta-
analysis 
All adults Primary, 
Secondary or 
Therapeutic 
use of any G-
CSF agent 
Prophylactic G-CSFs 
have little or no effect 
on mortality but 
decrease rates of 
infection in patients 
receiving cancer 
chemotherapy.  
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Table 3 2006 ASCO recommendation summary for the use of G-CSF  
 
 Indication Recommendation 
1. Primary 
prophylaxis 
CSF are recommended when the risk of febrile neutropenia is in the range of 
20% or higher based on the chemotherapy regimen. For patients requiring 
“dose-dense” regimens based on scientific evidence, CSF is required and 
recommended. Primary prophylaxis is recommended for the prevention of 
febrile neutropenia in patients who have a high risk of febrile neutropenia 
based on age, medical history, disease characteristics, and myelotoxicity of the 
chemotherapy regimen. 
2.  Primary 
prophylaxis: 
Special 
circumstances 
Certain clinical factors predispose to increased complications from prolonged 
neutropenia, including: patient age > 65 years; poor performance status; 
previous episodes of febrile neutropenia; extensive prior treatment including 
large radiation ports; administration of combined chemoradiotherapy; bone 
marrow involvement by tumor-producing cytopenias; poor nutritional status; 
the presence of open wounds or active infections; more advanced cancer, as 
well as other serious comorbidities. In such situations, primary prophylaxis 
with CSF is often appropriate, even with regimens with febrile neutropenia 
rates of  < 20%. 
3.  Secondary 
Prophylaxis 
Secondary prophylaxis with CSF is recommended for patients who 
experienced a neutropenic complication from a prior cycle of chemotherapy 
(for which primary prophylaxis was not received), in which a reduced dose 
may compromise disease-free or overall survival or treatment outcome. In 
many clinical situations, dose reduction or delay may be a reasonable 
alternative. 
4. Therapeutic 
use: Afebrile 
Neutropenia 
CSF should not be routinely used for patients with neutropenia who are 
afebrile. 
 
5.  Therapeutic 
use: Febrile 
Neutropenia 
CSF should not be routinely used as adjunctive treatment with antibiotic 
therapy for patients with fever and neutropenia. However, CSF should be 
considered in patients with fever and neutropenia who are at high-risk for 
infection-associated complications, or who have prognostic factors that are 
predictive of poor clinical outcomes. High-risk features include expected 
prolonged (> 10 days) and profound (< 0.1 + 109/L) neutropenia, age > 65 
years, uncontrolled primary disease, pneumonia, hypotension and multi-organ 
dysfunction (sepsis syndrome), invasive fungal infection, or being hospitalized 
at the time of the development of fever. 
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Table 4 Variables used in the analysis and their source from the SEER-Medicare data  
 
 
Variable Name Source Claims Codes Time when 
observed 
    
Independent 
variables 
   
    
Granulocyte Colony 
Stimulating Factor 
Medicare Claims J1440; J1441; J2505; J2820 Within the first five 
days of first course 
chemotherapy 
initiation.  
    
Demographic 
characteristics 
   
    
Age at diagnosis SEER  and 
Medicare 
Enrollment 
Database 
  
Race/Ethnicity SEER   
Marital Status SEER   
Education SEER (from 
census 
extraction) 
  
Income SEER (from 
census 
extraction) 
  
Urban residence SEER (from the 
area resource file 
extraction) 
  
Region SEER   
Year of Diagnosis SEER   
    
Clinical 
Characteristics 
   
    
Modified Charlson 
Charlson Index 
Medicare Claims Modified Charlson Charlson Index 
Algorithm (SEER Medicare website) 
One year prior to  
initiation of first 
course 
chemotherapy  
Presence of other 
cancers before 
SEER   
History of infection 
one month before 
chemotherapy 
initiation 
Medicare Claims ICD-9-CM Diagnosis: 001.xx-139.xx; 
320.xx; 321.xx; 323.0x-323.7x; 324.xx; 
326.xx; 460.xx-466.xx; 480.xx-487.xx; 
567.xx; 590.xx; 598.0x; 599.0x; 680.xx-
686.xx; 790.7x-790.8x; V09.xx, 995.90-
995.93 
One year prior to  
initiation of first 
course 
chemotherapy  
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Variable Name Source Claims Codes Time when 
observed 
Patients on antibiotics 
one month before 
chemotherapy 
initiation 
Medicare Claims ICD-9-CM Procedure: 99.21; 99.22 
CPT: 90788; 99556 
HCPCS: C1024 C9019 C9001 C9227 
G8012 G8366 G8367 Q0144 S0016 
S0072 S0021 S0024 S0029 S0030 S0032 
S0034 S0039 S0040 S0071 S0073 S0074 
S0075 S0080 S0081 S0085 S0096 S0177 
S5106 S5017 S9539 S9494 S9497 S9500 
S9504 J0120 J0200 J0278 J0286 J0285 
J0290 J0295 J0390 J0456 J0530 J0540 
J0550 J0560 J0570 J0580 J0637 J0690 
J0692 J0694 J0695 J0696 J0697 J0698 
J0710 J0713 J0715 J0720 J0740 J0743 
J0744 J0770 J1835 J1335 J1362 J1364 
J1450 J1452 J1455 J1570 J1580 J1590 
J1835 J1840 J1850 J1890 J1910 J1956 
J2010 J2020 J2070 J2185 J2248 J2460 
J2510 J2540 J2543 J2545 J2700 J2770 
J3000 J3260 J3305 J3320 J3370 J3465 
J7682 J7685 J7310 J7315 J7316 
One year prior to  
initiation of first 
course 
chemotherapy  
Recent hospitalization 
one month before 
chemotherapy 
initiation 
Medicare Claims Any Medpar hospitalization claim one 
month prior to chemotherapy initiation 
One year prior to  
initiation of first 
course 
chemotherapy  
Tumor Stage SEER ( AJCC 
staging) 
  
Tumor size SEER   
Tumor Grade  SEER   
Node + SEER   
ER status  SEER   
PR status  SEER   
    
Procedures 
Performed 
   
    
Surgery SEER and 
Medicare claims 
ICD-9-CM Diagnosis: V4571; V5041; 
V524; V4382 
ICD-9-CM Procedure: 85.20-85.29; 
85.33-85.39; 85.40-85.49; 85.50-85.59; 
85.70-85.79; 85.82-85.85; 85.87; 85.90-
85.99 
CPT: 19110-19126; 19160-19162; 19180-
19272; 00404-00406; 19340-19350; 
19357-19396;  00402 
HCPCS: S2066-S2068 
One indicator for 
surgery after 
diagnosis but 
before initiation of 
first course 
chemotherapy; 
Another indicator 
for surgery after  
initiation of first 
course 
chemotherapy and 
before the end of 
first course 
chemotherapy 
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Variable Name Source Claims Codes Time when 
observed 
Lymph node 
dissection 
SEER and 
Medicare claims 
CPT: 38500-38999 
ICD-9-CM Procedure: 40.20-40.99 
One indicator for 
dissection after 
diagnosis but 
before initiation of 
first course 
chemotherapy; 
Another indicator 
for  dissection after  
initiation of first 
course 
chemotherapy and 
before the end of 
first course 
chemotherapy 
Radiation Therapy  SEER and 
Medicare claims 
ICD-9-CM Diagnosis: V58.00- V58.09; 
V66.1; V67.1 
ICD-9-CM Procedure: 92.20-92.29 
CPT: 01922; 76950; 76960; 76965; 
77400-77499; 77520-77525; 77750-  
77799; 77261-77299; 77300-77399 
HCPCS: A4650; C9714-C9715; C9726; 
C9728; S8049 
Center: 0255; 0330; 0333; 0339; 0371 
DRG: 409 
Radiation after 
diagnosis but 
before initiation of 
first course 
chemotherapy 
Type of chemotherapy 
regimen in first cycle 
– Anthracycline  
Medicare Claims HCPCS: J9000; J9001; C9415; C1167; 
J9178; J9180; J9150; J9151; C9424; 
J9211; C9429; J9293 
Administration of  
Anthracycline in 
the first cycle 
Number of Drugs in 
first cycle 
Medicare Claims HCPCS: J9000 J9001 C9415 C1167 
J9178 J9180 J9150 J9151 C9424 J9211 
C9429 J9293 J8530 J9070 J9080 J9090 
J9091 J9092 J9093 J9094 J9095 J9096 
J9097 C9420 C9421 J8610 J9250 J9260 
J9170 J9190 J9264 J9265 C9127 C9431 
S1016 J9355 J8520 J8521C1084 J9160 
C1086 J8700 C1166 J9098 J9100 J9110 
C1178 J8510 C9017 S0178 C9004 J9300 
C9110 J9010 J0207 J0640 J3570 J8600 
J9245 J9015 J9017 J8560 J9181 J9182 
J9020 J9025 J9027 J9031 J9035 J9040 
J9041 J9045 J9050 J9055 J9060 J9062 
J9065 J9120 J9130 J9140 J9165 J9185 
J9200 J9201 J9202 J9208 J9209 J9212 
J9213 J9214 J9215 J9216 J9217 J9218 
J9219 J9225 J9226 J9230 J9261 J9263 
J9266 J9268 J9270 J9280 J9290 J9291 
J9303 J9305 J9310 J9320 J9340 J9350 
J9357 J9360 J9370 J9375 J9380 J9390 
J9395 J9600 Q2017 S0088 S0172 S0179 
S0182 
The different drugs 
administered in the 
first cycle 
Duration between first 
and second cycle 
Medicare Claims   
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Variable Name Source Claims Codes Time when observed 
Dependent Variables    
Neutropenia / 
Neutropenia 
Hospitalization 
Medicare 
Claims 
ICD-9-CM Diagnosis: 
288.0x 
Three indicators for the first 
hospitalization – one month 
after initiation of 
chemotherapy;  three 
months after initiation of 
chemotherapy;  six months 
after initiation of 
chemotherapy; 
Neutropenia 
Hospitalization – 
Length of Stay 
Medicare 
Claims 
Length of Stay associated with a 
288.0x 
 
Neutropenia 
Hospitalization - 
Expenditure 
Medicare 
Claims 
Expenditure associated with a 
288.0x 
 
Overall Expenditure Medicare 
Claims 
 Any expenditures after 
initiation of chemotherapy – 
within one month; within 
three months; within six 
months 
Any Infection Medicare 
Claims 
ICD-9-CM Diagnosis: 001.xx-
139.xx; 320.xx; 321.xx; 323.0x-
323.7x; 324.xx; 326.xx; 460.xx-
466.xx; 480.xx-487.xx; 567.xx; 
590.xx; 598.0x; 599.0x; 680.xx-
686.xx; 790.7x-790.8x; V09.xx, 
995.90-995.93 
Any infection after 
initiation of chemotherapy – 
within one month; within 
three months; within six 
months 
Radiation therapy 
during the first course 
treatment period 
SEER and 
Medicare claims 
ICD-9-CM Diagnosis: V58.00- 
V58.09; V66.1; V67.1 
ICD-9-CM Procedure: 92.20-92.29 
CPT: 01922; 76950; 76960; 76965; 
77400-77499; 77520-77525; 
77750-  77799; 77261-77299; 
77300-77399 
HCPCS: A4650; C9714-C9715; 
C9726; C9728; S8049 
Center: 0255; 0330; 0333; 0339; 
0371 
DRG: 409 
Any radiation after 
initiation of first course 
chemotherapy, until the end 
of the first course.  
Number of cycles in 
first course 
chemotherapy 
Medicare 
Claims 
ICD-9-CM Diagnosis: V58.1x 
ICD-9-CM Procedure: 99.25 
CPT: 96400-96549; 99555 
HCPCS: J9000-J9999; J8520; 
J8521; J8530; J8610; J8999; 
C9127; C9415; C9420; C9421; 
C9431; S1016; C8953-C8955; 
C8957; S9329-S9331; G0292; 
G0355; G0357-G0362; Q0083-
Q0085 
Center: 0331; 0332; 0335 
Betos: O1D 
DRG: 410; 492 
From chemotherapy 
initiation to end of first 
course 
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Variable Name Source Claims Codes Time when 
observed 
Other variables for 
inclusion and 
exclusion of 
observation 
   
Gender SEER and  
Medicare 
Enrollment 
Database 
  
Enrollment in both part 
A and B; no enrollment 
in HMO 
Medicare 
Enrollment 
Database 
 One year before 
and after 
diagnosis 
End stage renal disease Medicare 
Enrollment 
Database 
 Before and 
during the study 
period 
Stem cell or bone 
marrow transplantation 
Medicare Claims ICD-9-CM Diagnosis: V42.81-V4-82 
ICD-9-CM Procedure: 41.0x 
CPT: 38240-38242 
HCPCS: S2150 
Center: 362 
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Table 5 Descriptive statistics for the independent variables in the analyses, by receipt and 
duration of receipt of primary prophylactic G-CSF 
 
 
Variable name Receipt of G-CSF Duration of Receipt 
 No G-CSF 
(10104) 
G-CSF 
(337) 
G-CSF <5 days 
(151) 
G-CSF >=5 days 
(186) 
Socio-demographic 
characteristics 
    
Age at diagnosis  72.207* 
(4.954) 
71.712* 
(4.508) 
71.818 
(4.556) 
71.626 
(4.480) 
White     0.852** 
(0.355) 
    0.893** 
(0.309) 
    0.854** 
(0.354) 
    0.925** 
(0.265) 
Married 0.507  
(0.500) 
0.516 
(0.500) 
0.517 
(0.501) 
0.516 
(0.501) 
Education      
Proportion of adults with no high 
school diploma in the census tract 
0.154  
(0.116) 
0.161 
(0.125) 
    0.180** 
(0.144) 
    0.145** 
(0.105) 
Proportion of adults with only  
high school diploma in the census 
tract 
0.237  
(0.101) 
0.240 
(0.102) 
0.237 
(0.107) 
0.242 
(0.098) 
Proportion of adults with some 
college diploma in the census tract 
    0.244** 
(0.090) 
    0.270** 
(0.096) 
    0.258** 
(0.109) 
    0.280** 
(0.083) 
Proportion of adults with at least 4 
years of college in the census tract 
0.232  
(0.169) 
0.245 
(0.161) 
0.235 
(0.171) 
0.253 
(0.152) 
Household income  46881.27 
(23178.01) 
48246.40 
(19704.64) 
46326.19 
(20175.82) 
49805.28 
(19227.14) 
Urban/Rural Residence 0.983  
(0.128) 
0.994 
(0.077) 
0.987 
(0.115) 
1.000 
(0.000) 
Seer site/ Region     
San Francisco      0.035** 
(0.184) 
    0.074** 
(0.262) 
0.086 
(0.281) 
0.065 
(0.246) 
Connecticut     0.084** 
(0.278) 
    0.119** 
(0.324) 
0.113 
(0.317) 
0.124 
(0.330) 
Detroit 0.134  
(0.340) 
0.107 
(0.309) 
0.093 
(0.291) 
0.118 
(0.324) 
Hawaii     0.025** 
(0.156) 
    0.006** 
(0.077) 
0.013 
(0.115) 
0.000 
(0.000) 
Iowa     0.094** 
(0.291) 
    0.036** 
(0.186) 
0.026 
(0.161) 
0.043 
(0.203) 
New Mexico 0.028  
(0.165) 
0.015 
(0.121) 
0.020 
(0.140) 
0.011 
(0.103) 
Seattle 0.073  
(0.261) 
0.050 
(0.219) 
0.060 
(0.238) 
0.043 
(0.203) 
Utah     0.042** 
(0.202) 
    0.021** 
(0.143) 
0.026 
(0.161) 
0.016 
(0.126) 
Atlanta     0.048** 
(0.214) 
    0.024** 
(0.152) 
0.026 
(0.161) 
0.022 
(0.145) 
San Jose 0.027  
(0.163) 
0.021 
(0.143) 
0.033 
(0.180) 
0.011 
(0.103) 
Los Angeles     0.104** 
(0.306) 
    0.157** 
(0.365) 
0.132 
(0.340) 
0.177 
(0.383) 
Greater California     0.110** 
(0.313) 
    0.181** 
(0.386) 
0.166 
(0.373) 
0.194 
(0.396) 
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Variable name Receipt of G-CSF Duration of Receipt 
 No G-CSF 
(10104) 
G-CSF 
(337) 
G-CSF <5 days 
(151) 
G-CSF >=5 days 
(186) 
Kentucky    0.047** 
(0.211) 
    0.012** 
(0.108) 
    0.026** 
(0.161) 
    0.000** 
(0.000) 
Louisiana     0.040** 
(0.197) 
    0.065** 
(0.247) 
0.066 
(0.250) 
0.065 
(0.246) 
New Jersey  0.108  
(0.311) 
0.113 
(0.317) 
0.113 
(0.317) 
0.113 
(0.317) 
 
    
Diagnosis Year     
Year 1994     0.056** 
(0.230) 
    0.027** 
(0.161) 
0.040 
(0.196) 
0.016 
(0.126) 
Year 1995 0.056  
(0.230) 
0.036 
(0.186) 
0.040 
(0.196) 
0.032 
(0.177) 
Year 1996   0.055* 
(0.227) 
  0.033* 
(0.178) 
0.026 
(0.161) 
0.038 
(0.191) 
Year 1997   0.071* 
(0.256) 
  0.047* 
(0.213) 
0.040 
(0.196) 
0.054 
(0.226) 
Year 1998   0.087* 
(0.281) 
  0.059* 
(0.237) 
0.066 
(0.250) 
0.054 
(0.226) 
Year 1999 0.091  
(0.287) 
0.068 
(0.253) 
0.073 
(0.261) 
0.065 
(0.246) 
Year 2000 0.194  
(0.396) 
0.190 
(0.393) 
0.205 
(0.405) 
0.177 
(0.383) 
Year 2001     0.196** 
(0.397) 
    0.300** 
(0.459) 
0.258 
(0.439) 
0.333 
(0.473) 
Year 2002     0.195** 
(0.396) 
    0.240** 
(0.428) 
0.252 
(0.435) 
0.231 
(0.423) 
 
    
Clinical Characteristics     
Modified CCI 0.474  
(0.833) 
0.472 
(0.824) 
0.490 
(0.832) 
0.457 
(0.819) 
No other cancers before breast 
cancer 
0.944  
(0.230) 
0.932 
(0.253) 
  0.960* 
(0.196) 
  0.909* 
(0.289) 
History of infection one month 
before chemotherapy initiation 
0.108  
(0.311) 
0.131 
(0.337) 
    0.086** 
(0.281) 
    0.167** 
(0.374) 
Patients on antibiotics one month 
before chemotherapy initiation 
    0.031** 
(0.172) 
    0.053** 
(0.225) 
0.073 
(0.261) 
0.038 
(0.191) 
Recent hospitalization one month 
before chemotherapy initiation 
0.234  
(0.424) 
0.226 
(0.419) 
0.225 
(0.419) 
0.226 
(0.419) 
 
    
Tumor Characteristics     
Tumor Stage     
Stage 1 0.215  
(0.411) 
0.199 
(0.400) 
0.232 
(0.423) 
0.172 
(0.378) 
Stage 2 0.631  
(0.483) 
0.591 
(0.492) 
0.576 
(0.496) 
0.602 
(0.491) 
Stage 3     0.154** 
(0.361) 
    0.211** 
(0.408) 
0.192 
(0.395) 
0.226 
(0.419) 
Tumor Size       64.317** 
(187.019) 
     85.217** 
(228.277) 
    60.238* 
(173.506) 
  105.495* 
(263.272) 
Tumor Grade 0.456  
(0.498) 
0.430 
(0.496) 
0.457 
(0.500) 
0.409 
(0.493) 
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Variable name Receipt of G-CSF Duration of Receipt 
 No G-CSF 
(10104) 
G-CSF 
(337) 
G-CSF <5 days 
(151) 
G-CSF >=5 days 
(186) 
Node +   0.600*  
(0.490) 
  0.647* 
(0.479) 
  0.596* 
(0.492) 
  0.688* 
(0.464) 
ER status  0.570  
(0.495) 
0.549 
(0.498) 
0.563 
(0.498) 
0.538 
(0.500) 
PR status  0.459  
(0.498) 
0.451 
(0.498) 
0.457 
(0.500) 
0.446 
(0.498) 
Procedures Performed     
Surgery      
Surgery before chemotherapy 
initiation 
0.922 
(0.268) 
0.908 
(0.289) 
    0.954** 
(0.211) 
    0.871** 
(0.336) 
Surgery after chemotherapy 
initiation 
    0.035** 
(0.184) 
    0.059** 
(0.237) 
0.033* 
(0.180) 
0.081* 
(0.273) 
Surgery time unknown 0.031 
(0.175) 
0.021 
(0.143) 
0.007* 
(0.081) 
0.032* 
(0.177) 
Lymph node dissection before 
chemotherapy initiation 
0.431 
(0.495) 
0.439 
(0.497) 
0.411 
(0.494) 
0.462 
(0.500) 
Lymph node dissection after 
chemotherapy initiation 
0.013 
(0.114) 
0.018 
(0.132) 
0.013 
(0.115) 
0.022 
(0.145) 
Lymph node dissection time 
unknown 
0.501 
(0.500) 
0.490 
(0.501) 
0.510 
(0.502) 
0.473 
(0.501) 
Radiation before chemotherapy 
initiation 
0.186 
(0.389) 
0.199 
(0.400) 
0.192 
(0.395) 
0.204 
(0.404) 
Type of chemotherapy regimen in 
first cycle - Anthracycline  
    0.387** 
(0.487) 
    0.706** 
(0.456) 
     0.556** 
(0.498) 
    0.828** 
(0.378) 
Number of Drugs in first cycle 1.878 
(1.057) 
1.917 
(0.889) 
    1.755** 
(1.033) 
    2.048** 
(0.730) 
Square of Number of Drugs in first 
cycle 
4.645 
(3.412) 
4.463 
(2.921) 
  4.139* 
(3.143) 
4.726*  
(2.708) 
Duration between first and second 17.566 
(12.306) 
18.108 
(10.922) 
   20.228** 
(12.174) 
  16.387**  
(9.478) 
Square of Duration between first 
and second 
460.008 
(778.746) 
446.842 
(552.396) 
    556.422** 
(666.800) 
    357.882** 
(419.454) 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05
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Table 6 Regressions exploring primary prophylactic G-CSF administration and duration of 
primary prophylactic G-CSF administration 
 
 
Variable name Logistic 
regression for 
probability of 
G-CSF 
administration 
(10441)  
Logistic 
regression for 
probability of  
adequate G-
CSF 
administration 
(337) 
Linear 
regression for 
duration of G-
CSF 
administration 
(337) 
Socio-demographic characteristics    
Age at diagnosis 3.680E-05 
(0.013) 
0.010    
(0.032) 
-0.039    
(0.068) 
Race (White) 0.706** 
(0.218) 
0.348    
(0.543) 
-0.442   
(1.132) 
Marital Status (Married) 0.026    
(0.117) 
-0.346   
(0.290) 
-0.076   
(0.609) 
Education     
Proportion of adults with no high school 
diploma in the census tract 
-0.274   
(1.160) 
-3.992* 
(2.332) 
0.093    
(4.837) 
Proportion of adults with only  high school 
diploma in the census tract 
-2.120* 
(1.288) 
-0.207   
(2.604) 
4.136    
(5.522) 
Proportion of adults with some college diploma 
in the census tract 
1.160    
(1.170) 
0.346    
(2.252) 
-0.574    
(5.020) 
Proportion of adults with at least 4 years of 
college in the census tract 
-1.052    
(1.065) 
-1.494   
(2.006) 
3.412    
(4.496) 
Household income  -1.01E-05** 
(4.200E-06) 
0.000    
(0.000) 
0.000    
(0.000) 
Urban/Rural Residence 0.345    
(0.737) 
Dropped 5.231    
(4.279) 
Seer Site/Region     
Connecticut -0.188   
(0.284) 
0.773    
(0.671) 
1.023    
(1.405) 
Detroit -1.094** 
(0.284) 
0.145    
(0.670) 
0.199     
(1.454) 
Hawaii -1.847** 
(0.753) 
Dropped -1.615    
(4.033) 
Iowa -1.926** 
(0.391) 
-0.096    
(0.934) 
-1.335   
(1.949) 
New Mexico -1.585** 
(0.512) 
-0.289   
(1.209) 
-0.761   
(2.637) 
Seattle -1.331** 
(0.338) 
-0.541   
(0.804) 
4.249** 
(1.715) 
Utah -1.954** 
(0.454) 
0.109    
(1.135) 
0.142    
(2.390) 
Atlanta -1.488** 
(0.422) 
-0.746   
(1.145) 
-2.196   
(2.256) 
San Jose -1.032** 
(0.445) 
-0.657   
(1.183) 
-0.018   
(2.380) 
Los Angeles -0.413   
(0.261) 
0.766    
(0.597) 
1.193    
(1.281) 
Greater California -0.987** 
(0.274) 
0.137    
(0.662) 
1.450    
(1.407) 
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Variable name Logistic 
regression for 
probability of 
G-CSF 
administration 
(10441)  
Logistic 
regression for 
probability of  
adequate G-
CSF 
administration 
(337) 
Linear 
regression for 
duration of G-
CSF 
administration 
(337) 
Kentucky -2.669** 
(0.567) 
Dropped -2.287   
(3.097) 
Louisiana -0.866** 
(0.340) 
-0.114   
(0.831) 
-0.870   
(1.711) 
New Jersey  -0.787** 
(0.303) 
-0.109    
(0.742) 
0.489    
(1.570) 
Diagnosis Year    
Year 1995 0.225    
(0.452) 
0.033    
(1.104) 
0.674    
(2.380) 
Year 1996 0.134    
(0.462) 
1.693    
(1.245) 
0.992    
(2.505) 
Year 1997 0.150    
(0.429) 
0.850    
(1.098) 
3.254    
(2.353) 
Year 1998 0.251    
(0.415) 
0.276    
(1.027) 
-1.646   
(2.220) 
Year 1999 0.206    
(0.408) 
0.253    
(1.011) 
-0.787    
(2.228) 
Year 2000 0.787*   
(0.490) 
0.891    
(1.087) 
-1.184   
(2.371) 
Year 2001 1.224** 
(0.485) 
1.247    
(1.077) 
-0.106    
(2.354) 
Year 2002 0.994** 
(0.488) 
0.976    
(1.063) 
0.621    
(2.321) 
    
Clinical Characteristics    
Modified CCI 0.052    
(0.073) 
0.031    
(0.171) 
-0.356   
(0.367) 
No other cancers before breast cancer -0.309   
(0.230) 
-1.326** 
(0.643) 
-1.391   
(1.173) 
History of infection one month before 
chemotherapy initiation 
0.203    
(0.172) 
0.819*   
(0.454) 
0.522    
(0.889) 
Patients on antibiotics one month before 
chemotherapy initiation 
0.330    
(0.261) 
-1.104* 
(0.603) 
-3.434** 
(1.276) 
Recent hospitalization one month before 
chemotherapy initiation 
0.013    
(0.140) 
-0.231    
(0.344) 
-0.224   
(0.721) 
    
Tumor Characteristics    
Tumor Stage    
Stage 2 -0.287   
(0.197) 
0.030    
(0.486) 
-0.665   
(1.022) 
Stage 3 -0.017   
(0.261) 
0.144    
(0.662) 
-0.090   
(1.385) 
Tumor Size  1.060E-04 
(3.153E-04) 
0.001    
(0.001) 
0.001    
(0.002) 
Tumor Grade  -0.206* 
(0.120) 
-0.447    
(0.308) 
-0.899    
(0.664) 
Node +  0.044    0.198    1.274    
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Variable name Logistic 
regression for 
probability of 
G-CSF 
administration 
(10441)  
Logistic 
regression for 
probability of  
adequate G-
CSF 
administration 
(337) 
Linear 
regression for 
duration of G-
CSF 
administration 
(337) 
(0.167) (0.407) (0.873) 
ER status  -0.252   
(0.172) 
-0.885* 
(0.465) 
-0.680   
(0.961) 
PR status  0.140    
(0.169) 
0.547    
(0.463) 
0.719    
(0.941) 
    
Procedures Performed    
Surgery     
Surgery before chemotherapy initiation 0.119    
(0.577) 
-1.158    
(1.735) 
-1.525    
(3.334) 
Surgery after chemotherapy initiation 0.419    
(0.615) 
-0.646    
(1.876) 
-2.217   
(3.531) 
Surgery time unknown -0.437    
(0.679) 
0.430    
(1.976) 
2.227    
(3.636) 
Lymph node dissection before chemotherapy 
initiation 
-0.069    
(0.297) 
1.506*   
(0.861) 
1.021    
(1.644) 
Lymph node dissection after chemotherapy 
initiation 
-0.088   
(0.550) 
2.648    
(2.511) 
1.288    
(3.055) 
Lymph node dissection time unknown 0.030    
(0.291) 
1.125    
(0.849) 
1.538    
(1.634) 
Radiation before chemotherapy initiation 0.163    
(0.146) 
0.135    
(0.368) 
-0.811   
(0.764) 
Type of chemotherapy regimen in first cycle - 
Anthracycline  
1.553** 
(0.166) 
0.549    
(0.452) 
2.711** 
(0.967) 
Number of Drugs in first cycle -0.585** 
(0.230) 
1.384** 
(0.627)  
0.408    
(1.286)  
Square of Number of Drugs in first cycle 0.121*   
(0.064) 
-0.280   
(0.176) 
-0.120   
(0.369) 
Duration between first and second -0.034** 
(0.013) 
-0.083** 
(0.039) 
-0.191** 
(0.071) 
Square of Duration between first and second 3.479E-04* 
(1.868E-04) 
0.001    
(0.001) 
0.002    
(0.001) 
Indicator for only one cycle in the first course -1.561** 
(0.430) 
-1.087   
(1.156) 
-3.248   
(2.341) 
Constant -2.539   
(1.596) 
0.076    
(3.327) 
4.110    
(8.475) 
 
Note: Standard Errors in the parenthesis 
                          * Significance level α=0.10 
                          ** Significance level α=0.05 
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Table 7 Descriptive statistics for the main outcome variables in the analyses, by receipt and 
duration of receipt of primary prophylactic G-CSF 
 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name No G-CSF 
(10104) 
G-CSF 
(337) 
G-CSF <5 
days 
(151) 
G-CSF >=5 
days 
(186) 
Neutropenia Hospitalization      
1 month 0.023** 
(0.149) 
0.045** 
(0.207) 
0.060* 
(0.162) 
0.032* 
(0.130) 
3 month 0.054  
(0.226) 
0.059 
(0.237) 
0.073* 
(0.134) 
0.048* 
(0.136) 
6 month 0.071  
(0.257) 
0.074 
(0.262) 
0.079  
(0.271) 
0.070  
(0.256) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
1 month  
(245 Obs Before Matching) 
6.065  
(7.090) 
4.467 
(1.922) 
4.556  
(2.128) 
4.333  
(1.751) 
3 month 
(564 Obs Before Matching) 
5.645  
(5.387) 
4.500 
(1.850) 
4.364  
(1.963) 
4.667  
(1.803) 
6 month 
(744 Obs Before Matching) 
5.598  
(5.285) 
4.800 
(2.915) 
4.417  
(1.881) 
5.154  
(3.671) 
Logarithm  of Length of Stay - 1 month 
(245 Obs Before Matching) 
1.484  
(0.738) 
1.410 
(0.437) 
1.423  
(0.459) 
1.390  
(0.442) 
Logarithm  of Length of Stay - 3 month 
(564 Obs Before Matching) 
1.486  
(0.664) 
1.424 
(0.416) 
1.390  
(0.422) 
1.464  
(0.430) 
Logarithm  of Length of Stay - 6 month 
(744 Obs Before Matching) 
1.489  
(0.652) 
1.441 
(0.491) 
1.408  
(0.408) 
1.472  
(0.572) 
Neutropenia Hospitalization – Expenditure  if 
hospitalized 
    
1 month 
(245 Obs Before Matching) 
6855 
(10590) 
5502  
(2562) 
6318  
(2648) 
4280  
(2043) 
3 month 
(564 Obs Before Matching) 
5976  
(7233) 
5761  
(2410) 
6216  
(2570) 
5204  
(2214) 
6 month 
(744 Obs Before Matching) 
5875  
(6484) 
5703  
(2270) 
6101  
(2483) 
5336  
(2086) 
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching) 
8.619  
(0.554) 
8.504 
(0.499) 
8.662  
(0.471) 
8.266  
(0.479) 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching) 
8.542  
(0.501) 
8.564 
(0.468) 
8.648  
(0.458) 
8.461  
(0.486) 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching) 
8.536  
(0.491) 
8.561 
(0.448) 
8.634  
(0.439) 
8.494  
(0.462) 
Overall Expenditure     
1 year  17597** 
(17156) 
 30345** 
(19927) 
 26804** 
(20467) 
 3219** 
(19052) 
Logarithm  of Expenditure – 1 year 9.418** 
(0.926) 
10.101** 
(0.754) 
9.902** 
(0.886) 
10.262** 
(0.580) 
Systemic therapy     
Administration of radiation therapy during the first 
course of chemotherapy  
0.147** 
(0.354) 
0.205** 
(0.404) 
0.205  
(0.405) 
0.204  
(0.404) 
Number of Cycles in first course 8.831** 
(6.579) 
9.887** 
(7.445) 
8.775** 
(7.841) 
10.790** 
(6.999) 
Number of chemotherapy cycles in first course > 5 0.188** 
(0.390) 
0.273** 
(0.446) 
0.232  
(0.423) 
0.306  
(0.462) 
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Table 8 Descriptive statistics for the independent variables in the analyses, by receipt of 
primary prophylactic G-CSF, before and after matching 
 
 
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1423) 
G-CSF 
(337) 
Socio-demographic characteristics     
Age at diagnosis 72.207* 
(4.954) 
71.712* 
(4.508) 
71.897 
(4.704) 
71.712 
(4.508) 
White 0.852** 
(0.355) 
0.893** 
(0.309) 
0.863 
(0.344) 
0.893 
(0.309) 
Married 0.507 
(0.500) 
0.516 
(0.500) 
0.521 
(0.500) 
0.516 
(0.500) 
Education      
Proportion of adults with no high school 
diploma in the census tract 
0.154 
(0.116) 
0.161 
(0.125) 
0.156 
(0.108) 
0.161 
(0.125) 
Proportion of adults with only  high school 
diploma in the census tract 
0.237 
(0.101) 
0.240 
(0.102) 
0.243 
(0.095) 
0.240 
(0.102) 
Proportion of adults with some college 
diploma in the census tract 
0.244** 
(0.090) 
0.270** 
(0.096) 
0.265 
(0.089) 
0.270 
(0.096) 
Proportion of adults with at least 4 years of 
college in the census tract 
0.232 
(0.169) 
0.245 
(0.161) 
0.242 
(0.153) 
0.245 
(0.161) 
Household income  46881.27 
(23178.01) 
48246.40 
(19704.64) 
48202.50 
(20306.43) 
48246.40 
(19704.64) 
Urban/Rural Residence 0.983 
(0.128) 
0.994 
(0.077) 
0.996 
(0.059) 
0.994 
(0.077) 
Seer site/ Region     
San Francisco  0.035** 
(0.184) 
0.074** 
(0.262) 
0.052 
(0.222) 
0.074 
(0.262) 
Connecticut 0.084** 
(0.278) 
0.119** 
(0.324) 
0.113 
(0.317) 
0.119 
(0.324) 
Detroit 0.134 
(0.340) 
0.107 
(0.309) 
0.111 
(0.314) 
0.107 
(0.309) 
Hawaii 0.025** 
(0.156) 
0.006** 
(0.077) 
0.007 
(0.084) 
0.006 
(0.077) 
Iowa 0.094** 
(0.291) 
0.036** 
(0.186) 
0.053 
(0.225) 
0.036 
(0.186) 
New Mexico 0.028 
(0.165) 
0.015 
(0.121) 
0.013 
(0.115) 
0.015 
(0.121) 
Seattle 0.073 
(0.261) 
0.050 
(0.219) 
0.053 
(0.225) 
0.050 
(0.219) 
Utah 0.042** 
(0.202) 
0.021** 
(0.143) 
0.024 
(0.153) 
0.021 
(0.143) 
Atlanta 0.048** 
(0.214) 
0.024** 
(0.152) 
0.027 
(0.161) 
0.024 
(0.152) 
San Jose 0.027 
(0.163) 
0.021 
(0.143) 
0.025 
(0.155) 
0.021 
(0.143) 
Los Angeles 0.104** 
(0.306) 
0.157** 
(0.365) 
0.153 
(0.360) 
0.157 
(0.365) 
Greater California 0.110** 
(0.313) 
0.181** 
(0.386) 
0.181 
(0.385) 
0.181 
(0.386) 
Kentucky 0.047** 
(0.211) 
0.012** 
(0.108) 
0.014 
(0.118) 
0.012 
(0.108) 
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Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1423) 
G-CSF 
(337) 
Louisiana 0.040** 
(0.197) 
0.065** 
(0.247) 
0.061 
(0.240) 
0.065 
(0.247) 
New Jersey  0.108 
(0.311) 
0.113 
(0.317) 
0.112 
(0.315) 
0.113 
(0.317) 
     
Diagnosis Year     
Year 1994 0.056** 
(0.230) 
0.027** 
(0.161) 
0.041 
(0.198) 
0.027 
(0.161) 
Year 1995 0.056 
(0.230) 
0.036 
(0.186) 
0.040 
(0.196) 
0.036 
(0.186) 
Year 1996 0.055* 
(0.227) 
0.033* 
(0.178) 
0.018* 
(0.131) 
0.033* 
(0.178) 
Year 1997 0.071* 
(0.256) 
0.047* 
(0.213) 
0.039 
(0.193) 
0.047 
(0.213) 
Year 1998 0.087* 
(0.281) 
0.059* 
(0.237) 
0.058 
(0.233) 
0.059 
(0.237) 
Year 1999 0.091 
(0.287) 
0.068 
(0.253) 
0.110** 
(0.313) 
0.068** 
(0.253) 
Year 2000 0.194 
(0.396) 
0.190 
(0.393) 
0.195 
(0.397) 
0.190 
(0.393) 
Year 2001 0.196** 
(0.397) 
0.300** 
(0.459) 
0.276 
(0.447) 
0.300 
(0.459) 
Year 2002 0.195** 
(0.396) 
0.240** 
(0.428) 
0.223 
(0.417) 
0.240 
(0.428) 
     
Clinical Characteristics     
Modified CCI 0.474 
(0.833) 
0.472 
(0.824) 
0.425 
(0.766) 
0.472 
(0.824) 
No other cancers before breast cancer 0.944 
(0.230) 
0.932 
(0.253) 
0.963** 
(0.189) 
0.932** 
(0.253) 
History of infection one month before 
chemotherapy initiation 
0.108 
(0.311) 
0.131 
(0.337) 
0.092** 
(0.289) 
0.131** 
(0.337) 
Patients on antibiotics one month before 
chemotherapy initiation 
0.031** 
(0.172) 
0.053** 
(0.225) 
0.053 
(0.224) 
0.053 
(0.225) 
Recent hospitalization one month before 
chemotherapy initiation 
0.234 
(0.424) 
0.226 
(0.419) 
0.188 
(0.391) 
0.226 
(0.419) 
     
Tumor Characteristics     
Tumor Stage     
Stage 1 0.215 
(0.411) 
0.199 
(0.400) 
0.193 
(0.395) 
0.199 
(0.400) 
Stage 2 0.631 
(0.483) 
0.591 
(0.492) 
0.604 
(0.489) 
0.591 
(0.492) 
Stage 3 0.154** 
(0.361) 
0.211** 
(0.408) 
0.203 
(0.402) 
0.211 
(0.408) 
Tumor Size  64.317** 
(187.019) 
85.217** 
(228.277) 
73.558 
(204.874) 
85.217 
(228.277) 
Tumor Grade 0.456 
(0.498) 
0.430 
(0.496) 
0.436 
(0.496) 
0.430 
(0.496) 
Node + 0.600* 
(0.490) 
0.647* 
(0.479) 
0.663 
(0.473) 
0.647 
(0.479) 
  146
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1423) 
G-CSF 
(337) 
ER status  0.570 
(0.495) 
0.549 
(0.498) 
0.552 
(0.497) 
0.549 
(0.498) 
PR status  0.459 
(0.498) 
0.451 
(0.498) 
0.453 
(0.498) 
0.451 
(0.498) 
Procedures Performed     
Surgery      
Surgery before chemotherapy initiation 0.922 
(0.268) 
0.908 
(0.289) 
0.919 
(0.273) 
0.908 
(0.289) 
Surgery after chemotherapy initiation 0.035** 
(0.184) 
0.059** 
(0.237) 
0.055 
(0.228) 
0.059 
(0.237) 
Surgery time unknown 0.031 
(0.175) 
0.021 
(0.143) 
0.023 
(0.151) 
0.021 
(0.143) 
Lymph node dissection before chemotherapy 
initiation 
0.431 
(0.495) 
0.439 
(0.497) 
0.459 
(0.498) 
0.439 
(0.497) 
Lymph node dissection after chemotherapy 
initiation 
0.013 
(0.114) 
0.018 
(0.132) 
0.013 
(0.115) 
0.018 
(0.132) 
Lymph node dissection time unknown 0.501 
(0.500) 
0.490 
(0.501) 
0.488 
(0.500) 
0.490 
(0.501) 
Radiation before chemotherapy initiation 0.186 
(0.389) 
0.199 
(0.400) 
0.152** 
(0.359) 
0.199** 
(0.400) 
Type of chemotherapy regimen in first cycle - 
Anthracycline  
0.387** 
(0.487) 
0.706** 
(0.456) 
0.599** 
(0.490) 
0.706** 
(0.456) 
Number of Drugs in first cycle 1.878 
(1.057) 
1.917 
(0.889) 
1.944 
(0.875) 
1.917 
(0.889) 
Square of Number of Drugs in first cycle 4.645 
(3.412) 
4.463 
(2.921) 
4.543 
(2.856) 
4.463 
(2.921) 
Duration between first and second 17.566 
(12.306) 
18.108 
(10.922) 
17.261 
(9.501) 
18.108 
(10.922) 
Square of Duration between first and second 460.008 
(778.746) 
446.842 
(552.396) 
388.164** 
(430.288) 
446.842** 
(552.396) 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05
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Table 9 Descriptive statistics for the main outcome variables included, by receipt of primary 
prophylactic G-CSF, before and after matching 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1423) 
G-CSF 
(337) 
Neutropenia Hospitalization      
1 month 0.023** 
(0.149) 
0.045** 
(0.207) 
0.023** 
(0.151) 
0.045** 
(0.207) 
3 month 0.054 
(0.226) 
0.059 
(0.237) 
0.063 
(0.225) 
0.059 
(0.237) 
6 month 0.071 
(0.257) 
0.074 
(0.262) 
0.078 
(0.248) 
0.074 
(0.262) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 48 Obs After Matching) 
6.065 
(7.090) 
4.467 
(1.922) 
7.545 
(7.207) 
4.467 
(1.922) 
3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
5.645 
(5.387) 
4.500 
(1.850) 
6.342 
(5.710) 
4.500 
(1.850) 
6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
5.598 
(5.285) 
4.800 
(2.915) 
5.957 
(5.310) 
4.800 
(2.915) 
Logarithm  of Length of Stay - 1 month 
(245 Obs Before Matching; 48 Obs After Matching) 
1.484 
(0.738) 
1.410 
(0.437) 
1.754* 
(0.694) 
1.410* 
(0.437) 
Logarithm  of Length of Stay - 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
1.486 
(0.664) 
1.424 
(0.416) 
1.592 
(0.691) 
1.424 
(0.416) 
Logarithm  of Length of Stay - 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
1.489 
(0.652) 
1.441 
(0.491) 
1.534 
(0.687) 
1.441 
(0.491) 
Neutropenia Hospitalization – Expenditure  if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 48 Obs After Matching) 
6855.14 
(10590.41) 
5502.40 
(2562.37) 
7980.49* 
(4568.20) 
5502.40* 
(2562.37) 
3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
5975.47 
(7232.51) 
5760.90 
(2410.01) 
6615.18 
(3964.96) 
5760.90 
(2410.01) 
6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
5874.70 
(6483.62) 
5702.80 
(2270.21) 
6446.04 
(4141.91) 
5702.80 
(2270.21) 
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 48 Obs After Matching) 
8.619 
(0.554) 
8.504 
(0.499) 
8.853** 
(0.513) 
8.504** 
(0.499) 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
8.542 
(0.501) 
8.563 
(0.468) 
8.651 
(0.537) 
8.564 
(0.468) 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
8.536 
(0.491) 
8.561 
(0.447) 
8.632 
(0.535) 
8.561 
(0.448) 
Overall Expenditure     
1 year 17596.50** 
(17155.56) 
30344.69** 
(19926.37) 
18851.18** 
(15703.82) 
30344.69** 
(19926.37) 
Logarithm  of Expenditure – 1 year 9.418** 
(0.926) 
10.101** 
(0.754) 
9.544** 
(0.846) 
10.101** 
(0.754) 
Systemic therapy     
Administration of radiation therapy during the first 
course of chemotherapy  
0.147** 
(0.354) 
0.205** 
(0.404) 
0.146** 
(0.353) 
0.205** 
(0.404) 
Number of Cycles in first course 8.831** 
(6.579) 
9.887** 
(7.445) 
8.678** 
(6.534) 
9.887** 
(7.445) 
Number of chemotherapy cycles in first course > 5 0.188** 
(0.390) 
0.273** 
(0.446) 
0.186** 
(0.389) 
0.273** 
(0.446) 
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Table 10 Effect of primary prophylactic G-CSF administration and duration of G-CSF 
administration on the key outcome variables   
 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
Variable name Before 
Matching 
(10441) 
After 
Matching 
(1760) 
Effect of G-
CSF 
duration (<5 
days versus 
>=5 days)  
(337) 
Effect of G-
CSF duration 
with duration 
as a 
continuous 
variable 
(337) 
Neutropenia Hospitalization      
1 month 0.684** 
(0.352)         
0.366    
(0.284)      
-1.637* 
(0.826) 
-0.171*          
(-0.095) 
3 month 0.056   
(0.278)      
-0.181** 
(0.091) 
-1.855** 
(0.892) 
-0.217**         
(-0.084) 
6 month 0.100   
(0.251)      
-0.200** 
(0.088) 
-0.681* 
(0.308) 
0.004  
(0.067) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
Logarithm of Length of Stay – 1 month 
(245 Obs Before Matching; 48 Obs After Matching) 
-0.018 
(0.198)         
NA NA NA 
Logarithm of Length of Stay – 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
-0.078 
(0.150)      
-0.140 
(0.210) 
NA NA 
Logarithm of Length of Stay – 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
-0.049   
(0.132)      
-0.039 
(0.181) 
NA NA 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
    
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 48 Obs After Matching) 
-0.246   
(0.155)     
NA NA NA 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
-0.106   
(0.108) 
-0.227  
(0.187) 
NA NA 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
-0.073   
(0.094)     
-0.176 
(0.142) 
NA NA 
Overall Expenditure     
Logarithm – 1 year  0.408** 
(0.045)      
0.454** 
(0.045)     
0.179** 
(0.082) 
0.017** 
(0.008) 
Systemic Therapy      
Receipt of radiation therapy during the first course of 
chemotherapy 
0.404** 
(0.152)      
0.513** 
(0.177)    
0.060** 
(0.025) 
0.096**   
(0.041)      
Number of Cycles in the first course > 5 0.300**    
(0.145)      
0.419** 
(0.169) 
0.094** 
(0.038) 
0.168**   
(0.048)      
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Table 11 Marginal effect of primary prophylactic G-CSF administration on the key outcome 
variables after matching 
 
 
 
   Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name Probability 
without primary 
prophylactic      
G-CSF 
administration 
Probability with 
primary 
prophylactic      
G-CSF 
administration 
Marginal 
Effects 
after 
Matching 
(1760) 
Confidence 
Interval of 
Marginal 
Effects 
Percentag
e change 
due to G-
CSF 
administr
ation 
      
Neutropenia 
Hospitalization  
     
1 month 0.023 
(0.021) 
0.033 
(0.029) 
  0.010 
 (0.008) 
-0.006 to 0.025  41.64% 
3 month 0.054 
(0.014) 
0.046 
(0.011) 
-0.008**  
(0.002) 
-0.012 to -0.005 -15.47% 
6 month 0.072 
(0.021) 
0.060 
(0.015) 
-0.012** 
(0.003) 
-0.018 to -0.006 -16.65% 
Systemic Therapy       
Receipt of radiation 
therapy during the first 
course of 
chemotherapy 
0.184 
(0.132) 
0.261 
(0.162) 
0.077** 
(0.033) 
0.012 to 0.142 41.82% 
Number of Cycles in 
the first course > 5 
0.204 
(0.178) 
0.264 
(0.203) 
0.060** 
(0.030) 
0.001 to 0.118 29.16% 
Variable name Average length of stay Marginal 
Effects after 
Matching 
 Without G-CSF With G-CSF  
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
   
Length of Stay – 1 month 
(245 Obs Before Matching; 48 Obs After Matching) 
NA NA NA 
Length of Stay – 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
8.737 
(11.676) 
7.593 
(10.148) 
-14.99% 
Length of Stay – 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
7.433 
(7.768) 
7.152 
(7.473) 
-5.35% 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
   
Expenditure - 1 month 
(245 Obs Before Matching; 48 Obs After Matching)  
NA NA NA 
Expenditure - 3 month 
(564 Obs Before Matching; 96 Obs After Matching) 
8845.86 
(6908.23) 
7052.42 
(5507.63) 
-21.65% 
Expenditure - 6 month 
(744 Obs Before Matching; 119 Obs After Matching) 
8068.93 
(5797.94) 
6768.05 
(4863.19) 
-16.97% 
Overall Expenditure    
Overall  Expenditure – 1 year 20218.18 
(9246.02) 
31825.56 
(14554.21) 
57.25%** 
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Table 12 Marginal effect of duration of primary prophylactic G-CSF administration on the key 
outcome variables   
 
 
 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
 
Variable name Effect of 
G-CSF 
duration – 
Increase 
due to one 
additional 
day 
Probability 
with 
inadequate 
(<5 days)  
G-CSF 
receipt 
Probability 
with 
adequate 
(>=5 days)       
G-CSF  
receipt 
Marginal 
Effects 
Confidence 
Interval of 
Marginal Effects 
Percentage 
change due 
to G-CSF  
receipt 
       
Neutropenia 
Hospitalization  
      
1 month -0.007* 
(0.004) 
0.110 
(0.056) 
0.041 
(0.025) 
-0.070* 
(0.040) 
-0.148 to 0.009 -63.09% 
3 month -0.010** 
(0.004) 
0.135 
(0.070) 
0.045 
(0.011) 
-0.089** 
(0.031) 
-0.150 to -0.029 -66.32% 
6 month 0.000 
(0.000) 
0.117 
(0.070) 
0.079 
(0.046) 
-0.038* 
(0.021) 
-0.080 to 0.003 -32.72% 
Systemic 
Therapy  
      
Receipt of 
radiation therapy 
during the first 
course of 
chemotherapy 
0.013** 
(0.006) 
0.276 
(0.141) 
0.284 
(0.145) 
0.008** 
(0.004) 
0.001 to 0.016  02.97% 
Number of 
Cycles in the 
first course 
above 5 
0.018** 
(0.005) 
0.286 
(0.102) 
0.297 
(0.106) 
0.011** 
(0.005) 
0.001 to 0.020  03.76% 
Variable name Effect of G-CSF 
duration – Increase 
due to one additional 
day 
Average  expenditure 
without adequate G-
CSF administration 
Average  expenditure 
with adequate G-CSF 
administration 
Marginal 
Effect for 
adequate 
duration 
     
Overall 
Expenditure –  
1 year 
1.74%** 29654.82 
(11886.16) 
35473.20 
(14218.26) 
19.22%** 
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Table 13 Descriptive details about regional trends in G-CSF administration  
 
Region Number of 
women 
receiving 
primary 
prophylactic 
G-CSF 
(Sample Size)  
Rate of  
primary 
prophylactic 
G-CSF 
receipt in the 
region 
Number of 
physicians 
who 
sometimes 
administer 
primary 
prophylactic 
G-CSF 
(Number of 
patients under 
them) 
Number of 
physicians 
who 
administered 
primary 
prophylactic 
G-CSF to all 
of their 
patients 
(Number of 
patients under 
them) 
Percentage of 
physicians 
administering 
G-CSF  
(Total number 
of physicians in 
the data)  
Rate of primary 
prophylactic  
G-CSF 
administration 
by physicians 
who administer 
it 
San 
Francisco  
25 (379) 6.60% 16 (91) 3 (5) 15.20% (125) 26.04% 
Greater 
California* 
61 (1171) 5.21% 42 (262) 8 (10) 13.85% (361) 22.43% 
Louisiana* 22 (431) 5.10% 16 (73) 2 (2) 12.08% (149) 29.33% 
Los Angeles 53 (1107) 4.79% 34 (298) 3 (4) 11.97% (309) 17.55% 
Connecticut 40 (890) 4.49% 27 (230) 6 (9) 14.10% (234) 16.74% 
New Jersey* 38 (1132) 3.36% 33 (179) 6 (7) 10.51% (371) 20.43% 
Detroit 36 (1388) 2.59% 22 (366) 2 (2) 10.67% (225)   9.78% 
San Jose 7 (283) 2.47% 4 (26) 0 (0)   6.15% (65) 26.92% 
Seattle 17 (757) 2.25% 17 (107) 2 (2) 10.50% (181) 15.60% 
New Mexico 5 (287) 1.74% 2 (41) 0 (0)   2.08% (96) 12.20% 
Atlanta 8 (494) 1.62% 6 (40) 3 (3)   7.14% (126) 18.61% 
Utah 7 (436) 1.61% 7 (198) 0 (0) 14.00% (50)   3.54% 
Iowa 12 (959) 1.25% 9 (160) 1 (1)   5.05% (198)   7.45% 
Kentucky* 4 (474) 0.84% 4 (14) 1 (1)   3.21% (156) 26.67% 
Hawaii 2 (253) 0.79% 2 (16) 0 (0)   3.17% (63) 12.50% 
Rural 
Georgia 
0 (34) 0.00% 0 (0) 0 (0)   0.00% (23)   0.00% 
 
Note: *SEER regions that were added to the data in 2000.  
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Table 14 Components of total expenditure in the first year after chemotherapy initiation  
 
Type of 
Expenditure 
Unmatched Data Matched Data Duration of receipt if 
primary prophylactic G-
CSF administered 
 No primary 
prophylactic 
G-CSF 
(10104) 
Primary 
prophylactic 
G-CSF 
(337) 
No primary 
prophylactic 
G-CSF 
(1423) 
Primary 
prophylactic 
G-CSF 
(337) 
<5days 
(151) 
>=5days 
(186) 
First year G-CSF 
expenditure 
   1124** 
(2925) 
   7914** 
(6169) 
   1369** 
(3149) 
   7914** 
(6169) 
    6652** 
(6709) 
    8938** 
(5502) 
First year 
Chemotherapy 
expenditure 
    5687** 
(7123) 
  11242** 
(8876) 
    6444** 
(6713) 
  11242** 
(8876) 
 11621** 
(8933) 
  10774** 
(8811) 
       
Percentage of  
G-CSF 
expenditure in 
total first year 
expenditure  
     5.21%** 
(11.93%) 
   29.70%** 
(19.81%) 
      6.15%** 
(12.85%) 
    29.70%** 
(19.81%) 
28.93% 
(23.93%) 
30.33% 
(15.74%) 
Percentage of 
Chemotherapy 
expenditure in 
total first year 
expenditure 
    33.65%** 
(22.26%)    
   38.44%** 
(21.92%) 
    35.47%** 
(21.52%) 
    38.44%** 
(21.92%) 
    42.00%** 
(24.01%) 
 35.55%** 
(19.66%) 
  
 
 
 
FIGURES
2-5 days 
Beginning of patient level 
observation 
Figure 1 Standard treatment protocol in stage I to III breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:    Dotted arrow indicates treatment and is absent in control group patients 
 * Information Obtained from SEER 
 ** Information Obtained from Medicare 
 *** Information Obtained from SEER and Medicare 
Observation period for the neutropenia related outcomes in 
hypotheses 1 to 3 
6-7 weeks 
12 - 24 weeks 
3-6 weeks 
Biopsy for 
diagnosis * 
Surgery 
(lumpectomy/ 
mastectomy) *** 
Initiation of 
Chemotherapy  ** 
Initiation of Primary G-
CSF Prophylaxis ** 
Initiation of 
Radiation *** 
3-4 weeks 
End of patient level 
observation length due to 
mortality, recurrence, or 
year 2004  
Initiation of Hormonal 
Therapy ** 
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 Initiation of Chemotherapy  ** 
Beginning of patient level observation 
Figure 2 Treatment protocol in advanced levels of stage III breast cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:    Dotted arrow indicates treatment and is absent in control group patients 
 * Information Obtained from SEER 
 ** Information Obtained from Medicare 
 *** Information Obtained from SEER and Medicare 
Biopsy for 
diagnosis * 
Surgery 
(lumpectomy/ 
mastectomy) *** 
Initiation of Primary G-
CSF Prophylaxis ** Initiation of 
Radiation *** 
Initiation of Hormonal Therapy ** 
3-4 weeks 
3-6 weeks 
12 - 24 weeks 
2-5  days 
6-7 weeks 
End of patient level observation length 
due to mortality, recurrence, or year 
2004  
Observation period for the neutropenia related outcomes in hypotheses 1 to 3 
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5 
9 
Figure 3 Conceptual framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:        Solid arrow indicates treatment analyzed in this study 
 P= Primary Prophylaxis; T=Therapeutic Administration; S=Secondary Prophylaxis 
 
1 
7 
Chemotherapy:    
Intensity and 
Type 
Future intensity of 
chemotherapy  and 
radiation therapy 
administration after 
neutropenia occurrence 
Hypothesis 4 and 5 
Socio-demographic characteristics (Age, Race, Marital Status, SES, Geographic area, Urbanacity), Clinical characteristics (Comorbidities, 
Tumor Characteristics, Presence of other cancers), Other  therapies  
Chemotherapy 
outcomes – Breast 
Cancer recurrence 
and mortality.  
Neutropenia 
Occurrence 
 
G-CSF 
Neutropenia Related 
health service 
utilization:  
Hypothesis 1 and 2 
Neutropenia related, 
and Cancer related 
treatment costs: 
Hypothesis 3 
 
G-CSF 
4b 
4c 
2 3 
4a 
6a 
6b 
8 
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Figure 4 Data extraction and final observations used in the analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All individuals with any breast cancer diagnosis until 
2002 in the SEER data linked to Medicare claims until 
2003: 310835 
Inclusions based on characteristics from the PEDSF 
files: 
• Age of diagnosis at or above 65 years (68.13%)* 
• Only Female patients (99.88%) 
• Stages 1 to 3 of breast cancer (62.59%) 
• Diagnosis at or after 1991 in ensure availability of 
Medicare part B (75.20%) 
• Enrollment in both Part A and B, and non-HMO 
enrollee for a year before and after diagnosis 
(62.40%) 
   
Remaining observations: 72448 (23.31%) 
Women of interest in the sample: 10524 (14.53%) 
Inclusions based on characteristics from the claims: 
• Chemotherapy within 6 months of diagnosis 
(17.84%) 
• Diagnosis after 1994 since no patient before 1994 
received G-CSF (86.57%) 
• Absence of end stage renal disease (99.88%) 
• Absence of HIV/AIDS diagnosis (100%) 
• Absence of Stem cell or bone marrows 
transplantation one year before and after 
chemotherapy (94.15%) 
   
Retained observations without missing values for 
variables needed in the analysis e.g. race, education, 
income, and observations from SEER registry in rural 
Georgia dropped as no one had received prophylactic 
G-CSF (99.21%) 
Remaining observations: 10441 (99.21%) 
MATCHING 
Remaining observations: 1760 
* Parenthesis indicates percentage of observations with those characteristics 
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Figure 5 Receipt of primary prophylactic G-CSF by SEER region 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 Receipt of primary prophylactic G-CSF by chemotherapy regimen 
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Figure 7 Receipt of primary prophylactic G-CSF by race 
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Figure 8 Neutropenia hospitalization with and without primary prophylactic G-CSF  
 
 
 
 
Figure 9 Neutropenia hospitalization by days of primary prophylactic G-CSF  
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Figure 10 Neutropenia hospitalization by primary prophylactic G-CSF and tumor stage 
 
 
 
 
Figure 11 Neutropenia hospitalization by duration of primary prophylactic G-CSF and tumor 
stage 
 
 
  162
Figure 12 Neutropenia hospitalization by primary prophylactic G-CSF and tumor grade  
 
 
 
 
Figure 13 Neutropenia hospitalization by duration of primary prophylactic G-CSF and tumor 
grade 
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Figure 14 Neutropenia hospitalization by primary prophylactic G-CSF and size 
 
 
 
 
Figure 15 Neutropenia hospitalization by duration of primary prophylactic G-CSF and size 
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Figure 16 Neutropenia hospitalization length of stay by primary prophylactic G-CSF  
 
 
 
 
Figure 17 Neutropenia hospitalization length of stay by duration of primary prophylactic G-
CSF 
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Figure 18 Neutropenia hospitalization expenditure by primary prophylactic G-CSF 
 
 
 
 
Figure 19 Neutropenia hospitalization expenditure by duration of primary prophylactic G-CSF 
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Figure 20 Total Medicare expenditure by primary prophylactic G-CSF 
 
 
 
 
Figure 21 Total Medicare expenditure by duration of primary prophylactic G-CSF 
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Figure 22 Systemic therapy during the first course by primary prophylactic G-CSF 
 
 
 
 
Figure 23 Systemic therapy during the first course by duration of primary prophylactic G-CSF 
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APPENDIX 
 
Table A1 Descriptive statistics (mean and standard deviations) for the independent variables, by receipt 
of primary prophylactic G-CSF, before and after matching without controlling for therapeutic modalities 
while matching 
 
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1709) 
G-CSF 
(337) 
Socio-demographic characteristics     
Age at diagnosis 72.207* 
(4.954) 
71.712* 
(4.508) 
71.896 
(4.441) 
71.712 
(4.508) 
White 0.852** 
(0.355) 
0.893** 
(0.309) 
0.893 
(0.309) 
0.893 
(0.309) 
Married 0.507 
(0.500) 
0.516 
(0.500) 
0.514 
(0.500) 
0.516 
(0.500) 
Education      
Proportion of adults with no high school 
diploma in the census tract 
0.154 
(0.116) 
0.161 
(0.125) 
0.154 
(0.113) 
0.161 
(0.125) 
Proportion of adults with only  high school 
diploma in the census tract 
0.237 
(0.101) 
0.240 
(0.102) 
0.242 
(0.097) 
0.240 
(0.102) 
Proportion of adults with some college 
diploma in the census tract 
0.244** 
(0.090) 
0.270** 
(0.096) 
0.268 
(0.093) 
0.270 
(0.096) 
Proportion of adults with at least 4 years of 
college in the census tract 
0.232 
(0.169) 
0.245 
(0.161) 
0.245 
(0.157) 
0.245 
(0.161) 
Household income  46881.27 
(23178.01) 
48246.40 
(19704.64) 
49237.95 
(20820.18) 
48246.40 
(19704.640) 
Urban/Rural Residence 0.983 
(0.128) 
0.994 
(0.077) 
0.992 
(0.090) 
0.994 
(0.077) 
Seer site/ Region     
San Francisco  0.035** 
(0.184) 
0.074** 
(0.262) 
0.053 
(0.223) 
0.074 
(0.262) 
Connecticut 0.084** 
(0.278) 
0.119** 
(0.324) 
0.114 
(0.317) 
0.119 
(0.324) 
Detroit 0.134 
(0.340) 
0.107 
(0.309) 
0.119 
(0.323) 
0.107 
(0.309) 
Hawaii 0.025** 
(0.156) 
0.006** 
(0.077) 
0.009 
(0.093) 
0.006 
(0.077) 
Iowa 0.094** 
(0.291) 
0.036** 
(0.186) 
0.040 
(0.197) 
0.036 
(0.186) 
New Mexico 0.028 
(0.165) 
0.015 
(0.121) 
0.018 
(0.131) 
0.015 
(0.121) 
Seattle 0.073 
(0.261) 
0.050 
(0.219) 
0.053 
(0.225) 
0.050 
(0.219) 
Utah 0.042** 
(0.202) 
0.021** 
(0.143) 
0.023 
(0.151) 
0.021 
(0.143) 
Atlanta 0.048** 
(0.214) 
0.024** 
(0.152) 
0.027 
(0.162) 
0.024 
(0.152) 
San Jose 0.027 
(0.163) 
0.021 
(0.143) 
0.016 
(0.125) 
0.021 
(0.143) 
Los Angeles 0.104** 
(0.306) 
0.157** 
(0.365) 
0.154 
(0.361) 
0.157 
(0.365) 
Greater California 0.110** 
(0.313) 
0.181** 
(0.386) 
0.171 
(0.377) 
0.181 
(0.386) 
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Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1709) 
G-CSF 
(337) 
Kentucky 0.047** 
(0.211) 
0.012** 
(0.108) 
0.020 
(0.140) 
0.012 
(0.108) 
Louisiana 0.040** 
(0.197) 
0.065** 
(0.247) 
0.061 
(0.239) 
0.065 
(0.247) 
New Jersey  0.108 
(0.311) 
0.113 
(0.317) 
0.123 
(0.328) 
0.113 
(0.317) 
     
Diagnosis Year     
Year 1994 0.056** 
(0.230) 
0.027** 
(0.161) 
0.050* 
(0.217) 
0.027* 
(0.161) 
Year 1995 0.056 
(0.230) 
0.036 
(0.186) 
0.033 
(0.180) 
0.036 
(0.186) 
Year 1996 0.055* 
(0.227) 
0.033* 
(0.178) 
0.039 
(0.192) 
0.033 
(0.178) 
Year 1997 0.071* 
(0.256) 
0.047* 
(0.213) 
0.044 
(0.206) 
0.047 
(0.213) 
Year 1998 0.087* 
(0.281) 
0.059* 
(0.237) 
0.060 
(0.237) 
0.059 
(0.237) 
Year 1999 0.091 
(0.287) 
0.068 
(0.253) 
0.070 
(0.256) 
0.068 
(0.253) 
Year 2000 0.194 
(0.396) 
0.190 
(0.393) 
0.181 
(0.385) 
0.190 
(0.393) 
Year 2001 0.196** 
(0.397) 
0.300** 
(0.459) 
0.276 
(0.447) 
0.300 
(0.459) 
Year 2002 0.195** 
(0.396) 
0.240** 
(0.428) 
0.247 
(0.432) 
0.240 
(0.428) 
     
Clinical Characteristics     
Modified CCI 0.474 
(0.833) 
0.472 
(0.824) 
0.438 
(0.760) 
0.472 
(0.824) 
No other cancers before breast cancer 0.944 
(0.230) 
0.932 
(0.253) 
0.937 
(0.242) 
0.932 
(0.253) 
History of infection one month before 
chemotherapy initiation 
0.108 
(0.311) 
0.131 
(0.337) 
0.119 
(0.324) 
0.131 
(0.337) 
Patients on antibiotics one month before 
chemotherapy initiation 
0.031** 
(0.172) 
0.053** 
(0.225) 
0.043 
(0.202) 
0.053 
(0.225) 
Recent hospitalization one month before 
chemotherapy initiation 
0.234 
(0.424) 
0.226 
(0.419) 
0.233 
(0.423) 
0.226 
(0.419) 
     
Tumor Characteristics     
Tumor Stage     
Stage 1 0.215 
(0.411) 
0.199 
(0.400) 
0.188 
(0.391) 
0.199 
(0.400) 
Stage 2 0.631 
(0.483) 
0.591 
(0.492) 
0.618 
(0.486) 
0.591 
(0.492) 
Stage 3 0.154** 
(0.361) 
0.211** 
(0.408) 
0.194 
(0.395) 
0.211 
(0.408) 
Tumor Size  64.317** 
(187.019) 
85.217** 
(228.277) 
64.149* 
(182.780) 
85.217* 
(228.277) 
Tumor Grade – Indicator for higher grade 0.456 
(0.498) 
0.430 
(0.496) 
0.447 
(0.497) 
0.430 
(0.496) 
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Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1709) 
G-CSF 
(337) 
Node + 0.600* 
(0.490) 
0.647* 
(0.479) 
0.650 
(0.477) 
0.647 
(0.479) 
ER status  0.570 
(0.495) 
0.549 
(0.498) 
0.565 
(0.496) 
0.549 
(0.498) 
PR status  0.459 
(0.498) 
0.451 
(0.498) 
0.466 
(0.499) 
0.451 
(0.498) 
Procedures Performed     
Surgery      
Surgery before chemotherapy initiation 0.922 
(0.268) 
0.908 
(0.289) 
0.923 
(0.266) 
0.908 
(0.289) 
Surgery after chemotherapy initiation 0.035** 
(0.184) 
0.059** 
(0.237) 
0.037* 
(0.190) 
0.059* 
(0.237) 
Surgery time unknown  0.031 
(0.175) 
0.021 
(0.143) 
0.029 
(0.167) 
0.021 
(0.143) 
Lymph node dissection before chemotherapy 
initiation 
0.431 
(0.495) 
0.439 
(0.497) 
0.459 
(0.498) 
0.439 
(0.497) 
Lymph node dissection after chemotherapy 
initiation 
0.013 
(0.114) 
0.018 
(0.132) 
0.016 
(0.127) 
0.018 
(0.132) 
Lymph node dissection time unknown 0.501 
(0.500) 
0.490 
(0.501) 
0.475 
(0.500) 
0.490 
(0.501) 
Radiation before chemotherapy initiation 0.186 
(0.389) 
0.199 
(0.400) 
0.181 
(0.385) 
0.199 
(0.400) 
Type of chemotherapy regimen in first cycle - 
Anthracycline  
0.387** 
(0.487) 
0.706** 
(0.456) 
0.431** 
(0.495) 
0.706** 
(0.456) 
Number of Drugs in first cycle 1.878 
(1.057) 
1.917 
(0.889) 
1.891 
(1.032) 
1.917 
(0.889) 
Square of Number of Drugs in first cycle 4.645 
(3.412) 
4.463 
(2.921) 
4.638 
(3.328) 
4.463 
(2.921) 
Duration between first and second 17.566 
(12.306) 
18.108 
(10.922) 
17.656 
(11.610) 
18.108 
(10.922) 
Square of Duration between first and second 460.008 
(778.746) 
446.842 
(552.396) 
446.458 
(725.760) 
446.842 
(552.396) 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
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Table A2 Descriptive statistics (mean and standard deviations) for the outcome variables, by receipt of 
primary prophylactic G-CSF, before and after matching without controlling for therapeutic modalities  
 
 Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1709) 
G-CSF 
(337) 
Neutropenia Hospitalization     
1 month 0.023** 
(0.149) 
0.045** 
(0.207) 
0.029 
(0.167) 
0.045 
(0.207) 
3 month 0.054 
(0.226) 
0.059 
(0.237) 
0.054 
(0.226) 
0.059 
(0.237) 
6 month 0.071 
(0.257) 
0.074 
(0.262) 
0.072 
(0.259) 
0.074 
(0.262) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 64 Obs After Matching) 
6.065 
(7.090) 
4.467 
(1.922) 
6.551 
(6.699) 
4.467 
(1.922) 
3 month 
(564 Obs Before Matching; 112 Obs After Matching) 
5.645 
(5.387) 
4.500 
(1.850) 
6.141 
(5.650) 
4.500 
(1.850) 
6 month 
(744 Obs Before Matching; 149 Obs After Matching) 
5.598 
(5.285) 
4.800 
(2.915) 
6.177 
(5.180) 
4.800 
(2.915) 
Logarithm  of Length of Stay - 1 month 
(245 Obs Before Matching; 64 Obs After Matching) 
1.484 
(0.738) 
1.410 
(0.437) 
1.554 
(0.777) 
1.410 
(0.437) 
Logarithm  of Length of Stay - 3 month 
(564 Obs Before Matching; 112 Obs After Matching) 
1.486 
(0.664) 
1.424 
(0.416) 
1.535 
(0.729) 
1.424 
(0.416) 
Logarithm  of Length of Stay - 6 month 
(744 Obs Before Matching; 149 Obs After Matching) 
1.489 
(0.652) 
1.441 
(0.491) 
1.569 
(0.701) 
1.441 
(0.491) 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 64 Obs After Matching) 
6855.14 
(10590.41) 
5502.40 
(2562.37) 
6647.35 
(3977.51) 
5502.40 
(2562.37) 
3 month 
(564 Obs Before Matching; 112 Obs After Matching) 
5975.47 
(7232.51) 
5760.90 
(2410.01) 
6180.02 
(3616.70) 
5760.90 
(2410.01) 
6 month 
(744 Obs Before Matching; 149 Obs After Matching) 
5874.70 
(6483.62) 
5702.80 
(2270.21) 
6195.03 
(3651.04) 
5702.80 
(2270.21) 
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 64 Obs After Matching) 
8.619 
(0.554) 
8.504 
(0.499) 
8.687 
(0.516) 
8.504 
(0.499) 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 112 Obs After Matching) 
8.542 
(0.501) 
8.563 
(0.468) 
8.602 
(0.521) 
8.564 
(0.468) 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 149 Obs After Matching) 
8.536 
(0.491) 
8.561 
(0.447) 
8.607 
(0.504) 
8.561 
(0.448) 
Overall Expenditure     
1 year 17596.50** 
(17155.56) 
30344.69** 
(19926.37) 
19015.14** 
(16322.04) 
30344.69** 
(19926.37) 
Logarithm  of Expenditure – 1 year 9.418** 
(0.926) 
10.101** 
(0.754) 
9.525** 
(0.884) 
10.101** 
(0.754) 
Systemic therapy     
Administration of radiation therapy during the first 
course of chemotherapy  
0.147** 
(0.354) 
0.205** 
(0.404) 
0.165* 
(0.371) 
0.205* 
(0.404) 
Number of Cycles in first course 8.831** 
(6.579) 
9.887** 
(7.445) 
9.097* 
(6.838) 
9.887* 
(7.445) 
Number of chemotherapy cycles in first course > 5 0.188** 
(0.390) 
0.273** 
(0.446) 
0.197** 
(0.397) 
0.273** 
(0.446) 
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Table A3 Effect of primary prophylactic G-CSF administration and duration of G-CSF administration 
on the key outcome variables without controlling for treatment variables 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
Variable name Before 
Matching 
After 
Matching 
Effect of G-
CSF 
duration 
(<5 days 
versus >=5 
days) 
Effect of G-
CSF 
duration 
with 
duration as a 
continuous 
variable 
 10441 2046 337 337 
Neutropenia Hospitalization      
1 month 0.628** 
(0.278)        
0.355    
(0.315)      
-1.377* 
(0.828) 
-0.137  
(0.113) 
3 month 0.038   
(0.238)      
0.024 
(0.263) 
-1.153* 
(0.644) 
-0.116  
(0.094) 
6 month -0.004   
(0.215)      
-0.016 
(0.234) 
-0.711  
(0.568) 
-0.036  
(0.061) 
Neutropenia Hospitalization – Length of 
Stay if hospitalized 
    
Logarithm of Length of Stay – 1 month 
(245 Obs Before Matching; 64 Obs After 
Matching) 
-0.132 
(0.209)        
-0.481 
(0.300) 
NA NA 
Logarithm of Length of Stay – 3 month 
(564 Obs Before Matching; 112 Obs After 
Matching) 
-0.162 
(0.152)      
-0.286 
(0.213) 
NA NA 
Logarithm of Length of Stay – 6 month 
(744 Obs Before Matching; 149 Obs After 
Matching) 
-0.096   
(0.133)      
-0.113 
(0.173) 
NA NA 
Neutropenia Hospitalization – Expenditure 
if hospitalized 
    
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 64 Obs After 
Matching) 
-0.255*   
(0.148)     
-0.469 
(0.230) 
NA NA 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 112 Obs After 
Matching) 
-0.130   
(0.107) 
-0.191  
(0.143) 
NA NA 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 149 Obs After 
Matching) 
-0.080   
(0.093)     
-0.105 
(0.120) 
NA NA 
Overall Expenditure     
Logarithm – 1 year  0.513** 
(0.047)      
0.535** 
(0.047)     
0.290** 
(0.081) 
0.026** 
(0.008) 
Systemic Therapy      
Receipt of radiation therapy during the first 
course of chemotherapy 
0.338** 
(0.141)      
0.253* 
(0.154)    
0.084  
(0.324) 
0.049*   
(0.028) 
Number of Cycles in the first course > 5 0.412**    
(0.130)      
0.470** 
(0.144) 
0.275 
(0.310) 
0.126** 
(0.034) 
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Table A4 Marginal effect of primary prophylactic G-CSF administration on the key outcome variables 
without controlling for treatment variables 
  
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
 
 
 
 
Variable name Probability 
without primary 
prophylactic      
G-CSF 
administration 
Probability 
with primary 
prophylactic      
G-CSF 
administration 
Marginal 
Effects 
after 
Matching 
(2046) 
Confidence 
Interval of 
Marginal Effects 
Percentage 
change due to 
G-CSF 
administration 
Neutropenia 
Hospitalization  
     
1 month 0.030 
(0.032) 
0.042 
(0.043) 
0.012 
(0.011) 
-0.010 to 0.033  38.94% 
3 month 0.056 
(0.046) 
0.057 
(0.046) 
0.001  
(0.001) 
-0.001 to 0.003  02.18% 
6 month 0.074 
(0.048) 
0.073 
(0.047) 
-0.001 
(0.001) 
-0.002 to 0.000 -01.40% 
Systemic Therapy       
Receipt of radiation 
therapy during the 
first course of 
chemotherapy 
0.166 
(0.072) 
0.202 
(0.083) 
0.036* 
(0.012) 
0.013 to 0.059  21.97% 
Number of Cycles 
in the first course 
>5 
0.196 
(0.104) 
0.274 
(0.129) 
0.078** 
(0.026) 
0.026 to 0.129  39.45% 
Variable name Average length of stay Marginal Effects after 
Matching 
 Without  
G-CSF 
With G-CSF  
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
   
Length of Stay – 1 month 
(64 Obs After Matching) 
12.086 
(17.698) 
7.469 
(10.937) 
 
-40.92% 
Length of Stay – 3 month 
(112 Obs After Matching) 
7.692 
(6.805) 
5.780 
(5.113) 
 
-26.55% 
Length of Stay – 6 month 
(149 Obs After Matching) 
6.834 
(3.352) 
6.106 
(2.995) 
 
-11.97% 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
   
Expenditure - 1 month  
(64 Obs After Matching) 
10110.86 
(11695.66) 
6324.86 
(7316.24) 
 
-39.08% 
Expenditure - 3 month 
(112 Obs After Matching) 
7768.47 
(5407.69) 
6420.21 
(4469.16) 
 
-18.19% 
Expenditure - 6 month 
(149 Obs After Matching) 
6764.18 
(2270.89) 
6086.14 
(2043.26) 
 
-10.68% 
Overall Expenditure    
Overall Expenditure – 1 year 20152.48 
(7540.84) 
34393.25 
(12869.59) 
     
 70.47%** 
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Table A5 Marginal effect of duration of primary prophylactic G-CSF administration on the key outcome 
variables without controlling for treatment variables 
 
 
  
   Note: Standard Errors in the parenthesis 
             * Significance level α=0.10 
             ** Significance level α=0.05 
 
 
Variable name Effect of G-
CSF 
duration – 
Increase due 
to one 
additional 
day 
Probability 
with 
inadequate 
(<5 days) G-
CSF receipt 
Probability 
with 
adequate 
(>=5 days)       
G-CSF  
receipt 
Marginal 
Effects 
Confidence 
Interval of 
Marginal 
Effects 
Percentage 
change due 
to G-CSF  
receipt 
       
Neutropenia 
Hospitalization  
      
1 month -0.006 
(0.009) 
0.102 
(0.164) 
0.039 
(0.087) 
-0.063* 
(0.084) 
-0.227 to 0.101 -61.86% 
3 month -0.006 
(0.008) 
0.109 
(0.163) 
0.048 
(0.092) 
-0.061* 
(0.077) 
-0.212 to 0.090 -56.02% 
6 month -0.002 
(0.003) 
0.115 
(0.168) 
0.071 
(0.119) 
-0.044 
(0.053) 
-0.148 to 0.060 -38.58% 
Systemic 
Therapy  
      
Receipt of 
radiation therapy 
during the first 
course of 
chemotherapy 
0.007* 
(0.003) 
0.210 
(0.155) 
0.222 
(0.160) 
0.012 
(0.006) 
0.001 to 0.023 05.78% 
Number of 
Cycles in the 
first course > 5 
0.019** 
(0.010) 
0.256 
(0.192) 
0.301 
(0.209) 
0.044 
(0.021) 
0.003 to 0.085 17.23% 
Variable name Effect of G-CSF 
duration – Increase 
due to one additional 
day 
Average expenditure 
without adequate G-CSF 
administration 
Average  
expenditure with 
adequate G-CSF 
administration 
Marginal 
Effect for 
adequate 
duration 
     
Overall 
Expenditure  – 1 
year 
2.62%** 27759.42 
(9265.351) 
37091.89 
(12380.28)      
    33.18%** 
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Table A6 Descriptive statistics for the independent variables, by receipt of primary prophylactic G-CSF, 
before and after matching without controlling for chemotherapy and radiation therapy variables 
 
 
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1753) 
G-CSF 
(337) 
Socio-demographic characteristics     
Age at diagnosis 72.207* 
(4.954) 
71.712* 
(4.508) 
71.905 
(4.465) 
71.712 
(4.508) 
White 0.852** 
(0.355) 
0.893** 
(0.309) 
0.900 
(0.300) 
0.893 
(0.309) 
Married 0.507 
(0.500) 
0.516 
(0.500) 
0.537 
(0.499) 
0.516 
(0.500) 
Education      
Proportion of adults with no high school 
diploma in the census tract 
0.154 
(0.116) 
0.161 
(0.125) 
0.154 
(0.113) 
0.161 
(0.125) 
Proportion of adults with only  high school 
diploma in the census tract 
0.237 
(0.101) 
0.240 
(0.102) 
0.242 
(0.097) 
0.240 
(0.102) 
Proportion of adults with some college 
diploma in the census tract 
0.244** 
(0.090) 
0.270** 
(0.096) 
0.267 
(0.090) 
0.270 
(0.096) 
Proportion of adults with at least 4 years of 
college in the census tract 
0.232 
(0.169) 
0.245 
(0.161) 
0.244 
(0.157) 
0.245 
(0.161) 
Household income  46881.27 
(23178.01) 
48246.40  
(19704.64) 
48729.39 
(20509.73) 
48246.40 
(19704.64) 
Urban/Rural Residence 0.983 
(0.128) 
0.994 
(0.077) 
0.995 
(0.072) 
0.994 
(0.077) 
Seer site/ Region     
San Francisco  0.035** 
(0.184) 
0.074** 
(0.262) 
0.043** 
(0.202) 
0.074** 
(0.262) 
Connecticut 0.084** 
(0.278) 
0.119** 
(0.324) 
0.115 
(0.319) 
0.119 
(0.324) 
Detroit 0.134 
(0.340) 
0.107 
(0.309) 
0.108 
(0.311) 
0.107 
(0.309) 
Hawaii 0.025** 
(0.156) 
0.006** 
(0.077) 
0.006 
(0.079) 
0.006 
(0.077) 
Iowa 0.094** 
(0.291) 
0.036** 
(0.186) 
0.041 
(0.199) 
0.036 
(0.186) 
New Mexico 0.028 
(0.165) 
0.015 
(0.121) 
0.017 
(0.128) 
0.015 
(0.121) 
Seattle 0.073 
(0.261) 
0.050 
(0.219) 
0.056 
(0.230) 
0.050 
(0.219) 
Utah 0.042** 
(0.202) 
0.021** 
(0.143) 
0.024 
(0.153) 
0.021 
(0.143) 
Atlanta 0.048** 
(0.214) 
0.024** 
(0.152) 
0.025 
(0.155) 
0.024 
(0.152) 
San Jose 0.027 
(0.163) 
0.021 
(0.143) 
0.019 
(0.136) 
0.021 
(0.143) 
Los Angeles 0.104** 
(0.306) 
0.157** 
(0.365) 
0.170 
(0.376) 
0.157 
(0.365) 
Greater California 0.110** 
(0.313) 
0.181** 
(0.386) 
0.185 
(0.389) 
0.181 
(0.386) 
Kentucky 0.047** 
(0.211) 
0.012** 
(0.108) 
0.022 
(0.148) 
0.012 
(0.108) 
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Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1753) 
G-CSF 
(337) 
Louisiana 0.040** 
(0.197) 
0.065** 
(0.247) 
0.061 
(0.239) 
0.065 
(0.247) 
New Jersey  0.108 
(0.311) 
0.113 
(0.317) 
0.108 
(0.311) 
0.113 
(0.317) 
     
Diagnosis Year     
Year 1994 0.056** 
(0.230) 
0.027** 
(0.161) 
0.050* 
(0.217) 
0.027* 
(0.161) 
Year 1995 0.056 
(0.230) 
0.036 
(0.186) 
0.037 
(0.190) 
0.036 
(0.186) 
Year 1996 0.055* 
(0.227) 
0.033* 
(0.178) 
0.037 
(0.190) 
0.033 
(0.178) 
Year 1997 0.071* 
(0.256) 
0.047* 
(0.213) 
0.047 
(0.212) 
0.047 
(0.213) 
Year 1998 0.087* 
(0.281) 
0.059* 
(0.237) 
0.059 
(0.236) 
0.059 
(0.237) 
Year 1999 0.091 
(0.287) 
0.068 
(0.253) 
0.074 
(0.261) 
0.068 
(0.253) 
Year 2000 0.194 
(0.396) 
0.190 
(0.393) 
0.200 
(0.400) 
0.190 
(0.393) 
Year 2001 0.196** 
(0.397) 
0.300** 
(0.459) 
0.261 
(0.439) 
0.300 
(0.459) 
Year 2002 0.195** 
(0.396) 
0.240** 
(0.428) 
0.236 
(0.424) 
0.240 
(0.428) 
     
Clinical Characteristics     
Modified CCI 0.474 
(0.833) 
0.472 
(0.824) 
0.398* 
(0.676) 
0.472* 
(0.824) 
No other cancers before breast cancer 0.944 
(0.230) 
0.932 
(0.253) 
0.938 
(0.242) 
0.932 
(0.253) 
History of infection one month before 
chemotherapy initiation 
0.108 
(0.311) 
0.131 
(0.337) 
0.119 
(0.324) 
0.131 
(0.337) 
Patients on antibiotics one month before 
chemotherapy initiation 
0.031** 
(0.172) 
0.053** 
(0.225) 
0.030** 
(0.171) 
0.053** 
(0.225) 
Recent hospitalization one month before 
chemotherapy initiation 
0.234 
(0.424) 
0.226 
(0.419) 
0.244 
(0.429) 
0.226 
(0.419) 
     
Tumor Characteristics     
Tumor Stage     
Stage 1 0.215 
(0.411) 
0.199 
(0.400) 
0.182 
(0.386) 
0.199 
(0.400) 
Stage 2 0.631 
(0.483) 
0.591 
(0.492) 
0.626 
(0.484) 
0.591 
(0.492) 
Stage 3 0.154** 
(0.361) 
0.211** 
(0.408) 
0.192 
(0.394) 
0.211 
(0.408) 
Tumor Size  64.317** 
(187.019) 
85.217** 
(228.277) 
76.885 
(212.199) 
85.217 
(228.277) 
Tumor Grade – Indicator for higher grade 0.456 
(0.498) 
0.430 
(0.496) 
0.438 
(0.496) 
0.430 
(0.496) 
Node + 0.600* 
(0.490) 
0.647* 
(0.479) 
0.654 
(0.476) 
0.647 
(0.479) 
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Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1753) 
G-CSF 
(337) 
ER status  0.570 
(0.495) 
0.549 
(0.498) 
0.576 
(0.494) 
0.549 
(0.498) 
PR status  0.459 
(0.498) 
0.451 
(0.498) 
0.472 
(0.499) 
0.451 
(0.498) 
Procedures Performed     
Surgery      
Surgery before chemotherapy initiation 0.922 
(0.268) 
0.908 
(0.289) 
0.913 
(0.281) 
0.908 
(0.289) 
Surgery after chemotherapy initiation 0.035** 
(0.184) 
0.059** 
(0.237) 
0.055 
(0.229) 
0.059 
(0.237) 
Surgery time unknown 0.031 
(0.175) 
0.021 
(0.143) 
0.022 
(0.146) 
0.021 
(0.143) 
Lymph node dissection before 
chemotherapy initiation 
0.431 
(0.495) 
0.439 
(0.497) 
0.436 
(0.496) 
0.439 
(0.497) 
Lymph node dissection after chemotherapy 
initiation 
0.013 
(0.114) 
0.018 
(0.132) 
0.017 
(0.128) 
0.018 
(0.132) 
Lymph node dissection time unknown 0.501 
(0.500) 
0.490 
(0.501) 
0.505 
(0.500) 
0.490 
(0.501) 
Radiation before chemotherapy initiation 0.186 
(0.389) 
0.199 
(0.400) 
0.179 
(0.384) 
0.199 
(0.400) 
Type of chemotherapy regimen in first 
cycle - Anthracycline  
0.387** 
(0.487) 
0.706** 
(0.456) 
0.426** 
(0.495) 
0.706** 
(0.456) 
Number of Drugs in first cycle 1.878 
(1.057) 
1.917 
(0.889) 
1.905 
(1.026) 
1.917 
(0.889) 
Square of Number of Drugs in first cycle 4.645 
(3.412) 
4.463 
(2.921) 
4.679 
(3.323) 
4.463 
(2.921) 
Duration between first and second 17.566 
(12.306) 
18.108 
(10.922) 
17.782 
(11.936) 
18.108 
(10.922) 
Square of Duration between first and 
second 
460.008 
(778.746) 
446.842 
(552.396) 
458.590 
(768.238) 
446.842 
(552.396) 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
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Table A7 Descriptive statistics for the outcome variables, by receipt of primary prophylactic G-CSF, 
before and after matching without controlling for chemotherapy and radiation therapy variables 
 
 
Note: Standard Deviations in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name Before Matching After Matching 
 No G-CSF 
(10104) 
G-CSF 
(337) 
No G-CSF 
(1753) 
G-CSF 
(337) 
Neutropenia Hospitalization     
1 month 0.023** 
(0.149) 
0.045** 
(0.207) 
0.029 
(0.168) 
0.045 
(0.207) 
3 month 0.054 
(0.226) 
0.059 
(0.237) 
0.060 
(0.237) 
0.059 
(0.237) 
6 month 0.071 
(0.257) 
0.074 
(0.262) 
0.078 
(0.268) 
0.074 
(0.262) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 66 Obs After Matching) 
6.065 
(7.090) 
4.467 
(1.922) 
5.765 
(4.572) 
4.467 
(1.922) 
3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
5.645 
(5.387) 
4.500 
(1.850) 
5.381 
(4.027) 
4.500 
(1.850) 
6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
5.598 
(5.285) 
4.800 
(2.915) 
5.387 
(3.764) 
4.800 
(2.915) 
Logarithm  of Length of Stay - 1 month 
(245 Obs Before Matching; 66 Obs After Matching) 
1.484 
(0.738) 
1.410 
(0.437) 
1.477 
(0.758) 
1.410 
(0.437) 
Logarithm  of Length of Stay - 3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
1.486 
(0.664) 
1.424 
(0.416) 
1.446 
(0.702) 
1.424 
(0.416) 
Logarithm  of Length of Stay - 6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
1.489 
(0.652) 
1.441 
(0.491) 
1.468 
(0.673) 
1.441 
(0.491) 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
    
1 month 
(245 Obs Before Matching; 66 Obs After Matching) 
6855.14 
(10590.41) 
5502.40 
(2562.37) 
7168.26 
(4584.87) 
5502.40 
(2562.37) 
3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
5975.47 
(7232.51) 
5760.90 
(2410.01) 
6225.82 
(3718.85) 
5760.90 
(2410.01) 
6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
5874.70 
(6483.62) 
5702.80 
(2270.21) 
6273.75 
(3780.45) 
5702.80 
(2270.21) 
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 66 Obs After Matching) 
8.619 
(0.554) 
8.504 
(0.499) 
8.773* 
(0.535) 
8.504* 
(0.499) 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
8.542 
(0.501) 
8.563 
(0.468) 
8.624 
(0.507) 
8.564 
(0.468) 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
8.536 
(0.491) 
8.561 
(0.447) 
8.627 
(0.502) 
8.561 
(0.448) 
Overall Expenditure     
1 year 17596.50** 
(17155.56) 
30344.69** 
(19926.37) 
19610.49** 
(17150.94) 
30344.69** 
(19926.37) 
Logarithm  of Expenditure – 1 year 9.418** 
(0.926) 
10.101** 
(0.754) 
9.552** 
(0.876) 
10.101** 
(0.754) 
Systemic therapy     
Administration of radiation therapy during the first 
course of chemotherapy  
0.147** 
(0.354) 
0.205** 
(0.404) 
0.155** 
(0.362) 
0.205** 
(0.404) 
Number of Cycles in first course 8.831** 
(6.579) 
9.887** 
(7.445) 
9.031** 
(6.458) 
9.887** 
(7.445) 
Number of chemotherapy cycles in first course > 5 0.188** 
(0.390) 
0.273** 
(0.446) 
0.196** 
(0.397) 
0.273** 
(0.446) 
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Table A8 Effect of primary prophylactic G-CSF administration and duration of G-CSF administration 
on the key outcome variables without controlling for chemotherapy and radiation therapy variables 
 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
 
 
Variable name Before 
Matching 
After 
Matching 
Effect of 
G-CSF 
duration 
(<5 days 
versus 
>=5 days) 
Effect of G-
CSF 
duration 
with 
duration as 
a continuous 
variable 
 10441 2090 337 337 
Neutropenia Hospitalization      
1 month 0.635** 
(0.279)         
0.361    
(0.318)      
-1.107 
(0.889) 
-0.091  
(0.122) 
3 month 0.040   
(0.239)      
-0.081 
(0.261) 
-1.132 
(0.719) 
-0.098  
(0.104) 
6 month -0.005   
(0.215)      
-0.092 
(0.234) 
-0.795  
(0.633) 
-0.012  
(0.065) 
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
    
Logarithm of Length of Stay – 1 month 
(245 Obs Before Matching; 66 Obs After Matching) 
-0.166 
(0.210) 
-0.366 
(0.421) 
NA NA 
Logarithm of Length of Stay – 3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
-0.178 
(0.154) 
-0.079 
(0.194) 
NA NA 
Logarithm of Length of Stay – 6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
-0.104 
(0.134) 
-0.007 
(0.154) 
NA NA 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
    
Logarithm  of Expenditure - 1 month  
(245 Obs Before Matching; 66 Obs After Matching) 
-0.254 
(0.151) 
-0.297 
(0.327) 
NA NA 
Logarithm  of Expenditure - 3 month 
(564 Obs Before Matching; 125 Obs After Matching) 
-0.127 
(0.108) 
-0.196  
(0.138) 
NA NA 
Logarithm  of Expenditure - 6 month 
(744 Obs Before Matching; 162 Obs After Matching) 
-0.079 
(0.093) 
-0.132 
(0.119) 
NA NA 
Overall Expenditure     
Logarithm – 1 year 0.510** 
(0.046) 
0.495** 
(0.046)     
0.296** 
(0.081) 
0.027** 
(0.008) 
Systemic Therapy      
Receipt of radiation therapy during the first course of 
chemotherapy 
0.334** 
(0.144)      
0.318** 
(0.157)    
0.069**  
(0.040) 
0.067**   
(0.031) 
Number of Cycles in the first course > 5 0.392**    
(0.131)      
0.455** 
(0.144) 
0.296** 
(0.021) 
0.132** 
(0.036) 
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Table A9 Marginal effect of primary prophylactic G-CSF administration on the key outcome variables 
without controlling for chemotherapy and radiation therapy variables 
 
  
 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name Probability 
without primary 
prophylactic      
G-CSF 
administration 
Probability 
with primary 
prophylactic      
G-CSF 
administration 
Marginal 
Effects 
after 
Matching 
(2090) 
Confidence 
Interval of 
Marginal Effects 
Percentage 
change due to 
G-CSF 
administration 
      
Neutropenia 
Hospitalization  
     
1 month 0.031 
(0.039) 
0.044 
(0.050) 
0.012 
(0.012) 
-0.012 to 0.036  38.92% 
3 month 0.063 
(0.047) 
0.059 
(0.044) 
-0.004*  
(0.003) 
-0.010 to 0.001 -07.06% 
6 month 0.080 
(0.055) 
0.074 
(0.052) 
-0.006* 
(0.004) 
-0.014 to 0.001 -07.86% 
Systemic 
Therapy  
     
Receipt of 
radiation therapy 
during the first 
course of 
chemotherapy 
0.156 
(0.085) 
0.200 
(0.099) 
0.044** 
(0.015) 
 0.014 to 0.073   27.92% 
Number of Cycles 
in the first course 
> 5 
0.197 
(0.108) 
0.273 
(0.130) 
0.075** 
(0.024) 
 0.027 to 0.123  37.88% 
Variable name Average length of stay Marginal Effects after 
Matching 
 Without  
G-CSF 
With G-CSF  
Neutropenia Hospitalization – Length of Stay if 
hospitalized 
   
Length of Stay – 1 month 
(66 Obs After Matching) 
7.678 
(8.567) 
5.324 
(5.941) 
-36.54% 
Length of Stay – 3 month 
( 125 Obs After Matching) 
5.609 
(2.700) 
5.183 
(2.495) 
-9.34% 
Length of Stay – 6 month 
(162 Obs After Matching) 
5.502 
(2.525) 
5.466 
(2.508) 
-1.84% 
Neutropenia Hospitalization – Expenditure if 
hospitalized 
   
Expenditure - 1 month  
(66 Obs After Matching) 
8568.50 
(10680.35) 
6363.64 
(7932.06) 
-29.60% 
Expenditure - 3 month 
(125 Obs After Matching) 
6756.74 
(2535.27) 
5552.43 
(2083.39) 
-18.60% 
Expenditure - 6 month 
(162 Obs After Matching) 
6618.93 
(1833.87) 
5798.94 
(1606.67) 
-13.01% 
Overall Expenditure    
Overall Expenditure – 1 year 20691.19 
(8959.14) 
33927.10 
(14690.20) 
63.79%** 
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Table A10 Marginal effect of duration of primary prophylactic G-CSF administration on the key 
outcome variables without controlling for chemotherapy and radiation therapy variables 
 
 
 
 
Note: Standard Errors in the parenthesis 
          * Significance level α=0.10 
          ** Significance level α=0.05 
Variable name Effect of 
G-CSF 
duration – 
Increase 
due to one 
additional 
day 
Probability 
with 
inadequate 
(<5 days) G-
CSF receipt 
Probability 
with adequate 
(>=5 days)       
G-CSF  
receipt 
Marginal 
Effects 
Confidence 
Interval of 
Marginal 
Effects 
Percentage 
change due 
to G-CSF  
receipt 
Neutropenia 
Hospitalization  
      
1 month -0.004 
(0.006) 
0.092 
(0.166) 
0.044 
(0.105) 
-0.048 
(0.069) 
-0.183 to 0.088 -51.74% 
3 month -0.005 
(0.007) 
0.110 
(0.177) 
0.051 
(0.105) 
-0.058 
(0.080) 
-0.216 to 0.099 -53.26% 
6 month -0.001 
(0.001) 
0.122 
(0.186) 
0.073 
(0.131) 
-0.049 
(0.061) 
-0.169 to 0.072 -40.12% 
Systemic 
Therapy  
      
Receipt of 
radiation therapy 
during the first 
course of 
chemotherapy 
0.009** 
(0.005) 
0.216 
(0.184) 
0.226 
(0.187) 
0.009** 
(0.005) 
0.000 to 0.019  04.37% 
Number of 
Cycles in the 
first course > 5 
0.019** 
(0.011) 
0.260 
(0.210) 
0.306 
(0.226) 
0.046** 
(0.023) 
0.001 to 0.091  17.67% 
Variable name Effect of G-
CSF duration – 
Increase due to 
one additional 
day 
Average expenditure 
without adequate G-CSF 
administration 
Average  
expenditure with 
adequate G-CSF 
administration 
Marginal Effect 
for adequate 
duration 
     
Overall 
Expenditure – 1 
year 
     2.69%** 27789.74 
(10074.50) 
37356.51 
(13542.70) 
    33.98%** 
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